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Introduction 
1. Introduction 
1.1. Structure and importance of 2,2-disubstituted chromanols in natural products. 
 
Since the beginning of the last century, chromanols have been isolated from natural 
sources exhibiting a broad spectrum of biological and medicinal activities. In particular the 
structural motif of 2,2-disubstituted chromanols (figure 1), can be found in many important 
natural products, and made them of interest for organic chemists. 
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Figure 1: Structure of 2,2-disubstituted chromanols. 
 
In 1948, Hughes et al. have isolated acronycine 1 from Acronychia baueri Schott 
(Rutaceae),1 as depicted on figure 2. It exhibited a broad spectrum of activity against 
numerous solid tumors such as sarcoma, myeloma, carcinoma and melanoma, however, 
clinical trials only gave poor results. Several years later, the epoxide derivative 2 was isolated 
and led to the hypothesis of bioactivation by transformation of the double bond.2 In 2000, 
Costes et al. reported the synthesis of a novel class of derivatives,3 including diester 3 which 
was more potent and more active in vivo than acronycine 1, and was active on P388 leukemia 
and induces tumor regression of the resistant C38 adenocarcinoma. 
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Figure 2: Acronycine 1 and related derivatives 2-3.  
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In the 1940’s, cannabinoids such as 4 were identified and isolated from Cannabis 
sativa L (Cannabis), followed by Δ9-tetrahydrocannabinols 5 (Δ9-THC) 20 years later (figure 
3).4 These compounds exhibit strong psychoactive properties, in particular THC having 
analgesic and neuroprotective abilities. At least 66 cannabinoids have been isolated so far 
from the cannabis plant, and most of them include a 2,2-disubstituted chromanol unit. 
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Figure 3: Cannabinoids compound: cannabinols 4 and tetrahydrocannabinols 5.  
 
(-)-Siccanin 6 was isolated and its structure elucidated in 1962 by Ishibashi (scheme 1).5 
6 exhibits potent anti-fungal activity, particularly against the pathogenic fungi Trichophyton 
interdigitale and Trichophyton asteroids, as well as Epidermophytyon and Mycosporum.6 
Extensive studies allowed the isolation of other related analogues, siccanochromenes A-H by 
Hirai et al.,7 and recently, Trost et al. reported the first biomimetic enantioselective total 
synthesis of 6 from vinyl chroman 7.8
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Scheme 1: Structure of (-)-siccanin 6 and its biomimetic precursor 7. 
 
The dried leaves of the plant Rhododendron dauricum known as “Manshanfong” have 
been employed since the 1970’s in the northern part of China as an expectorant to treat acute-
chronic bronchitis. Recently MeOH extracts were founds to display significant anti-HIV 
activity (EC50≤20 μg/mL).9 Two novel isomeric chromanol derivatives were isolated, 
rhododaurichromanic acid A 8 and B 9, together with daurichromenic acid 10 (figure 4). 
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Figure 4: Compounds isolated from Rhododendron dauricum (Ericaceae). 
 
Interestingly, though 8 and 10 were potent anti-HIV compounds (EC50 = 0.37 μg/mL and 
5.67 ng/mL respectively), 9 did not exhibit any activity. Syntheses of these compounds were 
achieved in 2003 by Kang et al. and Kurdyumov et al. as enantiomeric mixtures.10 Numerous 
other polycyclic chromanols have been isolated and characterized over the last decades, such 
as Clusiacyclol A 11, Clusiacyclol B 12, Eriobrucinol 13 and Murrayamine M 14 (figure 5).11  
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Figure 5: Polycyclic chromanol type natural compounds 11-14. 
 
The chromanols belonging to the vitamin E family have been investigated for more than 
60 years mainly because of their potent antioxidant activity in tissues. Structures, biological 
availability and antioxidant properties of these compounds will be described in the following 
chapter, as well as its biosynthesis and more recent progress regarding its asymmetric 
synthesis. 
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1.2. Vitamin E – A highly potent radical chain-breaking antioxidant 
1.2.1. History, structure, and natural sources. 
 
 
The existence of Vitamin E was first discovered in 1922 by Evans and Bishop,12 during 
a study on female rat fertility. Upon a typical diet, rats became fertile and they were able to 
cure it by the administration of fresh green leaves of lettuce. The presence of a novel factor, 
called substance ‘X’, was believed to be responsible for the recovery of fertile rats, and in 
1925, Evans and Burr described it as Vitamin E.13 They discovered that Vitamin E was 
present in rather high concentrations in some cereals, in particular in wheat germ, from which 
they isolate a biologically active yellow, viscous oil. Characterization and structure 
elucidation of this novel factor was initiated by Evans et al. in 1935,14 who isolated a phenol 
which was named α-tocopherol (15), from tokos (childbirth) and phero (to bear). In 1938, 
Fernholz proposed a structure by empirical deductions,15 and in the following years, three 
new Vitamin E constituents were described, β-, γ- and δ-tocopherol 16-18.16 Complete 
elucidation of the configuration of the three chiral centers was accomplished thirty years later 
by Mayer et al.,17 who claimed that natural α-tocopherol was (R)-configurated. The Vitamin 
E family complemented by four related compounds, which have an unsaturated, long aliphatic 
chain, the α-, β-, γ- and δ-tocotrienols 19-22 (figure 6). 
 
 
OR2
HO
R1
4
2
5
7
4' 8'
OR2
HO
R1
4
2
5
7
3' 7'
15
16
17
18
19
20
21
22
R1 R2
R1 R2
CH3 CH3
CH3
CH3
CH3 CH3
CH3
CH3
H
H
H H
H H
H
H
α
β
δ
γ
α
β
δ
γ
 
Figure 6: Structure of tocopherols 15-18 and tocotrienols 19-22, constituents of Vitamin E. 
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The eight vitamin E compounds are widely distributed in nature; the richest sources are 
latex lipids (8% w/v), followed by edible plant oils. Sunflower seeds contain almost 
exclusively α-tocopherol (59.5 mg/g of oil), oil from soybeans contains the γ-, δ- and α-
tocopherols (62.4, 20.4, and 11.0 mg/g oil), and palm oil contains high concentrations of 
tocotrienols (17.2 mg/g oil) and α-tocopherol (18.3 mg/g oil).18  
 
1.2.2. Bio-availability, metabolism and anti-oxidant activity. 
 
Commercially available vitamin E supplements usually contain only racemic α-
tocopherol. Since the free phenol is less stable, it is commonly available as its acetate, 
succinate or nicotinate ester. For optimal absorption, the esters are hydrolyzed by a pancreatic 
esterase, leading to tocopherol.19  
Vitamin E is incorporated in the intestine into chylomicrons, lipoproteins made of 
phospholipids and apolipoproteins, together with cholesterol and other lipids, and could then 
enter to lymphatic system (figure 7). The absorption rate is generally incomplete and could 
reach up to 70%. One important enzyme in chylomicron catabolism is a lipoprotein lipase, 
which is bound to the endothelial lining of capillaries. This enzyme hydrolyses triglycerides, 
and also acts as a transfer protein. 
 
Dietary
Vitamin E
Excreted
Absorption
Intestine
Chylomicrons
Lymphatic
System
Catabolism LIVERα-TTP
Extrahepatic tissues
VLDL
(R,R,R)-α-tocopherol
 
Figure 7: Vitamin E: transport to extrahepatic tissues19 [VLDL=very low density lipoprotein, α-
TTP=α-tocopherol transfer protein] 
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Thus, during chylomicron lipolysis, part of vitamin E is distributed to tissues (adipose 
tissue, muscle, skin), whereas the other part is captured by the liver.20 In the liver, α-
tocopherol is specifically recognized by the 32 kDa α-tocopherol transfer protein (α-TTP), 
incorporated into very low density lipoproteins (VLDL), released into human plasma and 
consequently delivered to peripheral tissues.21 Remarkably, this protein also has a preference 
for (2R)-α-tocopherols, and recognizes only compounds having the phytyl-side chain. The 
other forms of vitamin E such as (2S)-isomers, γ-tocopherol or tocotrienols are excreted as 
bile, or by the urine.22 Concerning the urine excretion pathway, it has been established that ω-
hydroxylation of 15, followed by β-oxidation, catalyzed by cytochrome P450 CYP4F2 
produced α-carboxyethyl hydroxychroman (α-CEHC) 23, one of the main degradation 
product observed (scheme 2). A similar mechanism was discovered for tocotrienols 
degradation, together with a reduction of the unsaturated chain by CoA-reductases.22
 
O
HO
15
HO
O COOH
CYP4F2-mediated
ω-hydroxylationsβ-oxydations
23  
Scheme 2: Elimination of α-tocopherol 15 by the urinary excretion of α-CEHC 23. 
 
The other products usually observed in the urine are α-tocopheryl quinone 24, α-
tocopheryl hydroquinone 25 and α-tocopheronic acid (Simon metabolites23). These products 
are directly related to the anti-oxidant function of vitamin E.24 Indeed, it has been reported in 
the 1980’s by Burton and Ingold that tocopherols are highly potent radical-chain breaking 
anti-oxidants, and react much faster with free radicals than other phenols lacking the fused 6-
membered heterocyclic ring.25 Lipids can be easily oxidized and its peroxidations involve a 
free radical chain having three steps: initiation, propagation and termination, as depicted on 
scheme 3. The production of R. could be a non-enzymatic single-electron transfer (SET) or an 
enzymatic SET, and it reacts rapidly with oxygen to afford the peroxyl radical, which could 
then attack another lipid molecule (RH). 
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R + O2 ROO
. .
ROO + RH R + ROOH
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ArOH + ROO ArO + ROOH
. .
ArO + ROO molecular products
. .
k2
k1
k2 >> k1
 
Scheme 3: Lipid peroxidation process – Free radical chain mechanism. 
 
Chain-breaking antioxidants interfere in one or more propagation steps, and this is the 
case for most phenols, since the ‘chain-carrying’ peroxyl radicals are trapped.26 The phenoxyl 
radicals thus formed are resonance stabilized and usually proceed to the termination step, by 
reacting with another peroxyl radical. In 1996, Liebler et al. analysed the oxidation products 
of vitamin E by gas chromatography, and proposed the reaction with R-OO. and subsequent 
formation of tocopherol metabolites as shown (scheme 4). 
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Scheme 4: Oxidation of α-tocopherol 15 by peroxyl radicals. 
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The ability of tocopherols as antioxidants is a consequence of their fused 6-membered 
heterocyclic ring, as demonstrated by Burton and Ingold in 1986.25 During their studies 
determined the rate constant k2 of the reaction of peroxyl radical with tocopherols and simple 
phenols (see scheme 3) and found out that the best values should be obtained for 4-methoxy-
phenol, and that the best pattern for the other positions was achieved by four methyl groups. 
However, 4-methoxy-2,3,5,6-tetramethylphenol 26, which was expected to show a high k2 
value, was ten times lower that of α-tocopherol. This difference was explained by the greater 
stabilization of the phenoxyl radical formed from α-tocopherol, due to the better overlapping 
of the lone pair orbital of the oxygen para to the OH, with the semi-occupied molecular orbital 
(SOMO) in the radical (scheme 5).  Maximum stabilization is reached when the angle θ 
between the lone pair and the SOMO approaches 0°, and minimum stabilization corresponds 
to θ = 90°. X-ray analysis of 26 revealed that θ = 89° meaning that its radical was not 
stabilized by the oxygen lone pairs. It would explain the low rate constant k2 in comparison to 
α-tocopherol and simple chromanol 27 that showed an angle θ = 17°, which could be 
extrapolated to 15. 
 
O O
R
...
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OMe
HO
26
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O
HO
3
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..
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..
.. ..
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.
 
Scheme 5: The importance of the chromanol motif in the anti-oxidant activity of vitamin E. 
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The aromatic substitution pattern, the nature of the aliphatic side chain and the 
configuration at C-2 play an important role in the anti-oxidant activity, as depicted on table 1, 
(2R,4’R,8’R)-α-tocopherol being the best one (100%). 
 
Tocopherols / Tocotrienols α-Tocopherols stereoisomers 
(R,R,R)-15 100% (R,R,R)-15 100% 
(R,R,R)-16 30% (R,R,S)-15 90% 
(R,R,R)-17 10% (R,S,S)-15 73% 
(R,R,R)-18 1% (S,S,S)-15 60% 
all-E-(R)-19 30% (R,S,R)-15 57% 
all-E-(R)-20 3% (S,R,S)-15 37% 
all-E-(R)-21 - (S,R,R)-15 31% 
all-E-(R)-22 - (S,S,R)-15 21% 
 
Table 1: Relative in vivo antioxidant activity of tocopherols and tocotrienols.18b
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1.2.3. Biosynthesis of tocopherols – The tocopherol cyclase. 
 
The biosynthesis of tocopherols by photosynthetic organisms has been investigated over 
the last 30 years, and the pathway, depicted on scheme 6, has been accepted. Homogentisic 
acid 29, formed from p-hydroxyphenyl pyruvate 28 by the cytosolic enzyme HPP 
dioxygenase (HPPD),27 undergoes a condensation with phytyl diphosphate 30 catalyzed by 
homogentisate phytyltransferase (HPT),28 a membrane-bound chloroplast enzyme firstly 
discovered by Soll et al. in 1987.29
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SAM γ-TMT
 
Scheme 6: Biosynthesis of tocopherols in photosynthetic organisms. 
 
2-Methyl-6-phytyl-1,4-benzoquinol 31 (MPBQ) can be further methylated to afford 2,3-
dimethyl-6-phytyl-1,4-benzoquinol 32 (DMPBQ), via the S-adenosyl-methionine MPBQ 
methyl-transferase (SAM MPBQ).29,30  
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Cyclisation of 31 and 32 by the tocopherol cyclase, isolated from Anabaena variabilis 
Kützing (Cyanobacteria) by Woggon et al. in 1993,31 led to γ- and δ-tocopherol 17 and 18. 
The cyclisation affords exclusively the (R)-configuration at C-2. Finally, S-adenosyl-
methionine γ-tocopherol methyl transferase (SAM γ-TMT)32 catalyzed the methylation of 17 
and 18, leading to α- and β-tocopherol 15 and 16 respectively. The biosynthesis of 
tocotrienols is believed to be similar to the one of tocopherol, except that it starts from 
geranylgeranyl diphosphate, and is condensed with homogentisic acid by the homogentisic 
acid geranylgeranyl transferase (HGGT).33  
 
The mechanism of the cyclisation promoted by tocopherol cyclase has been studied and 
reported by Woggon et al. in 1994,31b using labeled compounds. Indeed, (O4-18O)-32 was 
synthesized and allowed to incubate with tocopherol cyclase in D2O, affording (3S)-(1-18O,3-
2H)-17 (scheme 7). 
 
HO
18O
H
18O
DHOTocopherol cyclase
D2O
2,6-di-O-methyl-
β-cyclodextrin2 2
(O4-18O)-32 (3S)-(1-18O,3-2H)-17  
Scheme 7: Cyclisation of labeled γ-tocopherol precursor in presence of tocopherol cyclase. 
 
This result suggested that tocopherol cyclase operates by si-protonation of the double 
bond of 32 and concomitant re-attack of the phenolic oxygen, the proposed mechanism is 
depicted on scheme 8. 
 
 
 
 
 
 
 
 
 
Scheme 8: Tocopherol cyclase mechanism as proposed by Woggon et al. [E=enzyme, 
S=substrate, P=product] 
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Based on this mechanism, a biomimetic synthesis has been developed in our group, by 
Woggon et al. in 2006,34 involving a chiral peptide auxiliary, covalently bound to the 
phytylhydroquinone unit that mimic the enzyme tocopherol cyclase in the si-protonation step 
(scheme 9). Indeed, it was believed that the Brönsted acid p-toluene sulfonic acid (pTsOH), 
was activated by the chiral peptide, thus leading to the si-protonation of the double bond of 
33, followed by re-attack of the phenolic oxygen leading to diastereo-enriched chromanol. 
After removal of the auxiliary, (R,R,R)-α-tocopherol 15 was finally obtained in 70% de, being 
the first diastereoselective biomimetic synthesis of tocopherols. 
 
OH
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N+
HN
O
COO-
H
pTsOH
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33
(R,R,R)-15
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O
2
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Scheme 9: Biomimetic synthesis of α-tocopherol, using a chiral auxiliary. 
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1.2.4. Recent progress in asymmetric synthesis of α-tocopherols. 
 
Though the industrial production of vitamin E, manufactured in about 35,000 tons per 
year worldwide, leads to (all-rac)-α-tocopherol,35 the synthesis of optically active α-
tocopherols has been of great interest for organic and bioorganic chemists over the last 
decades, and an excellent review by Netscher covers the reported synthesis of vitamin E 
analogues until 2007.35 Herein, we would like to report the most recent progresses done in the 
development of asymmetric synthesis of (R,R,R)-α-tocopherol 15. Several pathways were 
envisaged to reach optically active tocopherols, and are depicted on scheme 10. 
 
O
HO
2
(R,R,R)-15
Stoechimetric
use of chiral
auxiliaries
Chiral pool
starting material Biocatalysis
(microorganisms
or enzymes)
Asymmetric
catalysis
Optical
resolution  
Scheme 10: Possible strategies for the synthesis of optically active α-tocopherol 15.35  
 
Three main problems were addressed separately in most reports, i) the synthesis of 
chiral chromans, ii) the introduction of the side-chain chiral centers, and iii) the coupling 
between these two building blocks. Synthesis of the chiral side chain usually started from 
natural E-(R,R)-phytol 34 and derivatives, and synthesis of chiral chromans was extensively 
studied. Indeed, in the 1970’s, optical resolution was the first method employed,36 followed 
by an important contribution from the area of bio-catalysis. Lipases were successfully used 
over the last 30 years,37 giving access to functionalized precursor with high enantiomeric 
excess, as recently described by Chênevert and Courchesne in 2002 (scheme 11),38 leading to 
chroman 36 in >98% ee. 
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Scheme 11: Enzymatic desymmetrization of chroman 35 using Candida antartica lipase. 
 
Enantioselective catalysis also offered a promising approach, and several methods 
were successfully used, such as Sharpless epoxidation39 or Sharpless dihydroxylation.40 More 
recently, Trost et al. developed the use of a chiral palladium catalyst in enantioselective 
intermolecular and intramolecular allylic substitutions,41 leading to precursor 37 and chroman 
core 38 in high ee’s (scheme 12). In the mean time, Tietze et al. reported a powerful domino 
palladium-catalyzed Wacker-Heck reaction leading to chroman unit 39, in up to 97% ee.42  
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Scheme 12: Pd-catalyzed entioselective formation of compounds 37-39. 
 
The first synthesis of (R,R,R)-15 was reported by Mayer et al. in 1963,36c starting from 
E-(R,R)-phytol 34 and optically resolved carboxylic acid R-40 (scheme 13). Chiral aldehyde 
41 and phosphonium salt 42 were successfully coupled via a Wittig reaction to afford the 
acetate derivative (R,R,R)-43.  
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Scheme 13: The first synthesis of (R,R,R)-α-tocopherol by Mayer et al. 
 
This general approach has been used for most coupling of chiral chromans and chiral 
side-chains, and Trolox, its corresponding aldehyde 41, olefin 38 or sulfone 44 are very often 
key intermediates towards enantiomerically enriched 15 as recently reported by Netscher et al. 
in 2003 (scheme 14).43 Indeed, triflate 44, which synthesis was initiated in 1999 by Outten et 
al.,44 could react with magnesium bromide 45, derived from natural phytol, leading in 
excellent yields to (R,R,R)-15. 
 
O
OSO2CF3
BnO
44
BrMg
45
O
HO
(R,R,R)-15
1) Li2CuCl4 (cat.)
2) H2, Pd/C
 
Scheme 14: Synthesis of (R,R,R)-15 via a Grignard reaction. 
 
In 2007, Breit et al. took advantage of the o-DPPB-directed allylic substitution 
methodology developed in their group,45a and applied it in the synthesis of (R,R,R)-15 
(scheme 15).45b Construction of the side-chain was performed by highly enantio- and 
diastereoselective steps, leading to 46, which was coupled with 4744 in a o-DPPB-directed 
copper-mediated allylic substitution. 
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Scheme 15: o-DPPB-directing group – Application to the total synthesis of (R,R,R)-15. 
 
Efforts in our group lead to the first biomimetic synthesis of α-tocopherol, using a 
chiral peptide auxiliary (scheme 9 – section 1.2.3), and in 2008, Woggon et al. reported the 
highly stereoselective domino aldol/oxa-Michael reaction between aromatic aldehyde 48 and 
E-(R,R)-phytal 49, using a proline catalyst (scheme 16).46 (R,R,R)-15 was finally obtained in 
93% de, and in an overall yield of 29%, being one of the shorter routes to 15 described so far. 
 
O
OH
CHO
48
OHC
2
49
O
2
O
O O
N
H
OTES CF3
CF3
CF3F3C
1)
benzoic acid, toluene
2) PCC, CH2Cl2
O
2
HO
29% overall yield
93% de
(R,R,R)-15  
Scheme 16: Synthesis of (R,R,R)-15 via a domino aldol/oxa-Michael reaction. 
 
1.2.5. Synthesis of all-E-(2R)-α-tocotrienol 19. 
 
In comparison to its tocopherols analogue, all-E-(2R)-α-tocotrienol 19 has not been 
extensively studied, and only few examples of asymmetric synthesis have been reported. The 
first total synthesis of naturally occurring α-tocotrienol was published in 1976 by Scott et al.47  
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and was based on the optical resolution of acid 51, gained from trimethylhydroquinone 50 
(scheme 17) and using known methodologies for the stereoselective synthesis of trisubstituted 
olefins. 
 
HO
O
COOH
HO
O
COOH
OH
OH
50 rac-51 R-51
Optical
resolution
HO
O CHO
HO
O
O
HO
O CHO
2
HO
O
3
all-E-(2R)-19  
Scheme 17: First total synthesis of all-E-(2R)-α-tocotrienol 19. 
 
More recently, Chênevert et al. reported in 2006 the use of their chromanol building 
block 36 (scheme 11),48 and successfully coupled it with sulfone 52 to afford all-E-(2R)-19, 
after desulfonylation using LiBHEt3 in the presence of PdCl2(dppp) as catalyst (scheme 18). 
 
Candida antartica lipase
vinyl acetate, Et2O, 2 h O OH
OAc
HO
36
60% yield
>98% ee
35
O
HO
OSO2CF3
44
PhO2S
52
nBuLi, THF, HMPA O
HO SO2Ph
2
all-E-(2R)-19
 
 
Scheme 18: Application of the lipase-catalyzed resolution of 35 to the synthesis of all-E-
(2R)-19. 
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2. Aim of this work 
 
The main goal of this work concerned the development of new methods for the 
synthesis of optically active tocopherols and tocotrienols, in particular addressing the problem 
of chirality at C-2.  
 
The first part was inspired by the work in our group by Woggon et al.,34 regarding the 
application of the biomimetic synthesis of α-tocopherol, to the synthesis of α-tocotrienol 19. 
Since the biosynthesis of tocotrienols has been reported to proceed in the same manner as for 
tocopherols,33 meaning that there should be an equivalent of the tocopherol cyclase that 
promote the cyclisation to tocotrienols, we expected a similar si-protonation of the double 
bond, followed by a re-attack of the phenolic oxygen. By using a chiral peptide auxiliary, we 
should be able to form enantio-enriched α-tocotrienol 19 under acidic treatment (scheme 19). 
 
OH
(-)CamphO
N O
R
HO
O
3
'Biomimetic'
3
19α-Tocotrienol
Iridium hydrogenation
HO
O
15α-Tocopherol  
Scheme 19: Proposed common route for α-tocotrienol 19 and α-tocopherol 15. [R = OH, Amino 
acid] 
 
In combination with the work done by Pfaltz et al. concerning the asymmetric 
hydrogenation of olefins using chiral Iridium catalysts,49 a common synthetic route leading to 
α-tocotrienols and α-tocopherols was proposed. Finally, we expected to get important 
informations concerning the pro-asp-driven chromanol cyclisation, in order to explain the 
moderate diastereoisomeric excess observed, see page 19. 
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The second part of this work was directly oriented to the direct asymmetric synthesis 
of (R,R,R)-α-tocopherol 15 using two distinct strategies, based on the chromanol formation: 
(1) via an intramolecular epoxide ring opening, that would proceed under inversion of 
configuration, (2) by an asymmetric Lewis acid mediated oxa-Michael cyclisation (scheme 
20). 
 
HO
O
15α-Tocopherol
RO
OH
O
RO
OH
O
LA*
Lewis acid-mediated
oxa-Michael cyclisation
Epoxide ring opening
- 'Anti-Baldwin' cyclisation
 
 
Scheme 20: Possible approaches for the diastereoselective chromanol ring 
formation.[LA=Lewis acid] 
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3. Results and Discussions 
3.1. Biomimetic chromanol cyclisation: a common route to α-tocotrienol and α-
tocopherol. 
3.1.1. Design of the synthesis. 
 
The biomimetic synthesis of α-tocopherol reported by Woggon et al.34 in 2006 was based 
on the mechanism of chromanol formation catalyzed by the enzyme tocopherol cyclase from 
Cyanobacteria31 (scheme 8 – Section 1.2.3). Using a (S)-proline-(S)-aspartic acid dipeptide, 
chromanol ring 53 was formed with 80% de (2S), and 70% de (2R) when starting from DPro-
DAsp peptide (scheme 21).   
 
OH
(-)CamphO
N
HN
O
COOH
COOH
(-)CamphO
O
53
80% de (2S) from Pro-Asp
70% de (2R) from DPro-DAsp
2
4' 8'
33
pTsOH
H2CR:
R
 
 
9-pTsOH 10  
Scheme 21: Biomimetic cyclisation of 33 described by Woggon et al. 
 
In the mechanism proposed by Woggon et al.,34 the p-toluene sulfonic acid (pTsOH) is 
activated by hydrogen bonding of the asp moiety, thus leading in an increased acidity of its 
hydrogen. The chirality of the peptide is then transferred to the chromanol ring, leading to 
diastereo-enriched compounds (scheme 21). 
33-pT H  
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The moderate (70% de) to good (80% de) diastereoisomeric excess in the reaction 33 → 
53 suggested: i) a background reaction catalyzed by the excess of pTsOH without 
participation of the didpeptide linker and ii) the pro-asp residue is not absolutely efficient in 
creating a high-energy-conformation of the phytyl-hydroquinone which cyclises to a chroman 
system with >90% enantiomerical purity at C-2. Both aspects are important with respect to 
the plan of using the dipeptide linker for the synthesis of tocotrienols. In this context the 
experiment published by Yamamoto50 are briefly discusses. This group reported the use of a 
chiral [SnIV-BINOL] catalyst in the cascade asymmetric cyclisation of o-geranyl phenol 54, 
leading to the polycyclic product in >99% conversion and 54% ee (scheme 22). The 
mechanism of cyclisation, a “Lewis acid assisted, Bronsted acid supported reaction”51 
resembles to some extend, to the one proposed in the tocopherol biomimetic cyclisation, a 
“Bronsted acid assisted, Bronsted acid supported reaction”.34
 
OH
54
O
H
[SnIVBinol]
>99% conv
54% ee
O
O
SnCl4
H
R
O
H
 
Scheme 22: Biomimetic cyclisation of o-geranyl phenol 54, using a chiral SnIV catalyst. 
 
Using this information for cyclisation experiments with 55 one can predict a pro-asp 
triggered ring closure to the desired 56 or / and a mixture of polycylic compounds 57-59 that 
would be produced by a Yamamoto-type cyclization of the unsaturated side-chain of 55 
(scheme 23). The product distribution of the reaction of 55 in the presence of excess pTsOH 
would then allow us to estimate the participation of “free pTsOH” in the reaction which led to 
α-tocotrienol, see page 29.  
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Scheme 23: Possible product distribution of cyclisation reaction of 55. [R = OH, Amino acid] 
 
 
Further, cyclisation of 55 → 56 would enable us to prepare both α-tocotrienol 19 through 
removal of the chiral auxiliary (scheme 24) and α-tocopherol 15 by asymmetric iridium 
hydrogenation, based on the work reported by Pfaltz et al. in the hydrogenation of γ-
tocotrienyl acetate 60 with iridum catalyst 61 (scheme 25).52
 
 
OH
(-)CamphO
N O
55
R
HO
O
3
'Biomimetic'
3
α-Tocotrienol
Iridium hydrogenation
HO
O
α-Tocopherol  
Scheme 24: Planned synthesis of α-tocotrienol and α-tocopherol in a common route. 
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Scheme 25: Asymmetric hydrogenation of γ-tocotrienyl acetate 60 with Iridium catalyst 61. 
 
 
3.1.2. Synthesis of proline precursors 63. 
 
 
The key intermediate for cyclisation experiments with 55 is the all-E-geranyl-geranyl-
hydroquinone derivative 63 which can be obtained as shown in scheme 26.  
 
OH
O
N+ O
H
63
Mannich
reaction
N+
COOH
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O
HO
THP 65
OTHP
TIPSO
66
OH
HO
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3
3
3
TIPS=
THP=
Si
O
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Br
HO
O
O
O
OH
3
 
Scheme 26: Retrosynthetic approach to the synthesis of precursors 63. 
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Accordingly, the proline can be attached by a Mannich reaction with the iminium salt 
64 to the aromatic partner 65, which can be formed by an aromatic substitution of bis-
protected hydroquinone 66, and geranyl geranyl bromide 67. For the preparation of 66 and the 
Mannich reaction with 64, we took advantage of earlier work34, and since no mismatch was 
observed, (-)-camphanoyl ester was used for the phenol protection. 
 
 
3.1.2.1. Synthesis of (all-E)-geranyl geraniol 69. (Based on Pr. Chougnet work) 
 
The synthesis of the long unsaturated chain started from (all-E)-farnesyl acetone 70 (DSM 
Nutritional Products), which was converted to its ethylester derivative 71, by a Horner-
Wadsworth-Emmons reaction (scheme 27). Pure E-compound was obtained in 66% yield, and 
finally reduced to furnish desired (all-E)-geranyl geraniol 69 in 72% yield. 
 
O EtO2POCH2CO2Et
NaH, THF, r t, 1 h, 66%
(all-E )-Farnesylacetone, 70
O
EtO
DIBAL-H, Et2O,
0 °C to r t, 2 h, 72%
OH
71
69  
Scheme 27: Synthesis of (all-E)-geranyl geraniol 69. 
 
3.1.2.2. Coupling with the aromatic partner 66 – Mannich reaction. 
 
(all-E)-Geranyl geraniol 69 was converted to its bromide derivative 67, and directly 
coupled with bis-protected hydroquinone 66 to afford 72, which was not purified but mono-
deprotected to give easily separable products, affording 65 in 71% from 66.  
 
Finally, Mannich reagents of L-proline and D-proline were generated in situ by reaction 
with formaldehyde in MeOH, and then reacted with hydroquinone 65, to yield L-73 and D-73 
in 86% and 82% respectively. 
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Scheme 28: Synthesis of LProOH L-73 and DProOH D-73. 
 
3.1.2.3. Synthesis of cyclisation precursors L-63 and D-63. 
 
Final steps leading to desired precursors L-63 and D-63 consisted in the protection of the 
free phenol and the removal of the THP protecting group. Direct protection of the phenol was 
not possible in the presence of the free acid, which was firstly converted to its methyl ester 
derivatives. Then treatment with trimethylsilyl diazomethane in MeOH afforded L-74 and D-
74, in 90% and 85% yield respectively (scheme 29), subsequently protected with (-)-
camphanoyl chloride to yield L-75 (90%) and D-75 (93%). The difficult methyl ester cleavage 
was then performed by using LiI under a constant flow of N2, to eliminate the MeI formed 
and to drive the reaction to completion. The THP group was not stable under these conditions, 
and was partially cleaved. Hydrolysis was completed to afford desired cyclisation precursors 
L-63 in 86% yield, and D-63 in 83% over two steps. 
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Scheme 29: Synthesis of L-63 and D-63. 
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3.1.3. Yamamoto’s products and background reaction. 
 
In order to determine the importance of the “background” reaction in the biomimetic 
cyclisation, we tried to isolate and quantify the products resulting from a cascade cyclisation 
(scheme 23), involving the “non-chiral” pTsOH pathway. Since this pathway would be 
favoured in the absence of the dipeptide and a masked proline, preliminary experiments were 
conducted with protected LPro(OMe) precursor 76 (scheme 30).  
 
The synthesis went smoothly from L-75, by treatment with 1N HCl in THF, to yield 76 
in 86% yield. Cyclisation of 76 using established conditions, pTsOH in CH2Cl2:MeCN, 
showed a nice 70-80% conversion, but only <5% of a polycyclic compound. 
 
O
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3
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N COOMe
O
1N HCl, THF
rt, 2 h, 86%
OH
(-)CamphO
3
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N O
O
No H-donor
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90% conv
(-)CamphO
N COOMe
O
3
(-)CamphO
N COOMe
O
2
Others: - addition of H2O (~10%)
- decomposition (~10%)
- 76 (15%)
77, 50% 78, <5%  
Scheme 30: Cyclisation of 76 using pTsOH.H2O – Only <5% of Yamamoto’s products 
formed. 
 
Indeed, the main product isolated was the chroman derivative 77 in 50% yield, under the 
“chiral pathway”, and unreacted precursor 76 (15%). A further product (10%) displayed 
spectroscopic data (NMR/ESI-MS) corresponding to structure 77 with one H2O added to one 
of the double bonds of the side chain. Due to the limited amount of material the 
regioselectivity of water addition could not be determined.  
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These experiments clearly show that under conditions that favour polycyclization only a 
negligible amount of trycyclic compound such as 78 is produced. These results suggest that 
the excess of pTsOH used in cyclization experiment leading to the tocopherol or tocotrienol 
structure is not related to the moderate diastereoisomeric excess. It seems that the obtained de 
is indeed a result of limited conformationally control of the chiral auxiliary in an adduct such 
as 33-pTsOH (see scheme 21), which explains the requirement of two equivalent of pTsOH. 
 
 
 
3.1.4. Synthesis and cyclisation of ProAsp and DProDAsp precursors. 
 
 
Our efforts were then focused on the biomimetic synthesis of enantio-enriched α-
tocotrienol using ProAsp / DProDAsp as chiral auxiliaries.  
 
The synthesis started from proline derivatives L- and D-63, which reacted with Fm-
protected aspartic acids, as its TFA salts, using classical peptide chemistry (scheme 31), to 
afford L-79 and D-79 in 81% and 62% yield respectively. Subsequent deprotection with 
Et2NH in CH2Cl2, afforded the free acids L-80 (63%) and D-80 (40%), which COOH groups 
made purification on silica gel difficult. Cyclisation of L- and D-80 went smoothly, in the 
presence of 2 equivalents of pTsOH, to afford the corresponding chromanols, which were 
directly protected as their bis-methyl esters L-81 and D-81, in 81% and 41% yield 
respectively. Determination of the diastereoselectivity was not possible at this stage, since no 
suitable methods gave relevant results but was checked latter on. Nevertheless, we anticipated 
that L-81 would have a S configuration at C-2, whereas D-81, should have a R configuration at 
C-2 as shown in scheme 31. 
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Scheme 31: Synthesis and cyclisation of ProAsp L-80 and DProDAsp D-80 chromanols. 
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3.1.5. Synthesis of α-tocotrienol – Benzyl amine cleavage. 
 
Synthesis of α-tocotrienol 19 required the removal of the chiral auxiliary, i.e. the 
cleavage of the C-N bond. It is usually achieved by reductive hydrogenation,34 in the presence 
of palladium catalysts, however this method was obviously not compatible with substrate 81, 
since the olefins would also be hydrogenated. Several alternatives were envisaged, such as the 
Birch reduction53, but treatment of L-81 by a mixture of Li (1% Na) in EtNH2:THF (20:1) 
never afforded the desired product in yields higher than 10%, and the olefins were also 
partially hydrogenated (scheme 32).  
 
(-)CamphO
L-81
N HN
O
COOMe
COOMe
O
3
HO
19
<10% yield (C=C partia lly hydrogenated)
O
Li (1% Na), EtNH2
-78 °C, THF, 24 h
 
Scheme 32: Birch reduction of L-81 in the presence of Li and EtNH2. 
 
The Von Braun reaction54 appeared to be a promising alternative, being unreactive 
towards alkene functionalities (scheme 33). Accordingly to the mechanism of this reaction the 
amine moiety reacts on the cyanogen bromide, displacing the bromine atom, which then 
reacts to form the corresponding cyanamide and alkyl bromide. 
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Scheme 33: Von Braun reaction mechanism and application to L-81. 
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However, treatment of L-81 with BrCN was unsuccessful and the starting material was 
completely recovered. The Von Braun reaction have been studied extensively during the past 
century,55 but its limitations led to several modifications, such as the use of chloroformate 
reagents56, which are more reactive than BrCN. The reaction mechanism is similar, thus 
leading to alkyl chloride, and carbamate after two successive nucleophilic substitutions 
(scheme 34). 
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Scheme 34: Benzyl amine cleavage by using chloroformate reagents. 
 
 Thus treatment of L-81 and D-81 by an excess of 2,2,2-trichlorethyl chloroformate 
afforded the corresponding benzyl chloride all-E-(S)-82 and all-E-(R)-82 in 80% yield. The 
choice of the formate reagent is crucial, since dramatic decrease in yield was observed by 
using benzyl- or allyl- chloroformate (52% and <10% yield respectively). Tandem reductive 
elimination of the chlorine, and cleavage of (-)-camphanate ester by LiAlH4 finally yielded 
all-E-(S)-α-tocotrienol 19, and all-E-(R)-α-tocotrienol 19 in 92% yield (scheme 35). 
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Scheme 35: Final steps to α-tocotrienols – Determination of ee’s after hydrogenation. 
 
The enantiomeric excesses were then determined on the hydrogenated tocopherols, by 
treatment with Pd/C under H2 in EtOAc, which formed (4’RS,8’RS)-α-tocopherols. HPLC 
analysis using a chiral column (Chiracel OD-H) allowed the separation of the (2S) and (2R) 
isomers,57 leading to 70% ee (2S) for all-E-(S)-19, and 65% ee (2R) for all-E-(R)-19 (figure 
8). 
 
 
 a) b) 
HO
O
3
HO
O
3
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: HPLC chromatogram of (S,RS,RS)-15 and (R,RS,RS)-15.  [Chiracel OD-H, 0.5% EtOH 
in n-hexane, 1mL/min, 220 nm, 25 °C] 
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Accordingly, the cyclization of L-80 with the natural configuration of the chiral auxiliary 
yields predominantly the (2S) configuration at the chromanol of 19, whereas D-80 leads to the 
(2R) configuration. 
 
3.1.6. Asymmetric hydrogenation of α-tocotrienol – Synthesis of α-tocopherol. 
 
According to Pfaltz al.,52 the asymmetric hydrogenation of α-tocotrienol with Iridium 
catalyst was performed on the acetylated derivatives 83 (scheme 36). Iridium catalyst 61 was 
then applied to enantiomerically enriched α-tocotrienyl acetates all-E-(S)-83 and all-E-(R)-
83, easily obtained by treatment with acetic anhydride in pyridine. Hydrogenation went 
smoothly to afford α-tocopheryl acetates, directly reduced to desired α-tocopherols (S,R,R)-
15 and (R,R,R)-15 in excellent yields. 
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Scheme 36: Asymmetric hydrogenation of α-tocotrienyl acetates 83. 
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The ratio of the 8 possible diastereoisomers was determined by a combination of HPLC 
analysis of α-tocopherols and GC analysis of α-tocopheryl methylethers.57 As already 
discussed earlier, it was possible to separate (2S, 4’RS, 8’RS)-α-tocopherol and (2R, 4’RS, 
8’RS)-α-tocopherol on chiral HPLC (figure 8). On the other hand, GC analysis of α-
tocopheryl methylether allowed the separation of 4 couples of enantiomers, as depicted on 
figure 9. 
 
 
 
 
 
 
 
 
 
 
Figure 9: GC analysis of α-tocopheryl methylether. [CP-Sil-88 column, 50m x 0.25 mm, 0.25 μm; 
split injector (1:30), injector temp. 280 °C; FID detector, detector temp. 250 °C, carrier gas: H2, 90 kPa; 170 °C, 
140 min] 
 
Combination of both analyses led to simple equations which would give the ratio of all 8 
stereoisomers, as depicted on figure 10. 
 
%(2S)
%(2R) = y
HPLC
GC
%(RRS) + %(SRR) = a
%(RRR) + %(SSS) = b
%(RSR) + %(SRS) = c
%(RSS) + %(SRR) = d
%(RSS) =
%(RRR)=
%(SSR)=
%(RSR)=
%(SRR)=
%(SSS)=
%(RRS)=
%(SRS )=
%(SSR)
y
b -
y -
d
y
1
y
%(SRR)
y
c - ay
- y1y
d - %(RSS)
b - %(RRR)
a - %(SSR)
c - %(RSR)
 
Figure 10: Calculations used for determination of diastereoisomers ratio. 
Time (min) 
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Finally, α-tocopherols 15 were converted to their corresponding methyl ethers derivatives 
84 (scheme 37), and GC analysis showed, in both case, an excellent R:S ratio up to >99:1 at 
C-4’ and C-8’. 
 
HO
O
(S,R,R)-15
2
HO
O
2
(R,R,R)-15
MeI, NaH
DMF, rt, 3 h
86%
O
O
(S,R,R)-84
2
MeI, NaH
DMF, rt, 3 h
86%
O
O
2
(R,R,R)-84
>99:1, R:S
C-4' and C-8'>99:1, R:SC-4' and C-8'
 
Scheme 37: Methyl ether protection – Selectivity of Ir-hydrogenation at C-4’ and C-8’. 
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3.2. From Baldwin’s Rules to the design of a novel chromanol ring formation 
 
3.2.1. Design and retrosynthetic approach. 
 
 
 
In 1976, Jack E. Baldwin described rules related to ring-closure reaction.58 These 
rules, based on empirical results, allowed predicting favoured and disfavoured processes, 
depending on the nature of the cycle formed. Each reaction could be named using three 
parameters (scheme 38): (1) the size of the ring formed, (2) whether the breaking bond would 
be endocyclic (Endo) or exocyclic (Exo), (3) the geometry of the reacting carbon: Tet 
(tetrahedral), Trig (trigonal) or Dig (digonal). 
 
  
-X Y
n
-X Y
m
Exo Endo
X Y-
n X
Y-
m
X- Y
X Y
-
6-exo-tet
 
 
Scheme 38: Baldwin’s nomenclature in ring-closure reactions [n=1..5; m=0..4]. 
 
 
Indeed, depending on the geometry of the carbon atom undergoing the cyclisation, 
three rules were established (table 2). It relied on stereoelectronic requirements of transition 
state in ring-closure mechanisms, which referred to the angle α and the distance between the 
reacting atom and the reacting site (figure 11).  
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  Ring Size Tet Trig Dig   Ring Size Tet Trig Dig 
3 9 9 8 3 ? 8 9 
4 9 9 8 4 ? 8 9 
5 9 9 9 5 8 8 9 
6 9 9 9 6 8 9 9 
Ex
o 
7 9 9 9 
En
do
 
7 ? 9 9 
 
Table 2: Baldwin’s rules. [9 : favour, 8 : disfavour, ? : not known] 
 
Thus, for tetrahedral systems, favoured transition states should correspond to α = 
180°, as established by Walden et al.;59 for trigonal systems, Dunitz and Bürgi60 reported an 
angle of 109°, specially on addition reactions to carbonyl group; and empirical observations 
showed that digonal systems required an α of 120°. 
 
Y-X
α
Y
-X
α
C C
X-
+Y
α
α
Tetrahedralα = 180°
Trigonalα = 109° Digonalα = 120°  
 
Figure 11: Transition state requirements that defined Baldwin’s rules. [X=nucleophile] 
 
Since ‘disfavoured’ do not necessarily imply ‘impossible’, several efforts have been 
published over the past decades, to circumvent these rules, and in particular in the case of γ-
epoxy alcohol cyclisations. Two products could be formed, a 5-membered ‘furan’ ring (5-exo-
tet), and a 6-membered ‘pyran’ ring (6-endo-tet), being the disfavoured cycle, as depicted on 
scheme 39.  
 
O
O
Epoxy alcohol
O
OH
O
OH
H 5-exo-tet
Favored
6-endo-tet
Disfavored  
 
Scheme 39: γ-Epoxy alcohol cyclisations. 
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 Marin natural products were the starting point of many studies in regioselective γ-
epoxy alcohol cyclisations, since these types of compounds are usually constituted of several 
‘pyran’-type rings. In 1985, Nicolaou et al.61 described first the use of directing groups in 
order to favour the 6-membered ring formation in the synthesis of brevetoxin B 85 (scheme 
40). Indeed, in the presence of camphorsulfonic acid (CSA), cyclisation of epoxy alcohol 86 
could be driven to the ‘pyran’ product 87 by using allylic substituents, which have the ability 
to weaken the adjacent C-O bond, and to stabilize the positive charge formed.  
 
O
O
O
O
O
O
O
O
O
O O
O
CHO
HO
H
H
H
H
H
H
HH
H
H
H
H
HH
H
Brevetoxin B, 85
HO
O
R O R
OH
H
CSA, CH2Cl2
-40 to 25 °C O
OH
RH
86 87 88
R= CH2CH2CO2Me, 87:88 = 0:100
R= CH=CH2, 87:88 = 100:0  
 
Scheme 40: Directing group for the regioselective ‘pyran’ ring formation in Brevetoxin B. 
  
 Based on this principle, several marine product syntheses have been accomplished 
over the last twenty years,62 using a variety of different directing groups. Meanwhile, metal 
catalysts became more and more popular, and were also employed to direct regioselective 
cyclisation of epoxy alcohols. In 1994, Hanaoka et al.63 reported the use of CoIII catalysts and 
later, Murai et al.64 described the use of LaIII metal complexes which directed the 6-endo 
pathway. Nevertheless, specific binding sites on substrates were necessary and these 
conditions thus suffered of difficult and long chemical modifications. But in 1999, Jacobsen et 
al.65 reported the regio- and enantioselective cyclisation of epoxy alcohols, by using a chiral 
[CoIII(salen)] complex 90 (scheme 41), ending in a highly enantioselective kinetic resolution. 
Bio-inspired chemistry also gave good results, especially in the field of antibody catalysts, as 
reported by Lerner et al. in 199366 and Wilson et al. in1999.67
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HO
O
1-2 mol% 90
TBME
(+/-)-89
50%, 93% ee
N N
O O
tBu
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tBu
Co
OAc
HH
90
HO
O
O
OH
46%, 95% ee
 
 
Scheme 41: [CoIII(salen)] catalyst: kinetic resolution of epoxy alcohol 89. 
 
 Hapten 92 was designed to mimic the disfavoured transition state 91 of the endo 
reaction and was used to induce corresponding antibodies. The cationic nitrogen was 
supposed to induce one or more amino acid residues that stabilize the carbocation appearing 
in the transition state 91, while the anionic oxygen atom may induce positively charged amino 
acids to assist in the acid-catalyzed ring opening of the epoxyde (scheme 42). Induced 
antibody catalysts were screened and several gave excellent regioselectivity as well as 
stereoselectivity. 
Recently, Jamison et al. published an epoxide-opening cascade for the construction of 
ladder polyether marine natural products,68 such as brevetoxin B (scheme 40).  
 
O
H
R
O
O
H
R
OH δ+
δ-
'H+' O
R
HO
91
R= H, OCH3, NHCOCH3 Baldwin's disfavouredproduct
HN
N+
-O
O
KLH
O
92
O
H
O
R1 δ+
δ-
-q
base
acid
 
 
Scheme 42: Hapten 92 used to mimic transition state 91 and induce antibody catalysts [KLH = 
keyhole limpet hemocyanin].  
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 Under optimized conditions in water at pH = 7.0, a ration of 11:1 in favour of the 
pyran product 95 was accomplished (scheme 43). Though the epoxy alcohol 93 used in this 
study is templated towards pyran formation, it remains a rare example in which neither 
directing groups nor metal/antibody catalysts were used. 
 
HO
O
O
H
H
O
O
H
H
HO
H
H
O
H
H
HO
H
9394, 'THF' 95, 'THP'  
THP:THF
95:94
THP:THF
95:94
 
 
Scheme 43: Cyclisation of templated epoxy alcohol 93 – pH and solvent optimization. 
  
 From this last report, we were encouraged to envisage chromanol formation via an 
epoxide ring opening, which led to a retrosynthetic approach depicted on scheme 44. α-
Tocopherol 15 could then be obtained via hydroxy chromanol 96, endo product of the 
cyclisation of chiral epoxide 97, which could be formed from the allylic precursor 98. 
 
HO
O Rp
15
O
O Rp
OH O
OH Rp
O
96 97
O
RpO
PG2
PG1PG1 PG1
98
Rp: H2C 4' 8' 12'  
 
Scheme 44: Retrosynthetic proposal leading to α-tocopherol 15. [PG1, PG2=protecting groups]  
In all following schemes, figures and tables, Rp=(4’R,8’R)-4’,8’,12’-trimethyltridecanyl.
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First of all, this approach required the asymmetric epoxidation of a trisubstituted, 
unfunctionalized olefin. The stereoselective synthesis of epoxides has been extensively 
investigated69 including the direct asymmetric epoxidation of alkenes.70 But most of these 
methods are substrate dependent, and hence were not considered to be suitable for our 
strategy.  
It was the case of Sharpless epoxidation,70a which needed an allylic alcohol to induce 
high stereoselectivities, in the presence of a chiral titanium complex. Nevertheless, precursor 
99, easily available from our fridges, was submitted to Sharpless conditions, using TBHP as 
oxidant (scheme 45), that afforded epoxide 100 with a moderate 50% de. We expected the 
titan complex to bind to the phenolic oxygen, which was obviously too far away from the 
double bond to induce a reasonable de. 
 
OH
O
Rp
OH
(-)CamphO
Rp
O
100, 50% de99
Ti(OiPr)4, TBHP, MS (4A)
(-)-diethyl tartrate, CH2Cl2
-20 °C, 17 h
20%
O
O
O
 
Scheme 45: Sharpless epoxidation of 99. 
 
In 1997, Shi et al. reported the use of a chiral fructose-derived 101 catalyst in the 
epoxidation of trans disubstituted and trisubstituted olefins71,72 (scheme 46). The wide scope 
of reactive olefin substrates made it the catalyst of choice. 
R1
R2
R3
R1
R2
R3
O
O O
O
O
O
O
101
H2O2, MeCN  
 
Scheme 46: Shi epoxidation in MeCN, using H2O2 as a co-oxidant. 
 
 Several factors govern the selectivity of this reaction, in particular the size of the 
olefin substituents is significant such that small R1 and large R3 groups gave the best 
enantioselectivities.71  
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Further, Shi’s mechanism based correlation71 between catalyst configuration and product 
stereochemistry suggested that we could obtain the desired epoxide using ent-101 rather than 
the commercially available 101.73 In view of the given structure of our synthetic intermediate 
variation of the protecting groups at the hydroquinone was the only choice to enhance the 
difference in size of the substitutents at the trisubstituted double bond. 
 
3.2.2. Synthesis of allylic precursors 106. 
 
Precursors for the asymmetric epoxidation were synthesized starting from commercially 
available hydroquinone 50, and E-(R,R)-phytol 34 (>98.5:1.5 E:Z, DSM Nutritional 
Products). Monoprotection of 50 with bulky silylethers74 were accomplished in high yields to 
afford 102a, 102b and 102c, which could then react with phythyl bromide 103 (formed in situ 
from 34), yielding 104a (81%), 104b (97%) and 104c (94%), as depicted on scheme 47. 
Double Claisen rearrangement of phytyl ethers75 produced corresponding mono-protected 
phenols 105a, 105b and 105c, in moderate yields, due to isomerisation of double bond.  
OH
OH
R-Cl, N-imidazole
DMF, -35 °C to rt
OH
OR
R = TBS, 102a, 88%
TIPS, 102b, 85%
DPS, 102c, 94%
Rp
Br
, NaH
DMF, 0 °C to rt
O
OR
Rp
TBS, 104a, 81%
TIPS, 104b, 97%
DPS, 104c, 94%
R =
BF3-Et2O, CH2Cl2
-35 °C, 10' RpOR
HO
R = TBS, 105a, 66%
TIPS, 105b, 59%
DPS, 105c, 60%
50
103
 
Scheme 47: Synthesis of 105a, 105b and 105c via a double Claisen rearrangement. 
 
 A ratio of 9:1 E:Z was observed on the crude materials, but purification of E-isomers 
was difficult and led to the loss of materials. Nevertheless, pure E-compounds were necessary 
to investigate asymmetric epoxidation, and thus E:Z ratio determinations were carefully done 
either by 1H NMR for 105a and 105b, or by HPLC for 105c (figure 12). Three successive 
column chromatography allowed the isolation of pure E-isomer (>98.5:1.5, E:Z). 
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H
H
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DPS
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Figure 12: Determination of E/Z ratio. a) 1H NMR of 105a, δ(C9-CH3), b) 1H NMR of 105b, 
δ(C9-CH3), c) HPLC of 105c. 
 
Various modifications at the remaining phenol were possible, giving access to 
different precursors, as shown on scheme 48. Protection of 105a with TIPS- silyl ether, 
afforded 106a in 60% yield, whereas same procedure on 105b afforded 106c in 82% yield.  
 
RpO
HO
TBS
TIPSCl, NaH
THF, 0 °C to rt
60%RpO
TIPSO
TBS
(-)-CamphCl, DMAP
CH2Cl2, rt
99%
RpO
(-)-CamphO
TBS
105a106a 106b
RpO
HO
TIPS
TIPSCl, NaH
THF, 0 °C to rt
82%RpO
TIPSO
TIPS
MeI, NaH
DMF, 0 °C to rt
85%
RpO
MeO
TIPS
105b106c 106d
RpO
HO
DPS
DPSCl, NaH
DMF, 0 °C to rt
90%RpO
DPSO
DPS
MeI, NaH
DMF, 0 °C to rt
93%
RpO
MeO
DPS
105c106e 106f  
Scheme 48: Synthesis of precursors 106a-f. [Camph=camphanoyl] 
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(-)-Camphanoyl ester 106b was also envisaged, and formed from (-)-camphanoyl 
chloride in almost quantitative yield. Small protecting groups were also investigated, and 
protection of 105b and 105c to their methyl ethers afforded 106d and 106f in 85 % and 93% 
yield respectively. Finally, bis-DPS precursor 106e was formed in good yield from 105c.  
 
Other variations at the hydroquinone were synthesized, such as benzyl ether derivative 
106g, obtained from TIPS-deprotection of 106d, followed by reaction with benzyl chloride 
(scheme 49). 9-Methylanthracenyl derivative 106h was synthesized from 106b, after TBS-
deprotection using TBAF, and coupling with 9-methylanthracenyl chloride. Finally, MOMO-
/TIPSO- precursor 106i was obtained via mono-protection of hydroquinone 50 with MOMCl, 
followed by protection with TIPSCl to afford 107 in 14%. Finally, coupling of phytyl bromide 
103, on the lithiated bis-protected hydroquinone,34 yielded 106i in 74% (scheme 49). 
 
RpO
(-)-CamphO
TBS
106b
RpO
MeO
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1) TBAF, THF, rt
95%
2) Benzyl chloride, NaH
DMF, 0 °C to rt
90 %
RpO
MeO
106g
1) TBAF, THF, rt
98%
2) 9-methylanthracenyl
NaH, DMF, 0 °C to rt
87%
RpO
(-)-CamphO
106h
OH
OH
1) MOMCl, NaH
NaH, DMF
2) TIPSCl, NaH
DMF
14%50
OTIPS
OMOM
107
Rp
Br
nBuLi, TMEDA, Et2O, 0 °C
then , CuBr
Et2O, -20 °C to rt
74%
RpO
TIPSO
MOM
106i
103
 
Scheme 49: Synthesis of 106g, 106h and 106i. 
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3.2.3. Asymmetric epoxidation of precursors 106. (Based on Dr. A. Buss work) 
 
In order to synthesize α-tocopherol 15 R-configured at C-2 the preparation of the 
epoxide 108 must be accomplished. According to systematic experiments by Shi, the 
organocatalyst ent-101 was considered to be suitable.71 The synthesis of ent-101 has been 
described by Shi et al. in 2006,73 starting from L-sorbose. Precursors 106a-i were then 
submitted to Shi epoxidation procedure and converted to the corresponding epoxides 108a-i, 
using hydrogen peroxide as co-oxidant in acetonitrile (scheme 50). It was proposed that 
perimidic acid 109, generated from the reaction between MeCN and H2O2, is the actual 
oxidant, thus producing dioxirane 110. 
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Scheme 50: Shi epoxidation mechanism – Epoxidation of 106a-i to 108a-i. 
 
Results are presented in table 3, showing moderate to good yields, and good to 
excellent diastereoisomeric excesses. Two trends could be outlined from these results, relative 
to the size of the protecting groups: higher de’s were observed with (i) small R1 and (ii) bulky 
R2. Thus, DPS- and MeO- ethers gave an excellent 97% de, in 81% yield (entry 6). Note that 
the diastereoisomeric excesses were determined by comparison with references racemic at the 
epoxide, prepared by mCPBA epoxidation of 106a-i in CH2Cl2. 
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OR2
R1O
Rp OR2
R1O
Rp
O
108a-i106a-i
ent-101 (40 mol%)
H2O2, ACN:EtOH:CH2Cl2
8
9
 
entry epoxide R1 R2 yielda (%) deb (%) 
1 108a TIPS TBS 76 73 
2 108b (-)-Camphc TBS 73 79 
3 108c TIPS TIPS 75 82 
4 108d Me TIPS 78 85 
5 108e DPS DPS 81 91 
6 108f Me DPS 81 97 
7 108g Me Benzyl 87 73 
8 108h (-)-Camphc Anthrd 76 74 
9 108i TIPS MOM 62 66 
 
Table 3: Shi epoxidation of 106a-i. [General conditions: 1 equiv 106, 0.4 equiv ent-101, 5.4 equiv H2O2 
(30% aq) in a buffered (2 M K2CO3 / EDTA) mixture of MeCN:EtOH:CH2Cl2 (1:1:2) at 0 °C, for 10 h. a Isolated 
yields. b Determined by chiral HPLC (8S,9S). c (-)-camphanoyl. d 9-methylanthracenyl.] 
 
 
3.2.4. “Anti-Baldwin” epoxide ring opening. 
3.2.4.1.Preliminary studies on γ-tocopherol precursor. 
 
We initially started our studies on easily the available precursor 111,76 and took 
advantage of the chiral (-)-camphanoyl group for HPLC analysis of different products and 
isomers that could be formed during cyclisation (scheme 51). 2,3-Dimethylhydroquinone 68 
and E-(R,R)-phytol 34 were then converted to 99 in 6 steps, with 30% overall yield. Finally, 
treatment of 99 with mCPBA in CH2Cl2, afforded 111 in 80% yield, as a 1:1 mixture of 
diastereoisomers at the epoxide. 
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Scheme 51: Synthesis of cyclisation precursor 111. 
 
Jamison’s conditions were firstly considered,68b and 11 was heated at 50 °C in MeOH, 
in a sealed tube for 18 h (scheme 52). Full conversion of epoxide was observed, but to our 
surprise, the 5-membered ring 112 was almost exclusively formed, in 91% yield (99% 
conversion by HPLC), following Baldwin’s rules.  
 
RpOH
(-)CamphO
O
111
MeOH, 50 °C
Sealed tube
28 h
91% (99% conv.)
(-)CamphO
O
OH
Rp
112  
Scheme 52: Cyclisation of epoxide 111 under Jamison’s conditions. 
 
Basic conditions would probably also led to the ‘furan’ product, and hence we turned 
to acidic medias. Several conditions were screened in order to favour the ‘pyran’ product as 
presented in table 4. The different products formed were analysed by HPLC (Protonsil® 120-
5-CN, 3% iPrOH in n-heptane, 1 mL/min, 280 nm, 25 °C), which allowed a clean separation 
of epoxide 111 (15.1 and 15.9 min), pyran product 113 (22.9, 23.3, 24.3 and 25.8 min) and 
furan product 112 (17.5 and 18.4 min). In general, the 6-membered ring was favoured, and 
several conditions gave remarkable regioselectivity (entries 6, 11, 15, 18, 19, 20, 21) with 
excellent yields.  
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RpOH
(-)CamphO
O
111
(-)CamphO
O
OH
Rp
112
'H+' (-)CamphO
O Rp
OH
113  
entry acid solvent conversiona (%) ratio 113:112a
1b none MeOH 99 7:93 
2 1N HClaq MeOH:H2O (2:1) 75 84:16 
3 1N HClaq MeOH:H2O (3:1) 75 82:18 
4 1N HClaq MeOH:H2O (4:1) 75 82:18 
5 1N HClaq EtOH:H2O (1:1) 45 75:25 
6 1N HClaq PCc:H2O (3:1) 93 90:10 
7 1N HClaq DMF:H2O (3:1) 69 82:18 
8 1N HClaq THF:H2O (3:1) 69 79:21 
9 1N HClaq Aceton:H2O (3:1) 77 84:16 
10 1N HClaq Toluene:H2O (3:1) 11 57:43 
11 1N HClaq MeCN:H2O (3:1) 90 89:11 
12 6N HClaq MeCN:H2O (3:1) 73 89:11 
13 TFA (20%mol) CH2Cl2 83 74:26 
14 TFA (20%mol) MeCN <10 nd 
15 TFA (20%mol) MeCN:H2O (3:1) 85 89:11 
16 (+)-CSAd (1 eq.) CH2Cl2 99 59:41 
17 (+)-CSA (20%mol) CH2Cl2 99 57:43 
18 (+)-CSA (1 eq.) MeCN 99 94:6 
19 (+)-CSA (1 eq.) MeCN:H2O (3:1) 99 89:11 
20 AlCl3 (0.8 eq.) CH2Cl2 91 93:7 
21 Cu(OTf)2 (0.2 eq.) CH2Cl2 95 95:5 
 
Table 4: Screening of acidic conditions to favour pyran 113. [General conditions: 10.5 μmol 111, 3 
mL solvent, RT, 24h. [a] Determined by HPLC at 280 nm. [b] Reaction carried out at 50 °C for in a sealed tube. [c] 
propylene carbonate. [d] camphorsulfonic acid.] 
 
It is important to note that not only the formation of the 6-membered ring is required 
but also inversion of configuration during epoxide opening. This aspect was investigated by 
correlation of NOESY experiments and HPLC analysis of the 6-membered ring product 113. 
Cyclisation of 111 to its pyran product could afford 4 diastereoisomers, as depicted in scheme 
53. Entry 3 (table 4) was firstly investigated, and 113 was isolated and submitted to NOESY 
experiments. It revealed a weak NOE between CH3 at C-2 and H at C-3, versus a strong NOE 
between proton at C-1’ and H at C-3, indicating a trans relationship of the hydroxyl group and 
the side chain (scheme 53).  
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This result indicates that the reaction mainly proceeded with inversion of 
configuration, since only (2S,3R)-113 and (2R,3S)-113 would fit with the NOESY results.  
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(-)CamphO
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O
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H
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Scheme 53: Cyclisation of 111 to its 4 possible diastereoisomers – NOESY experiments 
revealed that (2S,3R)-113 and (2R,3S)-113 are mainly formed, under inversion of 
configuration. 
 
HPLC chromatogram showed 4 peaks in the region of 25.0 min, which would 
correspond to the 4 diastereoisomers of 113 (figure 13). In correlation to the NOESY 
experiment, peaks at 24.3 and 25.8 min were assigned to (2S,3R)-113 and (2R,3S)-113, 
whereas peaks at 22.9 and 23.3 min were assigned to (2R,3R)-113 and (2S,3S)-113. 
Accordingly, ≥96% of the reaction proceeded by inversion of configuration 
 
 
(2S,3R)-113 and (2R,3S)-113 
(2R,3R)-113 and (2S,3S)-113 
Figure 13: HPLC chromatogram of 113 (table 4 - entry 3). 
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Coming back to our first screening, the ratio between (2S,3R)/(2R,3S)-113 and 
(2S,3S)/(2R,3R)-113 were re-investigated by HPLC, especially for entries 6, 11, 15, 18, 19, 
20 and 21 (table 4) which gave excellent regioselectivities (table 5). 
 
RpOH
(-)CamphO
O
111
(-)CamphO
O
OH
Rp
112
'H+' (-)CamphO
O Rp
OH
113  
entry acid solvent conversiona (%) ratio 113:112a ratio (2S,3R)/(2R,3S) : (2S,3S)/(2R,3R) 
6 1N HClaq PCb:H2O (3:1) 93 90:10 92 :8 
11 1N HClaq MeCN:H2O (3:1) 90 89:11 92 :8 
15 TFA (20%mol) MeCN:H2O (3:1) 85 89:11 90 :10 
18 (+)-CSAc (1 eq.) MeCN 99 94:6 70 :30 
19 (+)-CSA (1 eq.) MeCN:H2O (3:1) 99 89:11 92 :8 
20 AlCl3 (0.8 eq.) CH2Cl2 91 93:7 90 :10 
21 Cu(OTf)2 (0.2 eq.) CH2Cl2 95 95:5 68 :32 
 
Table 5: Investigation relative to the inversion of configuration. [General conditions: 10.5 μmol 
111, 3 mL solvent, RT, 24h. [a] Determined by HPLC at 280 nm. [b] propylene carbonate. [c] camphorsulfonic 
acid.] 
 
The main feature that could be outlined from this table concerned the importance of 
water in the reaction: under anhydrous conditions, the amount of reaction which proceeded 
with inversion of configuration dramatically decreased – the worst case was reached for the 
most regioselective Lewis acid (entry 21). It was clearly illustrated when using (+)-CSA in 
dry MeCN (entry 18), leading to a ratio (2S,3R)/(2R,3S):(2S,3S)/(2R,3R) of 7:3, and 
compared with a similar reaction performed in MeCN:H2O (entry 19), which gave a ratio of 
92:8. 
3.2.4.2. Application to the cyclisation of epoxide from 108f. 
 
The results shown in Table 5 led us to apply conditions as entry 11 to the cyclisation 
of epoxide originating from 108f. Deprotection of the bulky DPS silylether was first 
attempted using usual conditions, that are TBAF in THF (scheme 54). To our surprise, 
deprotection occurred, but the free phenol 114 directly cyclized to the furan ring 115, in 99% 
yield. It was not possible to isolate or ‘see’ 114 on TLC during the reaction, even by lowering 
the reaction temperature to 0 °C or above.   
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Though in principle chiral 115 is an interesting product it was not useful for our 
purpose, inter alia since the anti-oxidant activity of such benzo-dihydro-furans were estimated 
by Smith et al.77 to be only 5% of that of α-tocopherol. 
 
RpO
DPS
MeO
108f
O TBAF, THF
rt, 1 h, 99%
MeO
O Rp
OH
115
RpOH
MeO
O
114  
Scheme 54: TBAF deprotection of 108f : direct cyclisation to furan product 115. 
 
To avoid the cyclisation to the undesired 5-membered ring, acidic conditions were 
envisaged, to yield the desired pyran product. Two recent publications from Nicolaou et al.78 
and Ye et al.79 reported the use of HCl for silylether deprotection of aromatic substrates, and 
substrate 106b, having chiral (-)-camphanoyl ester, was used to test these conditions. 
Treatment with mCPBA afforded (rac,R,R)-108b, in 91% yield, racemic at the epoxide 
(scheme 55). Aqueous HCl was used in MeCN, but neither the free phenol 116 nor the pyran 
product 117 were obtained, and despite a fast cleavage of the TBS group, the epoxide was not 
stable under these conditions. Indeed, 118 and 119 were mainly observed, in different ratios, 
resulting in the epoxide opening by Cl- or H2O (scheme 55). 
 
RpO
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(-)CamphO
(rac,R,R)-108b
OmCPBA
CH2Cl2, 1 h
91%
RpO
TBS
(-)CamphO
106b
1N HCl : MeCN (3:1)
or
6N HCl : MeCN (3:1)
or
1N HCl: MeCN:TFA (3:1:0.2)
RpOH
(-)CamphO
O
(-)CamphO
O Rp
OH
116 117
RpOH
(-)CamphO
X
OH
X = OH, 118
X = Cl, 119  
Scheme 55: Attempts for deprotection of silylether under acidic conditions. 
 
Hydrochloric acid solution in anhydrous organic solvents such as MeOH, dioxane or 
Et2O were then tested, but the epoxide was also unstable, and reactions led to epoxide 
opening, either by addition of Cl- or MeOH (scheme 56). 
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Scheme 56: TBS- deprotection using anhydrous HCl. 
 
Finally, Barrett et al.80 reported in 2007 the use of acetic acid in combination with 
TBAF, in a 1:1 ratio, for the deprotection of aromatic TBSO- groups on resorcinarenes, which 
gave excellent results in our case, after a slight optimization of the conditions. Then, treatment 
of (rac,R,R)-108b with TBAF:AcOH (1:10), in THF at rt, afforded the free phenol 116 in 
79% yield (scheme 57). This procedure was applicable to chiral epoxide 108f, which was 
successfully deprotected to afford 114 in 82% yield. 
 
RpO
TBS
(-)CamphO
(rac,R,R)-108b
O
RpOH
(-)CamphOTBAF (4 equiv)
AcOH (40 equiv)
THF, rt, 36 h
79%
O
116
RpO
DPS
MeO
108f
O
RpOH
MeOTBAF (4 equiv)
AcOH (40 equiv)
THF, rt, 36 h
82%
O
114  
Scheme 57: Deprotection of TBS and DPS group using TBAF:AcOH (1:10) 
 
 Best cyclisation conditions were tested on 114 (table 4, entry 11), but despite an 
excellent regioselectivity in preliminary case, treatment with 1N HCl : MeCN (1:3) afforded a 
mixture of pyran 121 and furan 115, in a 1:1 ratio (scheme 58). 
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RpOH
MeO
O
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O Rp
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Scheme 58: Cyclisation of 114 using optimized conditions. 
 
This result, unlikely predictable, could be input to the additional aromatic methyl of 
the α-tocopherol series, in comparison to the γ-tocopherol precursor 111, used for our initial 
screening. It implied that an additional investigation to favour the “anti-Baldwin” product in 
the α-tocopherol series was necessary to get reasonable selectivity. 
 
3.2.4.3. Optimisation of conditions in the cyclisation of α-tocopherol precursor 116. 
 
The epoxide 116 was then synthesized starting from 106b, which was treated with 
TBAF in THF, to afford free phenol 122 in 94% yield (scheme 59), which epoxidation using 
mCPBA in CH2Cl2 yielded 116 in 92%, racemic at the epoxide. Jamison’s conditions (MeOH, 
50 °C), which were furan-driving in the preliminary case, were tested with precursor 116, and 
with no surprise, produced the 5-membered ring 123 in 98% yield (99% conversion). Acidic 
conditions were then screened, in aqueous or anhydrous medias, and are reported in table 6. 
 
RpO
(-)CamphO
TBS
106b
TBAF, THF
rt, 1 h
94%
RpOH
(-)CamphO
122
mCPBA
CH2Cl2
92%
RpOH
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O
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Scheme 59: Synthesis and screening of precursor 116. 
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RpOH
(-)CamphO
O
116
(-)CamphO
O
OH
Rp
123
'H+'
(-)CamphO
O Rp
OH
124  
Entry acid (A) solvent (S) conva (%) ratio 123:124a
1b none MeOH 99 98:2 
2 1N HClaq MeCN:H2O (3:1) 94 51:49 
3 1N HClaq THF:H2O (3:1) 90 67:33 
4 1N HClaq MeOH:H2O (3:1) 92 56:44 
5 1N HClaq Aceton:H2O (3:1) 92 58:42 
6 1N HClaq PCc:H2O (3:1) 97 51:49 
7 1N HClaq DMF:H2O (3:1) 90 57:43 
8 1N HClaq CH2Cl2:H2O (3:1) 95 80:20 
9 6N HClaq MeCN:H2O (3:1) 92 35:65 
10 12N HClaq MeCN:H2O (3:1) 94 37:67 
11 TFA (20%mol) MeCN:H2O (3:1) 99 49:51 
12 TFA (20%mol) CH2Cl2 99 72:28 
13 (+)-CSAd (1 equiv) MeCN:H2O (3:1) 99 47:53 
14 (+)-CSA (0.5 equiv) MeCN 99 40:60 
15 (+)-CSA (1 equiv) MeCN 99 40:60 
16 (+)-CSA (2 equiv) MeCN 99 38:62 
17 2M HClMeOH MeOH 98 62:38 
18 2M HClEt2O CH2Cl2 92 54:46 
19 0.5M HClEt2O MeCN 95 26:74 
20 1M HClEt2O MeCN 97 26:74 
21 2M HClEt2O MeCN 98 23:77 
 
Table 6: Screening of acidic conditions to favour pyran 124. [General experimental conditions: 5 
μmol 116, 1 mL of a S:A (3:1), rt, 15 h. a Determined by HPLC, not identified side products were <1% in each 
case. b Reaction carried out at 50 °C for 15 h in a sealed tube. c Propylene carbonate. d Camphorsulfonic acid.] 
 
Aqueous hydrochloric acid did not exhibit any regioselectivity, independent of the 
solvent used (entry 2-10), and even favoured the furan product 123 under biphasic conditions 
(entry 8). Organic acids such as TFA or (+)-camphorsulfonic acid (CSA) did not improve the 
selectivity, despite an excellent conversion of epoxide 116 (entries 11-16). Finally, anhydrous 
HCl was envisaged, either in MeOH or Et2O, and we were pleased to improve the formation 
of the pyran ring 124, reaching a 124:123 ratio of 77:23 and 98% conversion (entry 21). It is 
important to note the Table 5 and 6 are only distinct due to difference of one methyl group in 
the structure of the epoxide. Having in hand an efficient method for “anti-Baldwin” 
cyclisation of γ-epoxy alcohols of type 116, synthesis of α-tocopherol was completed. 
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3.2.5. Synthesis of (R,R,R)-α-tocopherol 15. 
 
Chiral epoxide 114 was treated with our optimized conditions (table 6, entry 21), to 
afford pyran product 121 in 79% yield and 99% conversion (scheme 60). NOESY experiment 
of 121 also revealed a weak NOE between CH3 at C-2 and H at C-3, versus a strong NOE 
between proton at C-1’ and H at C-3, indicating a trans relationship of the hydroxyl group and 
the side chain.  
 
O
OH
H
H
H
MeO Strong NOEMeO
RpO
H
O
2M HClEt2O
MeCN, rt, 7 h
79% (99% conv)
114 121  
Scheme 60: Cyclisation of chiral epoxide 114 – NOESY experiments indicated a trans 
relationship between the hydroxyl group and the side chain. 
 
In addition, HPLC analysis of 121 allowed the separation of the 4 possible 
diastereoisomers, which identity was confirmed by the cyclisation of (rac,R,R)-114, racemic 
at the epoxide, and the cyclisation of (rac,R,R)-114’, racemic at the epoxide, with a ratio 
trans:cis 9:1 (scheme 61).  
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Scheme 61: Cyclisation of (rac,R,R)-114 and (rac,R,R)-114’, if the reaction proceeded with 
inversion of configuration. 
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Indeed, if the reaction would be with inversion of configuration, cyclisation of 
(rac,R,R)-114 should have mainly formed 2 products, whereas cyclisation of (rac,R,R)-114’, 
should have produced 2 additional compounds, corresponding to 10% of cis-epoxide. On the 
other hand, if the reaction wouldn’t be with inversion of configuration, the 4 diastereoisomers 
should all have been observed in both cases. HPLC analysis finally corresponded to the first 
case, meaning that the epoxide ring opening proceed with inversion of configuration (figure 
14). The diastereoisomeric excess of 121 was then determined to be 93%, slightly lower than 
for epoxide 108f, due to the extent carbenium formation during the epoxide ring opening. 
 
a) (2S,3R)  b) c) 
 (2R,3S) 
 
 (2R,3R) &  
(2S,3S) :  
~10%  
 
 
 
 
Figure 14: HPLC chromatograms from: a) cyclisation of (rac,R,R)-114; b) cyclisation of 
(rac,R,R)-114’; c) cyclisation of 114. 
 
Removal of the hydroxyl group was firstly envisaged by reductive elimination with 
hydrides. Pyran 121 was then converted to its mesylate derivative 126, or to its tosylate 
derivative 128, in good yields (scheme 62). But unfortunately, none of them could be cleaved 
either by using LiAlH4 or superhydride® (LiBEt3H), as already reported by Woggon et al.31 
This result could be explained by the steric hindrance through the adjacent tertiary ether, 
which blocks the reacting side. Inversion of the configuration at C-3 was envisaged, to 
unblock the reactivity of hydrides, but conversion of the hydroxyl group to its chloride or 
iodide analogues was not possible, since elimination of triphenylphosphine oxide occurred, 
yielding chromene 125, as a major side-product. The main disadvantage of chromene such as 
125, comes from the isomerisation at chiral C-2, due to a Cope rearrangement which can be 
induced by T > 250 °C and/or light.  
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Nevertheless, milder conditions, that are low temperature and absence of light, were 
applied, and elimination of TsO- with KOtBu at 0 °C in the dark, followed by Pd/C-
hydrogenation, afforded 84 in 96% yield from 128, with 93% de (2R,4’R,8’R). Finally, 
cleavage of the methoxy ether could be performed without any loss in chirality, by means of 
BF3.Me2S/AlCl3,46 giving (R,R,R)-α-tocopherol 15. 
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Scheme 62: Removal of the hydroxyl group - Tandem TsO- elimination / hydrogenation of 
128. 
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3.3. Lewis acid mediated cyclisation – 1,4-oxa-addition. 
3.3.1. Introduction 
3.3.1.1. Asymmetric Michael reactions. 
 
The well known Michael reaction, i.e. the addition of a nucleophile to an α,β-unsaturated 
carbonyl acceptor, belongs to the classical carbon-carbon bond forming reactions (scheme 
63). Since newly formed compounds present a stereogenic center, considerable efforts were 
devoted to the development of efficient stereoselective methods, either by starting from chiral 
Michael acceptor, like Oppolzer’s chiral bornane sultam auxiliaries,81 by using a chiral 
nucleophile such as chiral cuprates,82 or, more recently, by the use of chiral catalysts.83
 
RR1 Nuc- R1 R
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R*
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R1
O
R
R1 R
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Nuc*-
Chiral metal catalysts
R1 R
O
ML*
R1 R
ONucO
 
Scheme 63: Michael reaction – Possible strategies for asymmetric additions [Nuc = nucleophile]. 
 
Over the past years, several groups have focused in the development of new and efficient 
chiral metal complexes, able to promote high enantio- and diastereo-selectivities in Michael 
reactions. Various transition metals were tested and successfully used, such as nickel,84 
cobalt,85 rhodium,86 aluminium87 or heterobimetallic complexes,88 but copper remained the 
most noted, together with a broad variety of chiral ligands. Three main families of ligands 
used in copper-catalyzed 1,4-additions could be described: binaphtalene-derived ligand 
(figure 15), TADDOL-derived ligands (figure 16), and oxazoline-derived ligands (figure 17).  
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Figure 15: Binaphtalene-derived ligands. 
 
Although 1,1’-binaphtalene-2,2’-diol (BINOL) and 2,2’-bis(diphenylphosphino)-1,1’-
binaphtalene (BINAP) belong to the most frequently used chiral ligands, several binaphtalene 
derived ligand have been synthesized, such as 129 and 130, by Feringa et al.89 in the 1990’s, 
which were, in combination with a CuII salt, the first systems giving high enantioselectivities 
with acyclic Michael acceptors. BINOL oxazoline phosphites of type 131, by Pfaltz et al. in 
1997,90 and bis-phosphorous amidate 132, by Waldmann et al.91 in 2000 have also proven to 
be really efficient ligands. 
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Figure 16: TADDOL-derived ligands. 
 
TADDOLs ligands (α,α,α’,α’-tetraaryl-1,3-dioxolane-4,5-dimethanols) such as 133 were 
initially used in 1997 by Seebach et al.,92 catalyzing the addition of an alkyl magnesium 
chloride to a cyclic Michael acceptor. Alexakis et al. exploited these scaffolds in the late 
1990’s,93 thus leading to 134 and 135. 
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Figure 17: Oxazoline-derived ligands. 
 
Chiral oxazolines, readily available from their corresponding natural or unnatural amino 
acids, were firstly used in 1993, when Pfaltz et al.94 employed  the Cu-thiophenolate 136 for 
addition reactions to cyclic enones, realizing enantiomeric excesses up to 87% ee. One of the 
most versatile ligand used in asymmetric Michael reactions was bis-oxazoline 137, which was 
introduced by Scolastico et al. in 1996,95 and extensively studied by Evans et al.96 in 1999 
and 2000. 
 
3.3.1.2. The oxa-Michael addition.97 
 
In contrast to the important work related to C-C Michael additions, less attention has been 
shown for the hetero-Michael version, such as addition of amines,98 thiols,99 phosphorous100 
and alcohols as nucleophiles. This holds especially true for the oxa-Michael addition (scheme 
64), despite the first example was reported by Loyld in his work towards the synthesis of 
malic acid in 1878.101  
 
R O
H
R O-
R2
R1 O
X R2
O-
X
R1
RO
H+
Base
Base-H+
R2
O
X
R1
RO
*
*
 
Scheme 64: Mechanism of the oxa-Michael reaction. 
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Nevertheless, considerable progress has been made in the development of asymmetric 
oxa-Michael reactions within the past years, reaching high levels of chiral inductions. One 
way of achieving such a reaction consists of the use of chiral hydroxide equivalents. Enders 
and co-workers, pioneers in this field, reported the use of chiral N-formylnorephedrine 138 as 
auxiliary,102 which could react on a variety of nitroalkenes, further transformed in 2-amino 
alcohols, important chiral scaffold in natural products (scheme 65). 
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Scheme 65: Oxa-Michael addition of N-formylnorephedrine 138 on nitroalkenes. 
 
Recently, Dixon et al. developed another alternative to the synthesis of these valuable 
amino alcohols,103 by the use of 6-alkyl-δ-lactol 139 (scheme 66). Indeed, addition of 139 to 
nitroalkenes, in the presence of [18]crown-6, afforded the corresponding Michael products in 
high yields and up to >98% de. Although this reaction was originally developed for 
nitroalkenes as acceptors, it was recently extended to other systems such as α,β-malonate 
esters, unsaturated α-keto esters, α,β-disubstituted nitroolefins and activated α,β-unsaturated 
esters. 
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Scheme 66: Additions of 6-alkyl-δ-lactol 139 to nitroalkenes. 
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As an alternative to the use of chiral auxiliaries, catalytic enantioselective oxa-Michael 
reactions offer another straightforward strategy. Despite the rapid development of efficient 
organocatalysts in intermolecular104 as well as in intramolecular105 oxa-Michael reactions, 
examples of chiral Lewis acid remain rare. Jacobsen et al. applied their well-established 
(salen)aluminium complexes to the addition of oximes on α,β-unsaturated imides,106 as 
depicted on scheme 67. 
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Scheme 67: Addition of oximes to α,β-unsaturated imides, using (salen)aluminium 
complexes. 
 
The general mechanism of Lewis acid mediated oxa-Michael reaction is depicted on 
scheme 68. Coordination of the metal to the carbonyl group occurs and increases the 
reactivity of the Michael acceptor. The nucleophile can then react to form 140, in a 
prototropic equilibrium with 141, finally leading to enol 142 and regenerating the chiral metal 
complex. 
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Scheme 68: Proposed mechanism for the Lewis acid catalyzed oxa-Michael reaction. 
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Recently, Joergensen et al. also developed the asymmetric synthesis of chromans by 
embedding an oxa-Michael reaction in a domino process,107 using a bis-oxazoline magnesium 
complex (scheme 69). Nevertheless, substrate scope was limited since both an electron 
donating group on the phenol and the aromatic moiety on the acceptor were essential for high 
yield and enantioselectivity. 
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Scheme 69: Synthesis of chiral chromans, using a bis-oxazoline magnesium catalyst. 
 
Recently, Wang et al. reported a chiral N,N’-dioxide-NiII complex for the highly 
enantioselective synthesis of flavanones108 (scheme 70). The great advance by this group 
concerned the wide scope of substrate tolerated by this catalyst, especially aliphatic 
substituents at the double bond, being one of the first example that afforded high yield and 
enantioselectivity. 
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Scheme 70: Chiral N,N’ dioxide NiII complex – Synthesis of flavanones. 
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However, no asymmetric oxa-Michael reaction leading to 2,2-disubstituted chromans or 
flavanones have been reported yet, and, in all the cases described herein, catalysts were 
substrate dependent. 
 
3.3.1.3. Design of the synthesis. 
 
Based on this reaction, and on the broad literature available on chiral Lewis acid 
catalysts, we designed a retrosynthetic approach to the formation of the chromanol ring, as 
shown on scheme 71. It was based on a diastereoselective 1,4-oxa-addition on the α,β-
unsaturated carbonyl derivative, the phenol acting as nucleophile. By using a chiral metal 
complex, we expected a complexation at the oxygen of the carbonyl group, leading in a 
stereoselective addition of the phenol. 
O
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Rp O
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15
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Scheme 71: Retrosynthetic design via a diastereoselective oxa-Michael addition. [M = metal, L* 
= chiral ligand, R = protecting group, Rp=(4’R,8’R)-4’,8’,12’-trimethyltridecanyl] 
 
 
3.3.2. Synthesis of cyclisation precursor. 
 
 
Initial studies were conducted in the γ-tocopherol series, and cyclisation precursor 143 
was firstly envisaged. Its synthesis was designed from 2,3-dimethylhydroquinone 68 and E-
(R,R)-phytol 34, and two coupling strategies were considered: (1) a Friedel-Crafts (F-C) 
acylation, (2) a Grignard reaction (scheme 72). The acylation route would need a bis-protected 
hydroquinone and the acyl chloride 144 derived from phytol 34, whereas the Grignard 
pathway would require the bromo-hydroquinone and E-(R,R)-phytal 145. 
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Scheme 72: Retrosynthetic strategies for the formation of 143. [PG, R1, R2=protecting groups] 
 
Orthogonal protection of the hydroquinone would be advantageous to selectively 
unprotect the phenolic oxygen involved in the cyclisation; however, first investigations were 
conducted on symmetric protected hydroquinone, i.e. R1=R2. 
 
3.3.2.1. Friedel-Crafts acylation 
 
The well known Friedel-Crafts acylation, discovered in 1877,109 consists on the addition 
of an acyl chloride to an aromatic moiety, catalyzed by a Lewis acid. As the product contains 
a carbonyl group, it deactivates the aromatic ring, and avoids successive acylations. A model 
substrate was firstly envisaged, in order to test the synthetic route, and commercially available 
3-methyl-crotonic acid 146 was selected (scheme 73). Hydroquinone 68 was easily protected 
to its bis-methylether 148 and to its bis-MOM ether 150, in 87% and 88% yield respectively, 
and different F-C acylation methods were screened. 
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Scheme 73: Synthesis of bisprotected hydroquinones 148 and 150, and its F-C coupling. 
 
Acyl chloride 147 was generated in situ from reaction between acid 146 and oxalyl 
chloride in diethylether,110 and allowed to react with bis-protected hydroquinones using 
different Lewis acids. In both cases, it turned out that the use of POCl3/ZnCl2111 or 
POCl3 3/AlCl 112 was not successful and led to unreacted starting materials, or unidentified 
side-products. Despite these disappointing results, by switching to TiCl4 2 2, in CH Cl 113 the 
desired bis-OMe product 149 was obtained in 42% yield, but surprisingly, reaction with bis-
MOM hydroquinone 150 led to several byproducts and no F-C coupling was observed. One of 
the major side-product, 2,3-dimethyl quinone 151, probably came from the cleavage of the 
MOM- ether that could be achieved in the presence of a strong Lewis acid.114
 
Having found conditions that allowed the formation of the bis-OMe F-C product 149, it 
was applied to E-(R,R)-phytylic acid 152, which was synthesized from E-(R,R)-phytol 34. 
Oxidation with activated MnO2 in CH2Cl2 afforded E-(R,R)-phytal 145 in 82% yield, further 
oxidized to the acid, using a mixture of NaClO2 and NaH2PO4 in tBuOH:H2O, that yielded 
152 in 72%, as a single isomer (scheme 74).  
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Scheme 74: Synthesis of phytylic acid 152 and F-C coupling with bis-OMe hydroquinone 68. 
 
Thus, F-C coupling of 68 with in situ formed acyl chloride 144, in the presence of a slight 
excess of TiCl4, afforded the desired product 153 in 51% yield as a mixture of E- and Z-
isomers. It could be rationalized by a possible equilibrium, catalyzed by a Brönsted or Lewis 
acid, as depicted on scheme 75.  
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Scheme 75: Possible equilibrium that explains the isomerisation observed. 
 
Separation of both E-153 and Z-153 was possible by SiO2 chromatography, and NOESY 
experiments allowed the assignment of each isomer. It appeared that E-153 and Z-153 were 
highly sensitive to acids, and NMR samples in d1-chloroform directly isomerized to the 
original 7:3, E/Z ratio upon standing (figure 18). Filtration of CDCl3 over a pad of basic 
aluminium oxide solved the problem and avoided the fast isomerisation of 153. 
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a) b) c) 
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Figure 18: 1H NMR (400 MHz) spectra of E-153 at -C=CH-: a) directly after purification, b) 
upon standing for 17 h, c) upon standing for >24 h. 
 
 Several other protecting groups were envisaged at the hydroquinone, and synthesized 
from 2,3-dimethylhydroquinone 68 (scheme 76). Thus protection to TBS- and TES- 
silylethers went smoothly to afford 154 and 155 in quantitative yields, as well as bis-acetyl 
hydroquinone 156, gained in 97% yield from acetic anhydride and pyridine. But 
unfortunately, none of them reacted with acyl chloride 144, either in presence of 
POCl3/ZnCl2, AlCl3 or TiCl4, and investigations were then moved to Grignard coupling 
reaction. 
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Scheme 76: Synthesis of 154, 155 and 156, and F-C reaction with acyl chloride 144. 
 
3.3.2.2. Grignard reaction on E-(R,R)-phytal 145. 
 
Several years after Friedel and Crafts reported the acylation of aromatics, Grignard 
described the use of magnesium in synthesis and in particular the reactivity of 
organomagnesium compound with carbonyl groups.115 From the retrosynthetic proposal, we 
envisaged the coupling of an aromatic magnesium bromide with E-(R,R)-phytal 145. 
Synthesis of the aldehyde partner has already been described in previous part, by an oxidation 
of E-(R,R)-phytol 34, and bromination of the different bis-protected hydroquinones already 
used was necessary. To this end, N-bromosuccinimide was used as brominating agent, and 
showed excellent reactivities on hydroquinones 148, 150 and 154 (scheme 77). Grignard 
reagents were formed in situ by reaction of aromatic bromides with Mg in Et2O, in the 
presence of catalytic amounts of I2 and dibromoethane, and were allowed to react with 
aldehyde 145. Despite no reaction was observed in the case of TBS- and MOM- ethers and 
the aldehyde fully recovered, an excellent 91% yield was obtained for bis-methyl ether 
hydroquinone 159. Steric hindrance could be responsible for the absence of reaction with 157 
and 158, due to the bulkiness of TBS- and MOM- protecting groups. Benzylic alcohol 160 
was then obtained as a 1:1 mixture of diastereoisomers, giving two sets of signals on 1H NMR 
analysis, and could be oxidized to E-153, using activated MnO2, in 72% yield and pure E-
isomer (scheme 77). 
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Scheme 77: Bromination of bis-protected hydroquinones - Grignard reaction with (E)-phytal 
145. 
 
The advantage of this route in comparison with the F-C pathway described in previous 
part concerned the higher yields reached. Finally, deprotection of the methyl ether was 
investigated, and was based on a report of Vickery et al.116 in the use of boron tribromide and 
iodotrimethylsilane for the selective O-demethylation of catechol ethers. Thus, treatment of 
E-153 in the presence of 3 equivalents of BBr3 in CH2Cl2 afforded the corresponding 
hydroquinone 161, in 71% yield (scheme 78). But with no surprises, isomerisation of the 
double bond was also observed, giving a ratio of 6:4 E/Z, and isolation of pure E-161 made 
dropped the yield to 43%. Influence of the temperature was checked in order to decrease the 
isomerisation of the double bond, but surprisingly, when the reaction was carried out at -78 
°C and kept at this temperature, there was no influence on the isomerisation and mono-O-
demethylation occurred, leading to E-162 in 46% yield (65% conv, 7:3 E/Z).  
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Scheme 78: O-Demethylation of E-153 in the presence of BBr3 – Influence of the 
temperature. 
 
The difference in reactivity of the methyl ethers could be explained by the coordination 
of the boron to the carbonyl and to the ortho-methoxyether, thus leading in a regioselective 
deprotection at low temperatures. A similar H-bond was clearly observed on 1H NMR 
spectrum since the hydroxyl proton was shift in low fields to δ = 12.9 ppm for the E-isomer, 
and δ = 13.0 ppm for the Z-isomer. Having in hand two precursors for the Lewis acid 
mediated cyclisation, several metal sources were screened. 
3.3.3. Lewis-acid mediated cyclisation. 
3.3.3.1. Screening of metal salts. 
 
Precursor E-161 was then submitted to different Lewis acid, and the cyclisation was 
followed by HPLC (Protonsil® 120-5-CN, 1% to 2% iPrOH in n-heptane, 1 mL/min, 270 nm, 
25 °C), to determine the conversion to the desired product 163 (table 7). The first observation 
concerned the ‘integrity’ of the double bond since the unreacted starting material 161 was 
isolated as a E:Z mixture in some cases. It was obvious that Lewis acids that induced such 
isomerisations would not be considered as potential candidates for an asymmetric version of 
the reaction, since it would lead to the absence of diastereoselectivity. Several metals such as 
CuII and FeIII gave good results (entries 10, 15 and 16), that were excellent reactivity and no 
isomerisation observed during the reaction period. Influence of the solvent was crucial in the 
case of Cu(OTf)2, as its complete solubility in MeCN (entry 16) led to a fast and quantitative 
reaction. 
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OH
OH
O
O
O
HO
2 2
Lewis
Acid
E-161 163  
entry Lewis acid (LA) conversiona (%) ratio E-161:Z-161b
1 AlCl3 0 7:3 
2 Al(ClO4)3 0 7:3 
3 Al(OTf)3 0 7:3 
4 TiCl4 0 >98 :2 
5 ZnCl2 0 >98 :2 
6 Zn(BF4)2 traces >98 :2 
7 Zn(OTf)2 4 7:3 
8 CuCl2 3 7:3 
9c Cu(OTf)2 52 >98 :2 
10d Cu(OTf)2 >99 >98 :2 
11 NiCl2 0 8:2 
12 Ni(ClO4)2 0 8:2 
13c Sn(OTf)2 26 8:2 
14 SnCl4 4 7:3 
15 FeCl3 >99 >98 :2 
16 Fe(ClO4)3 >99 >98 :2 
17 Fe(ClO4)2 17 7:3 
18 CoCl2 0 8:2 
19 Co(BF4)2 0 8:2 
20 La(OTf)3 traces 8:2 
 
Table 7: Screening of Lewis acid for the intramolecular oxa-Michael reaction of E-161. 
[General conditions: 34.5 μmol E-161, 1.5 equiv LA, 1 mL CH2Cl2, RT, 15h. [a] Determined by HPLC at 270 
nm. [b] E:Z ratio of unreacted 161, determined by HPLC. [c] Complete conversion observed after >5 days. [d] 
Reaction performed in MeCN.] 
 
From the two metals showing outstanding results, CuII was selected to envisaged a 
diastereoselective reaction, since it is one of the most commonly used metal for asymmetric 
Michael reaction (see section 3.3.1.1 and references cited therein) and literature offers a 
broad variety of chiral ligands. 
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3.3.3.2. Copper catalyzed asymmetric cyclisation. 
 
A broad variety of chiral ligands were already described in copper catalyzed asymmetric 
reactions, of which several are commercially available and were used for preliminary 
experiments. C2-Symmetric bisoxazoline (BOX) ligands such as 164, 165 and 166 were 
selected, as well as pyridine bis-oxazoline (PyBOX) ligand 167 (figure 19), taking advantage 
of the work achieved by Evans and co-workers, on the formations, structures and applications 
of corresponding CuII complexes.96
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Figure 19: BOX and PyBOX ligands selected for preliminary experiments. 
 
Several factors were reported to be critical for both reactivity and stereoselectivity, 
such as the solvent, the choice of the metal counterions, the temperature or the use of 
additives. In 1995, Evans et al. reported a study on the counterion influence in BOX-copper 
complexes [CuII-(BOX)X2], for the enantioselective Diels-Alder reaction.117 Four anions were 
tested, BF4-, TfO-, PF6- and SbF6-, and a correlation between the coordination ability of the 
anion to the metal center and the efficiency of the copper catalyst was found: poor 
coordinating anions gave better results, SbF6- being the best. Accordingly, triflate (TfO-) and 
hexafluoroantimonate (SbF6-) counterion were selected for the oxa-Michael cyclisation. 
 
Formation of these copper-BOX complexes was intensively studied and reported by 
Evans et al.,96 and could be achieved by simply stirring the chiral ligands in the presence of 
the copper salt, in CH2Cl2, under a strictly anhydrous atmosphere (scheme 79). In the case of 
SbF6- counterion, the bis-chloro-complexes were first produced by reacting CuCl2 with the 
chiral ligands, followed by an anion exchange upon addition of AgSbF6, thus precipitating 
AgCl. These complexes are highly sensitive to moisture, since H2O could rapidly exchange 
with counterions, leading to the bis-aquo complexes. 
 
 80
Results & Discussions 
O
N N
O
R R
Cu(OTf)2
CH2Cl2, rt, 1 h
O
N N
O
R RCu
R= tBu, [CuII-164-(OTf)2]
Ph, [CuII-165-(OTf)2]
Bn, [CuII-166-(OTf)2]
O
N N
O
iPr iPr
N
CuCl2
CH2Cl2, rt, 1 h
O
N N
O
R RCu
Cl Cl
AgSbF6
O
N N
O
R RCu
2+
2 . TfO-
2+
2 . SbF6-
- AgCl
R= tBu, [CuII-164-(SbF6)2]
Ph, [CuII-165-(SbF6)2]
Bn, [CuII-166-(SbF6)2]
O
N N
O
R RCu
H2O OH2
H2O
H2O
O
N N
O
iPr iPr
N
Cu
2+
2 . TfO-
Cu(OTf)2
CH2Cl2, rt, 1 h
CuCl2
CH2Cl2, rt, 1 h
O
N N
O
iPr iPr
N
Cu
Cl Cl
AgSbF6
- AgCl
O
N N
O
iPr iPr
N
Cu
2+
2 . SbF6-
Bis-aquo-
complex
H2O
H2O
167
[CuII-167-(OTf)2]
[CuII-167-(SbF6)2]  
Scheme 79: Formation of CuII-BOX complexes. 
 
These complexes were then tested on the oxa-Michael cyclisation of precursor E-161, 
under different conditions, and results are presented in table 8. Note that the diastereoisomeric 
excesses were checked by comparison with a reference compound, racemic at C-2. Moderate 
conversions were observed and none of the chiral complexes showed diastereoisomeric 
excesses by chiral HPLC analysis (Chiralpak AD-H, 1% to 3% iPrOH in n-heptane, 0.5 
mL/min, 270 nm, 25 °C). However, it clearly revealed that SbF6- counterion was necessary to 
promote the cyclisation, since no reaction was observed when TfO--complexes were used. 
The use of an additive was also important, as reported by Kitajima et al. in 1997118 that 
increased the turnover of the catalyst, and avoided side-reactions by trapping the enolate 
formed.  
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OH
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Cu-BOX
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E-161 163  
entry catalyst load. (mol%) temp (°C) solvent (S) additive (A) conva (%) dea (%) ratio E-161:Z-161b
1 [Cu-164-(OTf)2] 100 rt MeCN - 0 - >98:2 
2 [Cu-164-(OTf)2] 100 -78 MeCN - 0 - >98:2 
3 [Cu-164-(OTf)2] 100 rt THF - 0 - >98:2 
4 [Cu-164-(OTf)2] 100 -78 THF - 0 - >98:2 
5 [Cu-164-(OTf)2] 100 rt CH2Cl2 - 0 - >98:2 
6 [Cu-164-(OTf)2] 100 -78 CH2Cl2 - 0 - >98:2 
7 [Cu-166-(OTf)2] 100 rt MeCN - 0 - >98:2 
8 [Cu-166-(OTf)2] 100 rt CH2Cl2 - 0 - >98:2 
9 [Cu-165-(OTf)2] 100 rt MeCN - 0 - >98:2 
10 [Cu-165-(OTf)2] 100 rt CH2Cl2 - 0 - >98:2 
11 [Cu-165-(OTf)2] 15 rt CH2Cl2 - 0 - >98:2 
12 [Cu-165-(OTf)2] 15 rt CH2Cl2 CF3CH2OH 0 - >98:2 
13c [Cu-167-(OTf)2] 100 rt CH2Cl2 - 9 0 >98:2 
14 [Cu-165-(SbF6)2] 30 rt CH2Cl2 - 15 0 80:20 
15 [Cu-165-(SbF6)2] 30 rt CH2Cl2 CF3CH2OH 38 0 80:20 
16 [Cu-165-(SbF6)2] 30 rt MeCN CF3CH2OH 0 - >98:2 
17 [Cu-165-(SbF6)2] 30 rt CF3CH2OH - 0 - >98:2 
18 [Cu-165-(SbF6)2] 30 rt CH2Cl2 DNBAc 49 0 67:33 
19 [Cu-165-(SbF6)2] 30 rt CH2Cl2 PFPd 50 0 53:47 
20 [Cu-167-(SbF6)2] 10 rt CH2Cl2 CF3CH2OH 20 0 90:10 
21 [Cu-167-(SbF6)2] 10 -78 CH2Cl2 CF3CH2OH 7 0 >98:2 
 
Table 8: Asymmetric oxa-Michael cyclisation of E-161 using chiral copper complexes. 
[General conditions: 34.9 μmol E-161, 1 mL S, 1 equiv A, 24 h. [a] Determined by chiral HPLC at 270 nm. [b] 
E:Z ratio of unreacted 161, determined by chiral HPLC. [c] 2,4-dinitrobenzyl alcohol. [d] pentafluorophenol.] 
 
To this end, 2,2,2-trifluoroethanol was used and successfully enhanced the reactivity 
from 15% (entry 14) to 38% conversion (entry 15). Other alcohol derivatives were envisaged, 
such as 2,4-dinitrobenzyl alcohol (entry 18) and pentafluorophenol (entry 19), but despite an 
increase of the reactivity up to 50% conversion, isomerisation of the unreacted precursor 161 
occurred in more than 30%, thus contributing in the absence of stereoselectivity. Different 
solvents were screened but none of them could promote a diastereoisomeric excess.  
 
 82
Results & Discussions 
The influence of the free phenol was also checked, and cyclisation of E-162 was 
performed with best conditions (table 8 – entries 15 and 20) and is depicted on scheme 80. 
The great advantage of 162 concerned the absence of isomerisation of the double bond, but 
the cyclisation did not occur in more than 10% conversion and no diastereoselectivity was 
observed by chiral HPLC analysis (Chiralpak AD-H, 0.5% to 5% iPrOH in n-heptane, 0.5 
mL/min, 270 nm, 25 °C). 
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Scheme 80: Cyclisation of E-162 using copper-BOX catalysts. 
 
The Lewis acidity of the chiral catalyst was then considered in order to increase the 
reactivity toward 161 and 162, and the choice of less electron donating ligands would be 
advantageous. Accordingly, we prepared bis-tosylated cyclohexyldiamine 170, and expected 
the tosyl group to withdraw the electrons from the nitrogen lone pairs, thus increasing the 
acidity of the coordinating metal center (scheme 81). Synthesis went smoothly from 
commercially available (R,R)-cyclohexyldiamine 169, which quantitatively afforded 170 upon 
treatment with tosyl chloride and triethylamine in THF.  
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Scheme 81: Synthesis of bis-tosylated cyclohexyldiamine 170 and formation of CuII-
complexes. 
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[Cu-170-(OTf)2] complex was then prepared by stirring 170 and Cu(OTf)2 in CH2Cl2, 
producing a clear blue solution. Preparation of the SbF6 analogue did not worked under Evans 
conditions, since no coordination occurred between CuCl2 and 170 in CH2Cl2. However, 
stirring of a mixture of 170, CuCl2 and AgSbF6 in CH2Cl2 for 4 h afforded a solid after 
filtration of silver salts and evaporation of solvent, which was used for cyclisation tests. 
Cyclisation of E-162 showed promising results, as depicted on scheme 82, with up to 79% 
isolated yield. However, no stereoselectivities were obtained in both cases. 
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Scheme 82: Cyclisation of E-162 using CuII-170 complexes   
 
Investigations on the catalyst structures were attempted by mass spectroscopy, using 
electro-spray ionization (ESI), and MeCN solutions of [Cu-170-(OTf)2] and [Cu-170-(SbF6)2] 
were analysed. The spectrum of the [Cu-170-(OTf)2] complex presented 2 major signals at 
m/z = 358+ and 557+ (figure 20), showing the typical isotopic pattern of copper, and thus were 
attributed to [CuII(MeCN)2(OTf)]+ and an in situ-reduced119 copper complex [CuI-170-
(H2O)4]+. 
 
 
 
 [CuI-170-(H2O)4]+
[CuII(MeCN)2(OTf)]+
 
 
 
 
 
 
 
Figure 20: MS-ESI spectrum of [Cu-170-(OTf)2] in MeCN. 
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Surprisingly, the MS-ESI spectrum of the expected [Cu-170-(SbF6)2] complex 
presented 2 main signals, at m/z = 529+ and 951+, but the isotopic pattern of the signals were 
rather corresponding to a silver complex than to a copper complex (figure 21). It clearly 
indicated that the complex formed and used for the cyclisation was a AgI complex since the 
signals were attributed to [AgI-170]+ and the dimer [AgI-(170)2]+ respectively. 
 
 
 
[AgI-170]+ [AgI-(170)2]+ 
 
 
 
 
 
 
 
 
 
Figure 21: MS-ESI spectrum of [Cu-170-(SbF6)2] in MeCN – Formation of the AgI complex. 
 
Coming back to results presented on scheme 82, the actual catalyst that promoted the 
cyclisation was [AgI-170-(SbF6)] and thus the investigation of asymmetric silver-catalyzed 
cyclisation was considered. 
 
3.3.3.3. Silver catalyzed asymmetric cyclisation. 
 
Structure elucidation of the silver complex [AgI-170-(SbF6)] was continued and 1H NMR 
analysis was done to determine the nature of the coordination. A 1:1 ratio of 170 and AgSbF6 
was analysed in MeCN-d3, and a typical shift of characteristic protons was observed, and is 
depicted on figure 22. The first important observation concerned the amine protons, which 
remained in the silver complex, indicating a non-covalent coordination at the nitrogen atoms.  
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a) 
CH3-Ph-SO2- 
Ts-NH-CH- 
 
 
b) 
Figure 22: 1H NMR in MeCN-d3 of: a) 170 alone, b) 170:AgSbF6 (1:1). 
 
Moreover, a slight shift of the aromatic methyl as well as the aromatic protons was also 
observed, that could be explained by a coordination of the silver atom to the π-system of one 
or both aromatic rings.  
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A 1H NMR titration revealed that it was most likely a 1:1 AgI+ : 170 complex, which 
structure is tentatively drawn on figure 23. However, despite a good reactivity of this 
complex, no selectivity was observed in the cyclisation of E-162 (scheme 82). 
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Figure 23: Proposed structure of [AgI-170-(SbF6)] complex 
 
Other ligands were tested, such as commercially available (R)-BINAP, which silver 
complex was already described by Yamamoto et al. for aldol reactions120 using triflate 
counterion. Cyclisation attempts using AgSbF6 or AgOTf as silver sources, in a 1:1 ratio with 
the chiral ligand, were not successful and no reaction occurred (scheme 83).  
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Scheme 83: Cyclisation of E-162 using binaphtalene derived ligands and AgI. 
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The Lewis acidity of the silver center was probably too weak due to the strong electron 
donating ability of the BINAP ligand. Using the same design as for 170, bis-tosylated (R)-
DABN 172 was synthesized from diamine 171, and its silver complex was used in the 
cyclisation of E-162. The chromanol product was formed in 75% yield, but no 
diastereoselectivity was observed. 
In the 1980’s, Helmchen et al. reported the use of camphor derived chiral auxiliaries in 
the asymmetric addition of organocopper compounds to enoates,121 in high 
diastereoselectivity. Readily available from our fridges, ligand 173 was envisaged for the 
silver catalyzed oxa-Michael cyclisation (scheme 84), and its silver complex, formed by 
stirring a CH2Cl2 solution of AgSbF6 and 173, in a 1:1 ratio, was characterized by MS-ESI 
and 1H NMR analysis. 
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Scheme 84: ‘Helmchen’s ligand’ 173 – Formation of [Ag-173-(SbF6)] complex. 
 
The MS-ESI analysis was performed on a MeCN solution of [Ag-173-(SbF6)] 
complex, and several peaks were observed, at m/z = 519.9+, 560.9+ and 592.9+, attributed to 
monomeric silver complexes [AgI-173]+, [AgI-173-(MeCN)]+ and [AgI-173-
(MeCN)(MeOH)]+ respectively (figure 24).  
 
[AgI-173]+
[AgI-173-(MeCN)]+ 
 [AgI-173-(MeCN)(MeOH)]+
 
 
 [AgI-(173)2]+
 
 
 
 
Figure 24: MS-ESI spectrum of [Ag-173-(SbF6)] in MeCN. 
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Note that the MeOH-complex observed was probably due to residual traces of 
methanol in the spectrometer, commonly used solvent for MS-experiments. A dimer was also 
found at m/z = 932.9+, attributed to [AgI-(173)2]+. 1H NMR analysis of a 1:1 mixture of 173 
and AgSbF6 was performed in CD2Cl2-d2, and a typical shift of characteristic protons was 
observed, and is depicted on figure 25. 
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Figure 25: 1H NMR in CD2Cl2-d2 of: a) 173 alone, b) 173:AgSbF6 (1:1) 
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The first important observation was relative to the hydroxyl proton which gave a very 
broad signal upon addition of the silver salt. It suggested that the AgI would be coordinated at 
the oxygen lone pairs. Moreover, the protons of the dimethyl-phenyl ring were all shifted, as 
well as the two aromatic methyls, which suggested an interaction of the silver center with the 
π system of the phenyl ring. In addition, the second aromatic ring did not show any typical 
shifts, suggesting that there was no coordination of the metal. Single crystals were obtained 
from slow evaporation of CD2Cl2, which X-Ray analysis gave the polymeric structure 
depicted on figure 26. 
 
a) 
 
 
b) 
Figure 26: X-Ray structure of [Ag-173-(SbF6)]. a) Monomeric unit, O=red, N=blue, 
S=yellow, F=green, Ag=pink. b) 1D polymeric structure, O=red, N=green, S=yellow, F=pink, 
Ag=grey. 
 90
Results & Discussions 
Interestingly, the silver atom coordinated to the hydroxyl group and to one oxygen 
atom of the sulfonamide. The other SO2-oxygen atom was then coordinated to the silver of the 
next unit. Moreover, the observation concerning the interactions between AgI and the 
dimethyl phenyl ring was confirmed. Unfortunately, this silver complex was absolutely not 
diastereoselective in the oxa-Michael cyclisation of E-162, though the reactivity was excellent 
(scheme 85). 
 
OH
OMe
O
O
O
MeO
E-162 168
Rp
[Ag-173-(SbF6)]
CH2Cl2, rt, 15 h
82% yield
0% de 2
 
Scheme 85: Cyclisation of E-162 using [Ag-173-(SbF6)]. 
 
Silver being known to also coordinate at double bonds, the reactivity of these 
complexes were shortly investigated on precursor 99, readily available and which synthesis 
has already been reported34 (scheme 86). Reactivity was excellent and product 174 isolated in 
up to 94% yield, but no diastereoisomeric excesses were found.  
 
RpOH
(-)CamphO
99
Ag-catalyst, CH2Cl2
rt, 15 h
(-)CamphO
174
O
2
[Ag-170-(SbF6)], 90% yield, 0% de
[Ag-173-(SbF6)], 94% yield, 0% de  
Scheme 86: Silver mediated cyclisation of 99. 
 
Since none of the chiral Lewis acids used have induced a diastereoselectivity in the 
oxa-Michael intramolecular cyclisation of 161 and 162, a new approach was proposed in 
which the chiral ligand would be covalently attached to the substrate (scheme 87). The 
absence of selectivity in the original design could be explained by the single binding site, the 
carbonyl oxygen atom or the double bond, probably not sufficient to induce a preferred 
conformation of the substrate, thus leading to a non-stereoselective attack of the phenolic 
oxygen atom. An additional conformational strength was expected from the covalently 
attached ligand, and since best results were obtained with precursor 99, binding at the C=C 
was preferred.  
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Scheme 87: New design using a covalently attached chiral ligand. 
3.3.3.4. Intramolecular chiral ligand design. 
 
The synthesis of 175 was inspired by the one developed in the biomimetic chromanol 
cyclisation (see part 3.1.1), and based on a Mannich coupling to attach the cyclohexyl 
diamine moiety, as depicted on scheme 88. The bulky (-)-camphanoyl ester was used for the 
same purpose, and the general remarks concerning the synthesis were kept. Mono-protected 
phytylhydroquinone 176, which synthesis has already been described by Woggon et al.,34 and 
cyclohexyl diamine 169 were the two initial building blocks. 
 
(-)CamphO
OH
NH HN Ts
Mannich
coupling
'Grütter'
RpO
THP
HO
H2N HN Ts
x175 
x x
H2N NH2
177 x  
Scheme 88: Retrosynthetic design for the synthesis of precursor 175. 
169 
176 
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Mono-tosylation of 169, in the presence of TsCl and Et3N, afforded 177 in 72% yield, 
after careful purification to ensure the complete removal of the base from the crystalline 
product (scheme 89). Having in hand the phytylhydroquinone 176, Mannich coupling was 
attempted with formaldehyde and acetic acid in refluxing MeOH, but to our surprise, the 
expected product was not isolated, as a ‘double Mannich’ reaction took place, directly leading 
to 178. The amino-acetal formed was then cleaved by acidic treatment with 1N HCl in THF, 
which conditions also cleaved the THP group (scheme 89). A hydroquinone / quinone mixture 
was obtained, and since it was the most stable compound, full oxidation to the quinone 179 
was done with activated MnO2. Protection of the phenol by the bulky (-)-camphanoyl group 
was investigated, by reduction of the quinone, directly followed by treatment with (-)-
CamphCl and DMAP, but the reaction was not regioselective and a complicate mixture was 
obtained. Both hydroxyl groups probably reacted, as well as the secondary amine. In order to 
remove one reacting site, protection of the amine was envisaged, at the quinone stage.  
 
RpO
THP
HO
H2N HN Ts
176
177
H2N NH2
HCHO, AcOH, MeOH
Reflux, 24 hTsCl, Et3N
CH2Cl2, 15 h
0 °C to rt
72%
168
O
THP
HO
NH
Rp
HN Ts
169 
O
THP
Rp
N
O
Ts
N
H
1) 1N HCl, THF, rt, 3 h
2) MnO2, CH2Cl2, rt, 1 h
70%
178
46% yield
O
O
Rp
NH HN Ts
1) Na2S2O4, THF
H2O, rt, 30'
2) (-)-CamphCl
DMAP, CH2Cl2
0 °C, 4 h
Complicated mixture
 179
Scheme 89: Mono-tosylation of 168 and its Mannich coupling with 176. 
 
Accordingly, treatment of the quinone 179 with TsCl and DMAP in CH2Cl2, afforded 
the corresponding bis-tosylated precursor 180 in 75% yield (scheme 90). Reduction with 
sodium dithionite, directly followed by treatment with (-)-CamphCl and DMAP led also to a 
complicated mixture. 
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Scheme 90: Protection of the secondary amine – Electrocyclisation of quinone 179. 
 
During the first attempts of amine tosylation, pyridine has been used as base and 
solvent, and the chromene 181 was isolated as a side-product. A short investigation revealed 
that the pyridine was responsible of the cyclisation, and 181 could be isolated in 40% yield, 
but unfortunately, no diastereoisomeric excess was found. This type of ‘electrocyclisation’ 
was already reported in 1963 by Linn et al. in the cyclisation of coenzyme Q122 and the 
proposed mechanism is depicted on scheme 91. After deprotonation at the benzylic position, 
rearrangement produced 182, suitable for an electrocyclisation leading to chromene 181. 
 
O
O
Rp
R
179 182
N
N+
H O
O
Rp
R
O
O
Rp
R
O Rp
O
R
N
N+
HO Rp
HO
R
181
HN TsN
H
H2CR=
 
Scheme 91: Proposed mechanism of the electrocyclisation of 179. 
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The use of chiral bases was shortly envisaged, but since the electrocyclisation went 
through intermediate 182, any asymmetric deprotonation of 179 would not be useful. Finally, 
this route was not investigated and other chiral Lewis acids were screened 
3.3.3.5. Miscellaneous chiral Lewis acids. 
 
Some other usual chiral Lewis acids were tested on the cyclisation of E-162, and the 
results are presented on scheme 92. Corey catalyst123 was applied but no reactivity was 
observed, as well as with a [FeIII(OTf)SALEN] complex. Various rhodium complexes were 
synthesized, but none of them were efficient.  
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Scheme 92: Cyclisation of E-162 using FeIII, RhI and Corey’s catalysts. [X=OH, Cl] 
 
Finally, (R)-Alpine-hydride® promoted the cyclisation of E-162 to chromene 183 in 30% 
yield, but no diastereoisomeric excess was found (scheme 93). 
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O
O
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2
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H
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Scheme 93: Cyclisation of E-162 using (R)-Alpine-hydride®. 
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4. Summary and Conclusions 
 
 
Based on the mechanism of tocopherol cyclase, isolated from Cyanobacteria, a 
biomimetic synthesis of α-tocopherol has already been developed in our group, using a 
covalently bonded peptide that mimicked the active site of the enzyme. Application of this 
strategy was presented in the first part, and allowed the synthesis of another important 
member of vitamin E family, α-tocotrienol 19. Indeed, the chromanol ring formation was 
induced by a Brönsted acid assisted – Brönsted acid supported reaction, leading to enantio-
enriched α-tocotrienols (scheme 94). The asymmetric hydrogenation of 19, as described by 
Pfaltz et al. with Iridium catalyst 61, furnished a common route for the synthesis of α-
tocotrienols and α-tocopherols. 
 
OH
(-)CamphO
N+ O
D-80
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HO
O
3
'Biomimetic'
3
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HO
O
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COO-
COOH
H
N
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O
P(oTol)2 Ir
BArF-
+
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Scheme 94: Biomimetic synthesis of α-tocotrienols 19 and its asymmetric hydrogenation to 
α-tocopherols 15. 
 
In a second project, novel diastereoselective syntheses of α-tocopherol were 
investigated and a retrosynthetic analysis outlined two possible strategies (scheme 95), 
concerning the chromanol ring formation.  
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Scheme 95: Retrosynthetic approaches for the chromanol ring formation in α-tocopherol. 
 
 
A first approach was designed based on an epoxide ring opening, in an ‘anti-Baldwin’ 
fashion. Taking advantage of the substrate scope of Shi catalyst ent-101, preparation of 
optically active epoxide 108f was achieved in high yield and high diastereoselectivity (scheme 
96).  
 
R1
R2
R3
R1
R2
R3
O
O O
O
O
O
O
101
H2O2, MeCN
O
MeO
O
DPS
2
81% yield
97% de (ent-101)  
Scheme 96: Asymmetric Shi epoxidation – Synthesis of optically active epoxide 108f. 
 
 
The epoxide ring opening conditions were then screened and interestingly a strong 
influence of the aromatic substituents could be outlined, since completely different media 
were necessary for γ-tocopherol and α-tocopherol series to favour the pyran ring (scheme 97). 
Application of best conditions on chiral epoxide produced the chromanol ring in good yield, 
under inversion of configuration. (2R,4’R,8’R)-α-Tocopherol was finally reached in 93% de 
after removal of the hydroxyl group. 
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Scheme 97: “Anti-Baldwin” epoxide ring opening – Optimisation and application to the 
synthesis of α-tocopherol 15.  
 
The second approach was based on an oxa-Michael cyclisation, using chiral Lewis 
acids that could be bound to the carbonyl group or the olefin, and would induce an 
asymmetric cyclisation (scheme 98). However, though carbon-carbon bond forming Michael 
reactions have been extensively studied, its oxa-analogue obviously missed sound precedents. 
Nevertheless, known chiral copper complexes as well as novel silver Lewis acids were 
applied on 161 and 162, but despite good reactivity up to 90%, none of them were 
diastereoselective. 
 
O
O
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CuIIL*
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Scheme 98: Lewis acid mediated oxa-Michael cyclisation of 161 and 162.  
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This drawback could be explained by the lack of supplementary binding sites for the 
chiral metal complex that would allow a preferential conformation of the substrate, leading to 
a diastereoselective cyclisation. To this end, a 1,3-dicarbonyl may be necessary, or the use of 
a directing group, as depicted on scheme 99, and research in these directions could be 
investigated. 
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Scheme 99: Possible strategies to achieve a diastereoselective oxa-Michael cyclisation to α-
tocopherol.  
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5. Experimental part 
5.1. General remarks 
5.1.1. Solvents and reagents 
 
Reagents were used as received from Fluka AG, Acros AG, Merck AG  and Aldrich 
unless otherwise stated. Chemicals of the quality purum, purum p. a. or >98% were used 
without further purification. 
Solvents for chromatography and extractions were distilled prior to use. Dry solvents 
used for reactions corresponded to the quality puriss p. a., abs., over Molecular Sieves from 
Fluka AG. HPLC-grade solvents were purchased and used for analytical LC and GC. For an 
inert atmosphere Argon 6.0 from PanGas AG was used. 
 
5.1.2. Materials and instruments 
 
Solvents were removed with a Büchi rotary evaporator. For weighing compounds and 
reagents Mettler balances P360, AE163 and AX205 were used. A high-vacuum pump 
TRIVAC D5E from Leybold Vakuum GmbH was used for drying compounds and reagents. 
For all non-aqueous reactions, glassware were flame-dried under vacuum and the atmosphere 
was exchanged by three cycles of evacuating and flushing with argon. Melting points were 
determined on an apparatus by the Werkstatt der Organischen Chemie der Universität Basel 
and are uncorrected. Description: m.p. given in °C. 
 
5.1.3. Chromatographic methods 
 
Analytical thin layer chromatography (TLC) was performed on precoated glass plates 
5x10 cm, silica gel 60 F254 from Merck AG and compounds were detected at 254 nm (UV), at 
366 nm (fluorescence) or were revealed by a Cer-DIP solution. Preparative TLC were 
conducted on precoated glass plates 20x20 cm, silica gel 60 F254 from Merck AG. Column 
chromatography was performed on silica gel 60 from Merck AG (0.040-0.063 mm, 230-400 
mesh). 
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Analytical HPLC were performed using a Protonsil 120-5-CN Bischoff, a Chiracel OD-
H or a Chiralpak AD-H column, either on an Agilent 1100 series HPLC system with solvent 
degasser  G1322A, BinPump G1312A, Autosampler G1313A, Thermostatic column housing 
G1316A, Diode array UV detector G1315B; or on a Shimadzu CBM-20A HPLC system with 
solvent degasser DGU-20A3, BinPump LC-20AB, Autosampler SIL-20A, Fluorescence 
detector RF-10AXL, Diode array UV detector SPD-M20A and a Fraction collector FRC-10A. 
Description: HPLC (conditions): retention times given in minutes. 
 
Gas chromatography (GC-MS) was performed on a Hewlett Packard 5890 series II 
using a 25m dimethyl silane column coupled with a Hewlett Packard 5971 series mass 
selective detector. Description: GC (conditions). 
5.1.4. Spectroscopic methods 
 
Ultra violet-visible absorption spectra (UV-Vis) were recorded on an Agilent 8453 Diode 
Array spectrophotometer using optical 110 QS Hellma cuvettes (10 mm light path). 
Description: UV (solvent): wavelength of maxima (λmax) in nm. 
 
Infrared spectra (IR) were measured on a FTIR-8400S spectrometer from Shimadzu. 
Description: IR (medium): wavenumbers of transmission maxima in cm-1. 
 
Electron impact mass spectra (EI) and fast atom bombardment mass spectra (FAB) were 
measured by Dr. H. Nadig on a Finnigan MAT 95Q spectrometer and Finnigan MAT 8400 
spectrometer. Electron spray ionization mass spectra (ESI) were recorded on a Bruker Esquire 
3000plus. Description: MS (medium): mass peaks in m/z. (Fragmentation peaks were not 
considered) 
 
1H-Nuclear magnetic resonance spectroscopy (1H NMR) was performed using either a 
Bruker av250 (250 MHz), Bruker DPX-NMR (400 MHz), Bruker DRX-500 (500 MHz) or 
Bruker DRX-600 (600 MHz) spectrometer. Solvents for NMR were obtained from 
Cambridge Isotope Laboratories. CDCl3 was filtered through basic alumina prior to use. All 
spectra were recorded at room temperature. If necessary for the interpretation, correlated 
spectra like COSY and NOESY were also recorded. Description: 1H NMR (frequency, 
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solvent): δH in ppm relative to TMS or residual solvent peaks (peak multiplicity: s=singlet, 
d=doublet, t=triplet, q=quartet, m=multiplet, br=broad; coupling constants J in Hertz). 
 
13C-Nuclear magnetic resonance spectroscopy (13C NMR) was 1H-decoupled and 
recorded on a Bruker DPX-NMR (100 MHz) or Bruker DRX-500 (125 MHz) spectrometer. 
For the assignment of carbons, DEPT, HMQC and HMBC experiments were carried out if 
necessary. Description: 13C NMR (frequency, solvent): δC in ppm relative to residual solvent 
peaks. 
 
Single crystal X-ray structure was determined by Dr. Markus Neuburger and Dr. Silvia 
Schaffner in the chemical crystallography laboratory of the department. Data collection was 
carried out on a Nonius KappaCCD diffractometer using the COLLECT software suite. The 
usual corrections were applied. No absorption correction was determined. The structure was 
solved by direct method using the program DIRDIF-99. Anisotopic least-squares refinement 
was carried out on all non-hydrogen atoms using the program CRYSTALS. Hydrogen atoms 
were in calculated positions. 
 
5.1.5. Miscellaneous 
 
The elemental analysis (EA) was carried out by Mr. H. Kirsch at the institute on a Perkin-
Elmer 240 Analyzer. Description: anal. calcd. for ‘chemical formula’: calculated abundance 
of C, H, O in %; found abundance of C, H, O in %. 
 
Optical rotations were measured on a Perkin-Elmer polarimeter 341 at λ = 589nm with 100 
mm cells, at 20 °C. Description: [α]D20 = given in °. 
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5.2. Syntheses 
 
THPO-/TIPSO-hydroquinone 66.76 To a solution of 2,3-
dimethylhydroquinone 68 (23.0 g, 166.5 mmol) in THF (150 mL) 
at -5 °C, was added 2,3-dihydropyrane (16.7 mL, 183.1 mmol), 
followed by pTsOH (285.2 mg, 1.50 mmol) and the mixture was 
stirred at room temperature for 5 h. The mixture was quenched 
with saturated NaHCO3 and extracted with TBME (3 ×). Combined organic phases were 
washed with H2O, brine (2 ×), dried over Na2SO4, evaporated to dryness and the residue 
purified by column chromatography on SiO2 (hexane – EtOAc, 5:1) to afford mono-OTHP 
hydroquinone (18.6 g, 50%) as a slight orange solid. Spectral data were identical to those 
already reported – Selected data. 
 
m.p. = 92 - 94 °C;  
1H NMR (300 MHz, CDCl3, 25 °C): δ = 1.60-1.70 (m, 3H, CH2-THP),1.85-1.95 (m, 2H, 
CH2-THP), 1.95-2.05 (m, 1H, CH2-THP), 2.17 (s, 3H, C2/3-CH3), 2.20 (s, 3H, C2/3-CH3), 3.62-
3.65 (m, 1H, CH2-THP), 3.90-3.98 (m, 1H, CH2-THP), 4.42 (s, 1H, OH), 5.24 (t, 1H, J = 3.3 
Hz, CH-THP), 6.56 (d, 1H, J = 8.7 Hz, HAr), 6.84 (d, 1H, J = 8.7 Hz, HAr) ppm. 
 
To a solution of mono-OTHP hydroquinone (2.63 g, 11.8 mmol) in THF (150 mL) at 0 °C, 
was added NaH (60% on mineral oil, 517.0 mg, 13.0 mmol), and the mixture stirred for 10 
min. Triisopropylsilylchloride (3.0 mL, 14.2 mmol) was added dropwise at 0 °C, and the 
mixture further stirred at room temperature for 3 h. The mixture was quenched with saturated 
NaHCO3 and extracted with TBME (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue purified by column chromatography on SiO2 (hexane – 
EtOAc, 97:3) to afford 66 (3.77 g, 84%) as a white solid.  
 
m.p. = 34 - 35 °C;  
1H NMR (300 MHz, CDCl3, 25 °C): δ = 1.10 (d, 18H, J = 6.5 Hz, CH3-TIPS), 1.21-1.33 (m, 
3H, CH-TIPS), 1.60-1.70 (m, 3H, CH2-THP), 1.84-1.95 (m, 2H, CH2-THP), 1.95-2.05 (m, 
1H, CH2-THP), 2.17 (s, 3H, C2/3-CH3), 2.18 (s, 3H, C2/3-CH3), 3.57-3.62 (m, 1H, CH2-THP), 
3.91-4.00 (m, 1H, CH2-THP), 5.23 (t, 1H, J = 3.3 Hz, CH-THP), 6.57 (d, 1H, J = 8.8 Hz, 
HAr), 6.79 (d, 1H, J = 8.8 Hz, HAr) ppm;  
O
O
14
OSi
66 
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13C NMR (100 MHz, CDCl3, 25 °C): δ = 13.0, 13.4, 18.5, 19.6, 25.8, 31.2, 62.6, 97.9, 115.0, 
115.4, 127.8, 128.3, 149.1, 149.5 ppm; 
IR (KBr) υmax 2942, 2866, 1540, 1477, 1384, 1247, 1091, 1038, 923, 883 cm-1;  
UV (CH2Cl2) λmax : 238 nm, 286 nm; 
anal. calcd. for C22H38O3Si: C 69.79, H 10.12; found: C 70.00, H 10.12.  
 
 
(all-E)-Geranyl geraniol 69. To a suspension of NaH 
(60% on mineral oil, 430mg, 10.8 mmol) in THF (25 
mL), was slowly added triethylphosphonoacetate (2 mL, 
10.0 mmol), and the mixture was stirred at room 
temperature for 1 h. Farnesylacetone (1.86g, 7.1 mmol) in THF (3 mL) was then added, and 
the mixture further stirred for 16 h. The reaction was quenched with cold saturated brine, 
extracted with EtOAc, and the organic phase washed with H2O, dried over Na2SO4 and 
evaporated to dryness. The residue was purified by column chromatography on SiO2 (hexane 
– Et2O, 20:1) to afford (all-E)-geranyl geranoyl ethylester 71 (1.48 g, 66%) as a colourless oil. 
Spectral data were identical to those already reported124 – Selected data. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.27 (t, 3H, J = 7.1 Hz, Et), 1.60 (s, 9H, CH3C=C), 
1.68 (s, 3H, CH3C=C), 1.90-2.20 (m, 15H, CH3C=C, CH2), 4.14 (q, 2H, J = 7.2 Hz, Et), 5.09 
(m, 3H, CH=C), 5.66 (s, 3H, C=CHCOOEt) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 14.7, 16.4, 18.1, 19.2, 26.1, 26.4, 27.0, 27.2, 40.1, 
41.4, 59.8, 116.0, 123.3, 124.5, 124.8, 131.7, 135.4, 136.6, 160.2, 167.3 ppm; 
GC (Optima-5 Ph-Me Si column, 25m x 0.2 mm, 0.35 μm; split injector (1:20), injector temp. 
250 °C; FID detector, detector temp. 270 °C, carrier gas: H2, 20 psi; 100°C to 270°C 
(6°C/min), 39 min): t(Z,E,E,E)= 26.6 min, t(E,E,E,E) = 27.4 min, E:Z ratio: >99:1. 
 
To a solution of (all-E)-geranyl geranoyl ethyl ester 71 (1.67 g, 5.25 mmol) in Et2O (20 mL), 
was added DIBAL-H (0.7-1.3 M in hexane, 10.0 mL) dropwise at 0 °C, and the reaction 
further stirred at room temperature for 2 h. The mixture was quenched by addition of H2O at 0 
°C, extracted with EtOAc, and the organic phase washed with H2O, dried over Na2SO4 and 
evaporated to dryness. The residue was passed through a pad of SiO2 (EtOAc) to afford (all-
OH
1769 
 105
Experimental part 
E)-geranyl geraniol 69 (1.1 g, 72%) as a slightly yellow oil. Spectral data were identical to 
those of an original sample – Selected data. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.60 (s, 9H, CH3C=C), 1.68 (s, 6H, CH3C=C), 1.90-
2.15 (m, 12H, CH2), 4.15 (t, 2H, J = 6.1 Hz, CH2OH), 5.10 (m, 3H, CH=C), 5.42 (m, 1H, 
C=CHCH2OH) ppm. 
 
 
Monoprotected hydroquinone 65. 
To a solution of nBuLi (1.6 M in 
hexane, 7.4 mL, 11.8 mmol) in Et2O 
(40 mL) at 0 °C, was added TMEDA 
(1.7 mL, 11.4 mmol) together with 66 
(4.3 g, 11.4 mmol) in Et2O (10 mL). The mixture was stirred for 3 h at 0 °C, and cooled down 
to -20 °C. CuBr (530 mg, 3.6 mmol) was added, followed by geranyl geranylbromid 6776 (3.2 
g, 9.11 mmol) in Et2O (10 mL), and the mixture was stirred for 6 h at room temperature. The 
reaction was quenched with saturated NaHCO3 and extracted with TBME (3 ×). Combined 
organic phases were dried over Na2SO4, evaporated to dryness and the residue purified by 
column chromatography on SiO2 (hexane – CH2Cl2, 3:1) to afford a mixture of 72 and 66 
(5.33g). 
 
To a solution of 72:66 (5.33g) in THF (70 mL), was added TBAF (1 M in THF, 10.5 mL, 10.5 
mmol) and the mixture was stirred at room temperature for 1 h. The reaction was quenched 
with saturated NaHCO3 and extracted with TBME (3 ×). Combined organic phases were dried 
over Na2SO4, evaporated to dryness and the residue purified by column chromatography on 
SiO2 (CH2Cl2) to afford 65 (3.20 g, 98%) as a slight yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ  = 1.48-1.63 (m, 12H, H3’/4’, C9/13/17-CH3), 1.66-1.70 
(dd, 6H, J = 5.7 and 1.0 Hz, C21-CH3), 1.77-1.87 (m, 1H, H5’), 1.90-2.02 (m, 6H, H14/18/3’/4’), 
2.02-2.16 (m, 6H, H10/11/15/19), 2.12 (s, 3H, C2-CH3), 2.21 (s, 3H, C3-CH3), 3.36 (d, 2H, J = 7.3 
Hz, H7), 3.44 (m, 1H, H2’), 4.04 (m, 1H, H2’), 4.49 (s, 1H, OH), 4.67 (m, 1H, H1’), 5.05-5.17 
(m, 3H, H12/16/20), 5.29 (t, 1H, J = 6.9 Hz, H8), 6.44 (s, 1H, H6) ppm;  
O
O
HO
13
1
2
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5
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8
9 13 17 21
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13C NMR (100 MHz, CDCl3, 25 °C): δ  = 11.9, 12.2, 14.0, 15.9, 16.0, 16.1, 17.6, 21.1, 25.1, 
25.6, 26.5, 26.7, 28.4, 31.2, 39.6, 39.7, 65.1, 103.7, 112.9, 120.8, 122.8, 124.1, 124.3, 131.2, 
132.7, 134.9, 136.1, 147.8, 149.6 ppm;  
MS (ESI - MeOH): 571.4+ (M + Na)+;  
IR (neat) υmax 3401, 2922, 2852, 1442, 1379, 1200, 1074, 1034, 954, 910, 833, 651 cm-1;  
UV (MeOH) λmax : 209 nm, 285 nm. 
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Mannich reaction – General procedure. A solution of D-proline or L-proline (39.9 mmol) in 
formaldehyde (35% aq, 41.9 mmol) was stirred at 40 °C, under a flow of N2, for 15 min. The 
sticky white solid was solved in MeOH (15 mL), and 65 (1.94 mmol) was added in MeOH (7 
mL). The mixture was stirred at 40 °C for 17 h, and allowed to cool down to room 
temperature. The reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 
(3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness and the 
residue purified by column chromatography on SiO2 (CH2Cl2 - MeOH, 9:1).  
 
D-ProOH derivative D-73. 989 mg (82% yield) as a pinky oil. 
1H NMR (400 MHz, CDCl3, 25 °C): δ  = 1.45-1.63 (m, 12H, H3’/4’, C9/13/17/21-CH3), 1.67 (s, 
3H, C9/13/17/21-CH3), 1.71-1.84 (m, 1H, H5’), 1.75 (s, 3H, C9/13/17/21-CH3), 1.84-2.00 (m, 8H, 
H14/18/3’/4’/4’’), 2.00-2.10 (m, 6H, H10/11/15/19), 2.11-2.31 (m, 7H, C2/3-CH3, H3’’), 2.39 (m, 1H, 
H3’’), 2.77 (m, 1H, H5’’), 3.25-3.52 (m, 3.5H, H7/2’/5’’), 3.57 (m, 0.5H, H7), 3.76 (m, 1H, H6’’), 
3.83-4.03 (m, 2H, H2’/1’’), 4.39 (m, 1H, H1’’), 4.59 (m, 1H, H1’), 5.00-5.16 (m, 4H, H8/12/16/20) 
ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ = 12.9, 14.4, 14.5, 15.9, 16.0, 16.5, 17.6, 21.2, 23.5, 
25.0, 25.6, 26.5, 26.7, 31.2, 39.6, 65.2, 65.4, 103.9, 123.7, 123.8, 124.0, 124.3, 131.2, 134.9, 
135.0, 135.3, 147.4 ppm;  
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MS (ESI - MeOH): 622.8+ (M + H)+, 644.5+ (M + Na)+;  
IR (neat) υmax 2920, 2851, 1619, 1450, 1377, 1251, 1202, 1074, 1033, 907, 645, 587 cm-1;  
UV (MeOH) λmax : 207 nm, 290 nm; 
anal. calcd. for C39H59NO5: C 75.32, H 9.56, N 2.25; found: C 74.84, H 9.29, N 2.18. 
 
L-ProOH derivative L-73. 1.58 g (86% yield) as a pinky oil.  
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.45-1.62m, 12H, (H3’/4’, C9/13/17/21-CH3), 1.67 (s, 3H, 
C9/13/17/21-CH3), 1.71-1.84 (m, 1H, H5’), 1.75 (s, 3H, C9/13/17/21-CH3), 1.84-2.01 (m, 8H, 
H14/18/3’/4’/4”), 2.02-2.10 (m, 6H, H10/11/15/19), 2.12-2.30 (m, 7H, C2/3-CH3, H3”), 2.38 (m, 1H, 
H3”), 2.76 (m, 1H, H5”), 3.21-3.51 (m, 3.5H, H7/2’/5”), 3.56 (m, 0.5H, H7), 3.75 (m, 1H, H5”), 
3.83-4.04 (m, 2H, H2’/1”), 4.39 (m, 1H, H1”), 4.59 (m, 1H, H1’), 5.01-5.14 (m, 4H, H8/12/16/20) 
ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 12.9, 14.4, 14.5, 15.9, 16.0, 16.5, 17.6, 21.2, 23.5, 
25.0, 25.6, 26.5, 26.7, 31.2, 39.6, 39.7, 65.2, 65.4, 103.9, 123.7, 123.8, 124.0, 124.3, 131.2, 
134.9, 135.0, 135.3, 147.4 ppm;  
MS (ESI - MeOH): 622.8+ (M + H)+, 644.5+ (M + Na)+;  
anal. calcd. for C39H59NO5: C 75.32, H 9.56, N 2.25; found: C 74.55, H 9.24, N 2.24. 
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Methylester protection – General procedure. To a solution of 73 (1.25 mmol) in MeOH (50 
mL) was added trimethylsilyl diazomethane (2 M in hexanes, 16.29 mmol) dropwise, at room 
temperature. The mixture was stirred for 2 h, quenched with saturated NaHCO3 and extracted 
with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness 
and the residue purified by column chromatography on SiO2 (CH2Cl2 - MeOH, 99.5:0.5). 
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D-ProOMe derivative D-74. 677.4 mg (85% yield) as a slight yellow oil. 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.45-1.64 (m, 12H, H3’/4’, C9/13/17/21-CH3), 1.67 (s, 
3H, C9/13/17/21-CH3), 1.74 (s, 3H, C9/13/17/21-CH3), 1.76-1.89 (m, 2H, H5’), 1.89-2.00 (m, 8H, 
H14/18/4’/3”/4”), 2.01-2.10 (m, 6H, H10/11/15/19), 2.16 (s, 3H, C2-CH3), 2.17-2.26 (m, 4H, C3-CH3, 
H3”), 2.34 (m, 1H, H4”), 3.04 (m, 1H, H4”), 3.24-3.34 (m, 2H, H7), 3.36-3.55 (m, 2H, H2’/2”), 
3.61 (dd, 1H, J = 13.4 and 8.5 Hz, H1”), 3.74 (s, 3H, CH3O), 3.93 (dd, 1H, J = 13.4 and 10.83 
Hz, H1”), 4.01 (m, 1H, H2’), 4.61(m, 1H, H1’), 4.97-5.15 (m, 4H, H8/12/16/20), 10.68 (s, 1H, OH) 
ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 11.9, 14.1, 15.9, 16.5, 17.6, 21.3, 23.2, 25.1, 25.6, 
25.7, 25.9, 26.6, 26.7, 29.5, 31.2, 39.6, 52.1, 52.5, 52.9, 53.2, 65.1, 65.2, 65.5, 65.7, 104.0, 
104.1, 117.8, 117.9, 122.2, 124.0, 124.3, 129.9, 131.2, 134.3, 134.8, 134.9, 135.0, 146.4, 
152.4, 173.8 ppm;  
MS (ESI - MeOH): 636.6+ (M + H)+, 658.4+ (M + Na)+;  
IR (neat) υmax 2919, 2850, 1741, 1438, 1377, 1250, 1203, 1076, 1033 cm-1;  
UV (MeOH) λmax : 224 nm, 289 nm; 
anal. calcd. for C40H61NO5: C 75.55, H 9.67, N 2.20; found: C 75.38, H 9.42, N 2.03.  
 
L-ProOMe derivative L-74. 1.16 g (90% yield) as a slight yellow oil.  
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.45-1.63 (m, 12H, H3’/4’, C9/13/17/21-CH3), 1.67 (s, 
3H, C9/13/17/21-CH3), 1.74 (s, 3H, C9/13/17/21-CH3), 1.76-1.89 (m, 2H, H5’), 1.89-2.00 (m, 8H, 
H14/18/4’/3”/4”), 2.01-2.10 (m, 6H, H10/11/15/19), 2.16 (s, 3H, C2-CH3), 2.17-2.26 (m, 4H, C3-CH3, 
H3”), 2.34 (m, 1H, H5”), 3.04 (m, 1H, H5”), 3.24-3.34 (m, 2H, H7), 3.36-3.55 (m, 2H, H2’/2”), 
3.61 (dd, 1H, J = 13.4 and 8.5 Hz, H1”), 3.74 (s, 3H, CH3O), 3.93 (dd, 1H, J = 13.4 and 10.83 
Hz, H1”), 4.01 (m, 1H, H2’), 4.61(m, 1H, H1’), 4.97-5.15 (m, 4H, H8/12/16/20), 10.68 (s, 1H, OH) 
ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ = 11.9, 14.1, 15.9, 16.5, 17.6, 21.3, 23.3, 25.1, 25.6, 
26.6, 26.7, 29.5, 31.2, 34.9, 39.6, 52.0, 52.5, 63.6, 65.1, 65.2, 65.5, 65.7, 104.1, 117.9, 122.2, 
124.0, 124.2, 124.3, 129.9, 130.0, 130.1, 131.2, 134.3, 134.9, 135.0, 146.4, 152.4, 173.8 ppm;  
MS (ESI - MeOH): 636.6+ (M + H)+, 658.4+ (M + Na)+;  
anal. calcd. for C40H61NO5: C 75.55, H 9.67, N 2.20; found: C 75.28, H 9.41, N 2.36. 
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(-)-Camphanoyl protection – General procedure. To a solution of 74 (1.01 mmol) in CH2Cl2 
(40 mL) was added DMAP (3.54 mmol), followed by (-)-camphanoyl chloride (3.84 mmol), 
at room temperature. The mixture was stirred for 3 h, quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and the residue purified by column chromatography on SiO2 (CH2Cl2 - MeOH, 99:1). 
  
(-)-CamphanoylO-/THPO- D-ProOMe derivative D-75. 769.0 mg (93% yield) as a slight 
yellow oil. 
1H NMR (400 MHz, CDCl3, 25 °C): δ  = 1.10-1.22 (m, 9H, C5”’/7”’-CH3), 1.46-1.63 (m, 12H, 
H3’/4’, C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.69-1.87 (m, 7H, C9/13/17/21-CH3, H5’/3”/4”’), 
1.88-2.00 (m, 9H, H11/14/15/18/19/4’/5’/4”), 2.00-2.12 (m, 11H, C2-CH3, H10/11/15/19/3”/4”’), 2.18-2.33 
(m, 4H, C3-CH3, H3”’), 2.36-2.70 (m, 2H, H5”/3”’), 2.72-3.00 (m, 1H, H5”), 3.15 (m, 0.5H, H2”), 
3.24-3.54 (m, 4.5H, H7/2’/1”/2”/7”), 3.54-3.95 (m, 4H, H7/1”/7”), 3.96-4.06 (m, 1H, H2’), 4.71 (d, 
1H, J = 5.8 Hz, H1’), 4.97-5.13 (m, 4H, H8/12/16/20) ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 9.63, 13.7, 14.5, 15.9, 16.5, 17.0, 17.6, 21.1, 25.0, 
25.6, 26.6, 26.7, 28.9,  31.2, 31.4, 39.6, 54.8, 64.4, 65.1, 90.9, 103.9, 124.1, 124.3, 126.6, 
131.1, 134.8 ppm;  
MS (ESI - MeOH): 816.6+ (M + H)+, 838.5+ (M + Na)+;  
IR (neat) υmax 2921, 2852, 1795, 1748, 1448, 1377, 1261, 1232, 1166, 1063, 1033, 632, 534 
cm-1;  
UV (MeOH) λmax : 208 nm, 270 nm; 
anal. calcd. for C50H73NO8: C 73.59, H 9.02, N 1.72; found: C 72.82, H 8.72, N 1.65.  
 
 (-)-CamphanoylO-/THPO- L-ProOMe derivative L-75. 1.33 g (90% yield) as a slight 
yellow oil.  
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.12-1.21 (m, 9H, C5”’/7”’-CH3), 1.46-1.63 (m, 12H, 
H3’/4’, C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.71-1.88 (m, 7H, C9/13/17/21-CH3, H5’/3”/4”’), 
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1.88-2.00 (m, 9H, H11/14/15/18/19/4’/5’/4”), 2.00-2.12 (m, 11H, C2-CH3, H10/11/15/19/3”/4”’), 2.18-2.30 
(m, 4H, C3-CH3, H3”’), 2.36-2.66 (m, 2H, H5”/3”’), 2.68-3.03 (m, 1H, H5”), 3.15 (m, 0.5H, H2”), 
3.27-3.54 (m, 4.5H, H7/2’/1”/2”/7”), 3.54-3.92 (m, 4H, H7/1”/7”), 3.96-4.06 (m, 1H, H2’), 4.71 (d, 
1H, J = 5.8 Hz, H1’), 4.97-5.15 (m, 4H, H8/12/16/20) ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ = 9.62, 13.6, 13.7, 14.5, 15.9, 16.5, 16.8, 17.6, 21.1, 
21.2, 25.0, 25.4, 26.5, 26.6, 31.2, 39.6, 52.0, 54.2, 54.8, 65.1, 90.9, 103.9, 124.1, 124.3, 126.6, 
131.1, 134.2, 134.8, 144.3, 152.7, 165.8, 174.5 ppm;  
MS (ESI - MeOH): 816.6+ (M + H)+, 838.5+ (M + Na)+;  
anal. calcd. for C50H73NO8: C 73.59, H 9.02, N 1.72; found: C 73.02, H 8.82, N 1.64. 
 
 
(-)-CamphanoylO-/OH, L-ProOMe 
derivative 76. To a solution of L-75 
(71.2 mg, 0.087 mmol) in THF (6 
mL) was added 1N HCl (2.5 mL) at 
room temperature and the mixture 
was stirred for 4 h, quenched with 
saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases were dried 
over Na2SO4, evaporated to dryness and the residue purified by column chromatography on 
SiO2 (CH2Cl2 - MeOH, 98:2) to afford 76 (57.1 mg, 86%) as a slight yellow oil. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.11-1.21 (m, 9H, C5”/7”-CH3), 1.54-1.63 (m, 9H, 
C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.73-1.89 (m, 7H, C9/13/17/21-CH3, H3’/4’/4”), 1.91-
2.01 (m, 6H, H14/18/4’), 2.01-2.13 (m, 13H, C2-CH3, H3’/4’’/10/11/15/19), 2.15 (s, 3H, C3-CH3), 2.23 
(m, 0.5H, H3”), 2.39 (m, 1H, H5’), 2.57 (m, 1H, H3”), 2.75 (m, 0.5H, H5’), 2.90 (m, 0.5H, H5’), 
3.12 (m, 0.5H, H1’), 3.26 (m, 0.5H, H2’), 3.37 (m, 0.5H, H2’),3.48-3.62 (m, 4H, COOMe, 
H1’/7), 3.62-3.75 (m, 2H, COOMe, H1’), 3.88 (m, 0.5H, H1’), 5.00-5.10 (m, 3H, H12/16/20), 5.15 
(m, 1H, H8), 5.38 (br, 1H, OH) ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 10.1, 12.7, 16.4, 16.5, 16.7, 17.3, 18.1, 26.1, 26.7, 
27.0, 27.2, 28.8, 40.0, 40.1, 55.3, 122.6, 123.9, 124.6, 124.8, 125.4, 131.6, 135.3, 136.1 ppm;  
MS (ESI - MeOH): 732.5+ (M + H)+, 754.3+ (M + Na)+;  
IR (neat) υmax 3485, 1794, 1747, 1732, 1446, 1380, 1091, 1084 cm-1;  
UV (MeOH) λmax : 208 nm, 284nm. 
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Yamamoto’s cyclisation - 
Chromanol 77. To a solution of 76 
(55.0 mg, 0.075 mmol) in 
CH2Cl2:MeCN (4:1, 5 mL) was 
added pTsOH (28.5 mg, 0.165 mmol) 
at room temperature and the mixture 
was stirred for 2 d, quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue 
purified by column chromatography on SiO2 (hexane - TBME, 98:2) to afford 77 (26.2 mg, 
50%) as a colourless oil. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.11-1.21 (m, 9H, C5”’/7”’-CH3), 1.21-1.30 (m, 3H, 
C2-CH3), 1.54-1.63 (m, 11H, C3/4’/8’/12’-CH3), 1.68 (s, 3H, C4’/8’/12’-CH3), 1.70-1.84 (m, 4H, 
H3’’/4’’/4”’), 1.91-2.12 (m, 18H, C7/8-CH3, H2’/5’/6’/9’/10’/3’’/4’’’), 2.24 (m, 1H, H3”’), 2.37 (m, 1H, 
H5’’), 2.57 (m, 1H, H3”’), 2.70-3.00 (m, 2H, H4/5’’), 3.08 (m, 1H, H1’’/5’’), 3.24 (m, 0.5H, H2’’), 
3.38 (m, 0.5H, H2’), 3.44-3.62 (m, 2H, COOMe, H1’), 3.62-3.75 (m, 2H, COOMe, H1’), 3.83 
(m, 0.5H, H1’), 5.00-5.14 (m, 3H, H3’/7’/11’) ppm;  
MS (ESI - MeOH): 732.6+ (M + H)+, 754.4+ (M + Na)+ , 770.2+ (M + K)+;  
IR (neat) υmax 2996, 2854, 1794, 1747, 1446, 1377, 1242, 1164, 1091, 1043, 644 cm-1;  
UV (MeOH) λmax : 206 nm, 288nm. 
 
OH
O
D-63
N COOH
OH
(-)CamphO
3
L-63
N COOH
1
2
3
4
5
6 7
8
9 13 17 21
1 '
2 '
4 '
6 '
O
O
O
1 ''2 ''3 ''
4 ''
5 '' 6 ''
7 ''
 
 
Cleavage of methylester and THP – General procedure. To a solution of 75 (0.90 mmol) in 
EtOAc (7 mL), was added LiI (24.6 mmol). The solution was stirred at 60 °C under a flow of 
N2 (addition of EtOAc, ca. 3 mL / h) for 8 h, then the reaction was quenched with saturated 
NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue filtrated over a pad of SiO2 (CH2Cl2 - MeOH, 99:1) to 
afford a crude oil used directly without further purification.  
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The crude material is solved in THF (60 mL) and 1 N HCl (30 mL) was added. The 
mixture was stirred 2 h at room temperature. The reaction was quenched with saturated 
NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue purified by column chromatography on SiO2 (CH2Cl2 - 
MeOH, 99:1). 
 
(-)-CamphanoylO-/OH D-ProOH derivative D-63. 531.4 mg (83% yield over two steps) as 
a slight yellow oil. 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.11-1.21 (m, 9H, C5”/7”-CH3), 1.54-1.63 (m, 9H, 
C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.73-1.89 (m, 5H, C9/13/17/21-CH3, H4”), 1.91-2.01 
(m, 6H, H14/18/4’), 2.01-2.13 (m, 11H, C2-CH3, H10/11/15/19), 2.17 (s, 3H, C3-CH3), 2.21-2.33 (m, 
2H, H3’/3”), 2.56 (m, 1H, H3”), 2.88 (m, 1H, H5’), 3.39 (m, 1H, H5’), 3.42-3.61 (m, 2H, H7), 
3.62-3.75 (m, 1H, H2’), 3.75-4.07 (m, 2H, H1’), 5.00-5.20 (m, 4H, H8/12/16/20) ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 9.6, 12.5, 13.7, 15.9, 16.0, 16.4, 16.7, 17.1, 17.6, 
24.3, 25.5, 25.6, 26.2, 26.3, 26.5, 26.7, 28.6, 29.6, 31.1, 39.5, 39.6, 54.8, 90.1, 90.7, 120.5, 
123.3, 124.1, 124.3, 128.1, 131.1, 134.9, 135.7, 140.2, 151.8, 165.9, 177.5 ppm;  
MS (ESI - MeOH): 718.6+ (M + H)+, 740.5+ (M + Na)+, 756.3+ (M + K)+;  
IR (neat) υmax 3537, 2916, 2853, 1794, 1755, 1635, 1448, 1381, 1311, 1240, 1161, 1090, 
1034, 845, 735 cm-1;  
UV (MeOH) λmax : 205 nm, 288 nm; 
anal. calcd. for C44H63NO7: C 73.61, H 8.84, N 1.95; found: C 72.55, H 8.86, N 1.80.  
 
(-)-CamphanoylO-/OH L-ProOH derivative L-63. 821.6 mg (86% yield over two steps) as a 
slight yellow oil.  
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.12-1.19 (m, 9H, C5”/7”-CH3), 1.56-1.61 (m, 9H, 
C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.73-1.85 (m, 5H, C9/13/17/21-CH3, H4”), 1.91-2.01 
(m, 6H, H14/18/4’), 2.01-2.15 (m, 11H, C2-CH3, H10/11/15/19), 2.17 (s, 3H, C3-CH3), 2.21-2.33 (m, 
2H, H3’/3”), 2.54 (m, 1H, H3”), 2.88 (m, 1H, H5’), 3.35 (m, 1H, H5’), 3.41-3.57 (m, 2H, H7), 
3.62 (m, 1H, H2’), 3.73-3.95 (m, 2H, H1’), 5.01-5.14 (m, 4H, H8/12/16/20) ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 9.6, 12.5, 13.6, 15.9, 16.0, 16.4, 16.7, 17.1, 17.6, 
24.4, 25.6, 26.2, 26.3, 26.5, 26.7, 28.6, 29.6, 31.2, 39.5, 39.6, 54.0, 54.8, 90.6, 120.4, 123.3, 
124.1, 124.3, 128.1, 131.2, 134.9, 135.7, 140.4, 141.1, 151.7, 162.7, 177.5 ppm;  
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MS (ESI - MeOH): 718.6+ (M + H)+, 740.5+ (M + Na)+, 756.3+ (M + K)+;  
anal. calcd. for C44H63NO7: C 73.61, H 8.84, N 1.95; found: C 72.63, H 8.77, N 1.69. 
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Coupling of aspartic acid – General procedure. A solution of 63 (0.705 mmol) and HCTU 
(2.61 mmol) in CH2Cl2 (20 mL) was stirred at room temperature for 0.5 h. Then D-
Asp(Fm)2.TFA or L-Asp(Fm)2.TFA (1.41 mmol) and DIEA (4.23 mmol) were added and the 
mixture stirred at room temperature for 5 h. The reaction was quenched with saturated NH4Cl 
and extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue purified by column chromatography on SiO2 (CH2Cl2 - 
MeOH, 95:5).  
 
(-)-CamphanylO-/OH D-Pro-D-Asp(Fm)2 derivative D-79. 512.4 mg (62% yield) as a 
colourless oil. 
1H NMR (500 MHz, CDCl3, 25 °C): δ = 1.07-1.22 (m, 9H, C5”/7”-CH3), 1.49-1.62 (m, 9H, 
C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.69-1.86 (m, 5H, C9/13/17/21-CH3, H4”), 1.86-2.34 
(m, 23H, C2/3-CH3, H10/11/14/15/18/19/3’/4’/3”), 2.35-2.70 (m, 3H, H5’/3”), 2.70-2.98 (m, 2H, H10’), 
3.02-3.84 (m, 6H, H7/1’/2’), 4.09-4.20 (m, 2H, H12’), 4.25-4.55 (m, 4H, H11’), 4.75-4.90 (m, 1H, 
H8’), 4.93-5.15 (m, 4H, H8/12/16/20), 5.21 (s, 1H, OH), 7.19-7.43 (m, 7H, HAr-Fm), 7.46-7.60 
(m, 4H, HAr-Fm), 7.64-7.79 (m, 4H, HAr-Fm) ppm;  
13C NMR (125 MHz, CDCl3, 25 °C): δ = 9.6, 12.2, 13.5, 15.9, 16.0, 16.2, 16.8, 16.9, 17.6, 
25.5, 25.6, 26.2, 26.5, 26.7, 28.8, 35.8, 39.5, 39.6, 46.5, 51.3, 54.7, 66.8, 70.5, 119.9, 121.1, 
123.3, 124.1, 124.3, 124.9, 127.0, 127.2, 127.7, 131.1, 134.8, 135.7, 141.1, 143.4, 143.5, 
151.2, 170.8 ppm;  
MS (ESI - MeOH): 1190.7+ (M + H)+, 1212.3+ (M + Na)+, 1227.8+ (M + K)+;  
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IR (neat) υmax 3365, 2966, 2914, 1792, 1738, 1668, 1506, 1448, 1263, 1227, 1163, 1092, 
1047, 739 cm-1; 
anal. calcd. for C76H88N2O10: C 76.74, H 7.46, N 2.36; found: C 76.12, H 7.51, N 2.22.  
 
(-)-CamphanylO-/OH L-Pro-L-Asp(Fm)2 derivative L-79. 368.5 mg (81% yield) as a 
colourless oil.  
1H NMR (500 MHz, CDCl3, 25 °C): δ = 1.13-1.24 (m, 9H, C5”/7”-CH3), 1.51-1.65 (m, 9H, 
C9/13/17/21-CH3), 1.67 (s, 3H, C9/13/17/21-CH3), 1.69-1.87 (m, 5H, C9/13/17/21-CH3, H4”), 1.86-2.30 
(m, 23H, C2/3-CH3, H10/11/14/15/18/19/3’/4’/3”), 2.39-2.79 (m, 3H, H5’/3”), 2.79-3.02 (m, 2H, H10’), 
3.02-3.24 (m, 1H, H2’), 3.26-3.40 (m, 1H, H1’), 3.41-3.67 (m, 3H, H7/2’), 3.68-3.86 (m, 1H, 
H1’), 4.08-4.23 (m, 2H, H12’), 4.23-4.52 (m, 4H, H11’), 4.53-4.74 (m, 0.5H, H8’), 4.85-5.18 (m, 
4.5H, H8/12/16/20/8’), 5.25-5.41 (m, 1H, OH), 7.23-7.32 (m, 3H, HAr-Fm), 7.33-7.44 (m, 4H, 
HAr-Fm), 7.48-7.61 (m, 4H, HAr-Fm), 7.68-7.80 (m, 4H, HAr-Fm) ppm;  
13C NMR (125 MHz, CDCl3, 25 °C): δ = 9.7, 12.2, 14.3, 15.9, 16.0, 16.2, 16.9, 17.3, 17.6, 
24.1, 25.7, 26.2, 26.6, 26.7, 28.9, 30.6, 30.9, 31.3, 31.6, 35.9, 39.6, 39.7, 46.5, 46.6, 48.3, 
51.2, 53.4, 54.3, 54.9, 60.9, 66.8, 67.4, 120.0, 121.5, 123.4, 124.2, 124.3, 124.9, 125.0, 127.1, 
128.3, 129.5, 131.2, 132.7, 134.9, 135.8, 141.2, 141.3, 143.3, 143.5, 166.6, 170.3, 174.7, 
177.8 ppm;  
MS (ESI - MeOH): 1189.7+ (M + H)+, 1212.3+ (M + Na)+, 1227.5+ (M + K)+;  
anal. calcd. for C76H88N2O10: C 76.74, H 7.46, N 2.36; found: C 76.15, H 7.50, N 2.20. 
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Fm-deprotection – General procedure. To a solution of 79 (0.129 mmol) in CH2Cl2 (10 mL) 
was added Et2NH (2.5 mL) and the mixture was stirred at room temperature for 2 h. Solvents 
were removed in vacuum, the crude product solved in CH2Cl2, and extracted with KHSO4 
(100 mg in 5 mL H2O). The aqueous phase was washed with CH2Cl2 (3 ×), combined organic 
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phases were dried over Na2SO4, evaporated to dryness and the residue purified by column 
chromatography on SiO2 (CH2Cl2 - MeOH, 75:25).  
 
(-)-CamphanoylO-/OH D-Pro-D-Asp(OH)2 derivative D-80. 42.9 mg (40% yield) as a 
colourless oil. 
1H NMR (600 MHz, DMSO, 25 °C): δ = 0.96 (s, 3H, C5”/7”-CH3), 1.00 (s, 3H, C5”/7”-CH3), 
1.06-1.15 (s, 3H, C5”/7”-CH3), 1.44-1.51 (m, 9H, C9/13/17/21-CH3), 1.51-1.73 (m, 8H, C9/13/17/21-
CH3, H3’/4’/4”), 1.78-2.00 (m, 16H, C3-CH3, H10/11/14/15/18/19/3’/4’), 2.00-2.33 (m, 6H, C2-CH3, 
H3”/4”), 2.39 (m, 1H, H5’), 2.46-2.62 (m, 1H, H5’), 2.62-2.78 (m, 0.2H, H8’), 2.93-3.63 (m, 7H, 
H7/1’/2’/5’/10’), 3.69-4.17 (m, 0.8H, H8’), 4.87-5.12 (m, 4H, H8/12/16/20), 7.44-7.84 (m, 1H, NH), 
7.98-8.68 (m, 2H, OH) ppm;  
13C NMR (125 MHz, DMSO, from 2D exp. HMQC/HMBC, 25 °C): δ = 9.1, 12.7, 13.0, 15.4, 
16.2, 16.3, 17.2, 23.6, 25.1, 25.8, 26.2, 27.9, 30.8, 38.8, 39.1, 47.6, 49.9, 52.8, 53.9, 54.4, 
55.3, 64.2, 66.4, 90.7, 123.7, 124.7, 125.6, 127.5, 130.6, 134.3, 140.7, 150.9, 177.8 ppm;  
MS (ESI - MeOH): 834.0+ (M + H)+, 856.0+ (M + Na)+, 877.9+ (M + 2Na)+, 832.0- (M - H)-;  
IR (neat) υmax 3353, 2968, 2918, 1795, 1751, 1595, 1423, 1416, 1238, 1163, 1091, 1048, 930 
cm-1;  
UV (MeOH) λmax: 240 nm, 284 nm. 
 
(-)-CamphanoylO-/OH L-Pro-L-Asp(OH)2 derivative L-80. 154.8 mg (63% yield) as a 
slight yellow solid.  
m.p. = 127-132 °C; 
1H NMR (500 MHz, DMSO, 25 °C): δ = 0.95-1.19 (m, 9H, C5”/7”-CH3), 1.41-1.56 (m, 9H, 
C9/13/17/21-CH3), 1.57-1.79 (m, 8H, C9/13/17/21-CH3, H3’/4’/4”), 1.79-2.05 (m, 16H, C3-CH3, 
H10/11/14/15/18/19/3’/4’), 2.05-2.26 (m, 5H, C2-CH3, H3”/4”), 2.26-2.75 (m, 4.5H, H5’/10’/3”), 2.89-
3.89 (m, 5.9H, H7/1’/2’/5’/8’), 3.92-4.44 (m, 0.6H, H8’), 4.80-5.20 (m, 4H, H8/12/16/20), 7.61-8.66 
(m, 2H, OH, NH) ppm;  
13C NMR (125 MHz, DMSO, from 2D exp. HMQC/HMBC, 25 °C): δ = 9.1, 12.7, 13.0, 15.4, 
16.2, 16.3, 17.2, 23.6, 25.1, 25.8, 26.2, 27.9, 30.8, 38.8, 39.1, 47.6, 49.9, 52.8, 53.9, 54.4, 
55.3, 64.2, 66.4, 90.7, 123.7, 124.7, 125.6, 127.5, 130.6, 134.3, 140.7, 150.9, 177.8 ppm;  
MS (ESI - MeOH): 833.5+ (M + H)+, 855.4+ (M + Na)+, 877.4+ (M + 2Na)+, 831.9- (M - H)-;  
anal. calcd. for C48H66N2O10Na2: C 65.74, H 7.59, N 3.19; found: C 64.56, H 7.66, N 2.87.  
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Cyclisation and protection of diacid – General procedure. To a solution of 80 (40.82 μmol) in 
CH2Cl2 (35 mL) was added pTsOH.H2O (85.7 μmol) in ACN (2 mL), and the mixture was 
stirred at room temperature for 48 h. The reaction is quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and the crude oil was dried under high vacuum. 
 
The residue was then solved in MeOH:CH2Cl2 (4:1, 2.5 mL) and trimethyl diazomethane (2 M 
in hexanes, 1.2 mmol) was added. The mixture was stirred at room temperature for 1 h, and 
the reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
Combined organic phases were dried over Na2SO4, evaporated to dryness and purified by 
column chromatography on SiO2 (CH2Cl2 - MeOH, 98.5:1.5). 
 
(-)-Camphanoyl D-Pro-D-Asp(OMe)2 cyclised derivative D-81. 15.2 mg (45% yield over 
two steps) as a colourless oil. 
1H NMR (500 MHz, CDCl3, 25 °C): δ = 1.10-1.32 (m, 9H, C5”’/7”’-CH3), 1.49-1.89 (m, 23H, 
C2/4’/8’/12’-CH3, H3/1’/3”/4”/4”’), 1.89-2.31 (m, 19H, C7/8-CH3, H2’/5’/6’/9’/10’/3”/3”’/4”’), 2.35-3.42 (m, 
9H, H4/2”/5”/10’/3”’/4”’), 3.53-3.89 (m, 8H, COOCH3, H1”), 4.53-4.99 (m, 1H, H8”), 5.00-5.23 (m, 
3H, H3’/7’/11’), 7.68-8.17 (m, 1H, NH) ppm;  
13C NMR (125 MHz, CDCl3, from 2D exp. HMQC/HMBC, 25 °C): δ = 9.6, 12.2, 13.5, 17.0, 
17.3, 21.3, 23.0, 25.5, 25.7, 28.7, 28.9, 30.8, 35.3, 39.4, 39.7, 52.2, 53.9, 55.2, 59.5, 61.4, 
63.1, 64.6, 69.3, 74.2, 75.4, 77.2, 77.4, 85.7, 89.3, 90.8, 92.6, 124.3, 131.2, 134.9, 141.2, 
143.2, 171.4, 178.1 ppm;  
MS (ESI - MeOH): 861.8+ (M + H)+, 883.7+ (M + Na)+; 
IR (neat) υmax 3365, 2921, 2853, 1794, 1739, 1674, 1502, 1436, 1376, 1225, 1163, 1092, 
1044 cm-1;  
anal. calcd. for C50H72N2O10: C 69.74, H 8.43, N 3.25; found: C 69.23, H 8.36, N 3.15;  
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Determination of diastereoisomeric excess from HPLC analysis was not possible at this stage 
– peaks were not properly resolved. 
 
(-)-Camphanoyl L-Pro-L-Asp(OMe)2 cyclised derivative L-81. 83.7 mg (81% yield over 
two steps) as a colourless oil. Spectral data were identical to those of D-81.  
HPLC (Protonsil® 120-5-CN, 10% to 20% iPrOH in n-heptane, 1 mL/min, 25°C, 290 nm): 
t(2S,3’E,7’E) = 29.9 min (82.6%), t(2R,3’E,7’E) = 31.5 min (17.4%), Diastereoisomeric excess 
(overlapped peaks) = 65% (9S);  
UV (MeOH) λmax : 205 nm, 289 nm. 
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Cleavage of chiral peptide – Benzyl chlorides all-E-(R)-82 and all-E-(S)-82. To a solution 
of benzylic amine 81 (21.4 μmol) in benzene (2 mL) was added 2,2,2-trichlorethyl 
chloroformate (0.64 mmol). The solution was refluxed for 24 h, and the mixture was allowed 
to cool down to room temperature. The reaction was quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and purified by column chromatography on SiO2 (CH2Cl2) to afford benzyl chloride 
82 as a colourless oil. (80% yield). Analytics were identical for both diastereoisomers.  
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.14-1.29 (m, 9H, C5”/7”-CH3), 1.50-1.72 (m, 18H, 
C2/4’/8’/12’-CH3, H1’/4”), 1.72-1.91 (m, 4H, H3/5’/9’), 1.89-2.16 (m, 15H, C5/7/8-CH3, 
H2’/5’/6’/9’/10’/4”), 2.29 (m, 1H, H3”), 2.62 (m, 1H, H3”), 2.82 (m, 2H, H4), 4.36-4.67 (m, 2H, 
CH2Cl), 5.05-5.17 (m, 3H, H3’/7’/11’) ppm;  
13C NMR (100 MHz, CDCl3, 25 °C): δ  = 9.6, 12.2, 13.2, 15.8, 15.9, 16.8, 17.6, 19.1, 22.0, 
25.6, 26.5, 26.6, 28.9, 29.2, 30.6, 31.4, 37.8, 39.6, 54.3, 54.9, 75.3, 91.1, 117.9, 123.9, 124.0, 
124.3, 127.4, 131.2, 134.9, 135.3, 150.0, 166.0, 177.9 ppm;  
MS (ESI - MeOH): 661.5+ (M + Na)+, 675.3+ (M + [HCl])+. 
 
all-E-(R)-82 all-E-(S)-82 
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Reductive cleavage with LiAlH4 - α-Tocotrienols all-E-(R)-19 and all-E-(S)-19. To a 
solution of benzyl chloride 82 (59.8 μmol) in THF (2.5 mL) was added LiAlH4 (1 M in THF, 
0.150 mmol) and the mixture was refluxed 18 h. The reaction was quenched with H2O / 1 N 
HCl, and extracted with Et2O (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and purified by column chromatography on SiO2 (CH2Cl2) to afford α-
tocotrienol 19 as a colourless oil (92% yield). Spectral data were identical to those of an 
original sample – Selected data; Analytics were identical for both enantiomers.  
 
1H NMR (500 MHz, CDCl3, 25 °C): δ = 1.26 (s, 3H, C2-CH3), 1.57-1.70 (m, 14H, H1’, 
C4’/8’/12’-CH3), 1.75-1.87 (m, 2H, H3), 1.90-2.20 (m, 19H, C5/7/8-CH3, H2’/5’/6’/9’/10’), 2.61 (t, 2H, 
J = 6.8 Hz, H4), 4.20 (s, 1H, OH), 5.05-5.18 (m, 3H, H3’/7’/11’) ppm. 
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Acetate-protection - α-Tocotrienyl acetates all-E-(R)-83 and all-E-(S)-83. To a solution of 
α-tocotrienol 19 (55.0 μmol) in pyridine (2 mL) was added acetic anhydride (400 μL) and the 
mixture was stirred at room temperature for 4 h. The reaction was quenched with 1 N HCl, 
and extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and purified by column chromatography on SiO2 (CH2Cl2) to afford α-
tocotrienyl acetate 83 as a colourless oil (>99% yield). Analytics were identical for both 
enantiomers.  
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.26 (s, 3H, C2-CH3), 1.57-1.70 (m, 14H, H1’, 
C4’/8’/12’-CH3), 1.75-1.87 (m, 2H, H3), 1.92-2.18 (m, 19H, C5/7/8-CH3, H2’/5’/6’/9’/10’), 2.33 (s, 3H, 
CH3(CO)O), 2.60 (t, 2H, J = 6.6 Hz, H4), 5.05-5.22 (m, 3H, H3’/7’/11’) ppm;  
all-E-(R)-19 all-E-(S)-19 
all-E-(R)-83 all-E-(S)-  
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13C NMR (100 MHz, CDCl3, 25 °C): δ  = 11.7, 12.0, 12.8, 15.8, 15.9, 17.6, 20.5, 22.1, 25.6, 
26.5, 26.7, 39.6, 74.7, 91.1, 117.2, 123.0, 124.1, 124.3, 126.6, 131.2, 134.9, 135.0, 140.4, 
149.3, 169.6 ppm;  
MS (ESI - MeOH): 489.6+ (M + Na)+, 505.4+ (M + K)+. 
 
 
(R,R,R)-15
HO
(S,R,R)-15
8
6
O
2
4
4' 8 ' 12' O 2
HO
 
 
Asymmetric hydrogenation - α-Tocopherols (R,R,R)-15 and (S,R,R)-15. To a solution of 
α-tocotrienyl acetate 83 (55.0 μmol) in CH2Cl2 (0.5 mL) was added Iridium catalyst 61 (0.55 
μmol) and the mixture was stirred at room temperature, under 50 bar H2 for 3 h. The solvent 
was removed in vacuum and hexane (1 mL) was added. Solids were filtered off (0.45 μm 
filter), and washed with hexane. The solvent was removed in vacuum, and the crude 
colourless oil directly used for next step. 
 
The crude oil was solved in THF (1 mL) and LiAlH4 (1 M in THF, 0.38 mmol) was added. 
The mixture was stirred at room temperature for 2 h. The reaction was quenched with H2O, 
and extracted with Et2O (3 ×). Combined organic phases were dried over Na2SO4, evaporated 
to dryness to afford α-tocopherol 15 as a colourless oil (90% yield). The crude material was 
used without further purification. Spectral data were identical to those of an original sample – 
Selected data. Analytics were identical for both diastereoisomers.  
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 0.80-0.91 (m, 12H, C4’/8’/12’-CH3), 0.97-1.57 (m, 
24H, C2-CH3, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’/11’/12’), 1.78 (m, 2H, H3), 2.11 (s, 6H, C5/7/8-CH3), 2.16 (s, 
3H, C5/7/8-CH3), 2.60 (t, 2H, J = 6.9 Hz, H4), 4.19 (s, 1H, OH) ppm;  
HPLC (Chiracel OD-H, 0.5% EtOH in n-hexane, 1 mL/min, 25°C, 220 nm): t(2R,4’RS,8’RS) = 7.9 
min, t(2S,4’RS,8’RS) = 9.0 min;  
Diastereoisomeric excess at C-2 = 65% (2R) from D-Pro-D-Asp; 73% (2S) from L-Pro-L-
Asp. 
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Methylether protection - α-Tocopheryl methylethers (R,R,R)-84 and (S,R,R)-15. To a 
suspension of NaH (60% on mineral oil, 74.0 μmol) in DMF (0.5 mL) at 0 °C was added a 
solution of α-tocopherol 15 (49.5 μmol) in DMF (1 mL). The mixture was stirred 30 min at 0 
°C and MeI (59.0 μmol) was added. The solution was allowed to warm up to room 
temperature and stirred for 3 h. The reaction was quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and the residue purified by column chromatography on SiO2 (hexane – EtOAc, 9:1) to 
afford α-tocopheryl methylether 84 as a colourless oil (86% yield). Spectral data were 
identical to those already reported52 – Selected data. Analytics were identical for both 
diastereoisomers.  
 
1H NMR (500 MHz, CDCl3, 25 °C): δ = 0.85 (d, 3H, J = 6.6 Hz, C4’/8’-CH3), 0.86 (d, 3H, J = 
6.6 Hz, C4’/8’-CH3), 0.87 (d, 6H, J = 6.6 Hz, C12’-CH3); 0.90-1.19 (m, 7H, H2’/3’/5’/6’/7’/9’/10’), 
1.23 (s, 3H, C2-CH3), 1.19-1.47 (m, 13H, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’/11’), 1.53 (m, 1H, H12’), 1.78 
(m, 2H, H3), 2.09 (s, 3H, C5-CH3), 2.14 (s, 3H, C8-CH3), 2.18 (s, 3H, C7-CH3), 2.58 (t, 2H, J 
= 6.8 Hz, H4), 3.63 (s, 3H, CH3O) ppm;  
GC (CP-Sil-88 column, 50m x 0.25 mm, 0.25 μm; split injector (1:30), injector temp. 280 °C; 
FID detector, detector temp. 250 °C, carrier gas: H2, 90 kPa; 170 °C, 140 min): t(2R,4’R,8’S / 
2S,4’S,8’R) = 136.9 min, t(2R,’4R,8’R / 2S,4’S,8’S) = 138.9 min, t(2R,4’S,8’R / 2S,4’R,8’S) = 140.7 min, t(2R,4’S,8’S / 
2S,4’R,8’R) = 144.9 min;  
Diastereoisomeric excess at C-4’ = >98% (R);  
Diastereoisomeric excess at C-8’ = >98% (R). 
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(-)-CamphanoylO-/OH epoxide 
– Sharpless epoxidation. In a 
two-neck round bottom flask filled 
with molecular sieves (6 mg), was 
added CH2Cl2 (0.7 mL) followed 
by Ti(OiPr)4 (15 μL, 0.048 mmol) and (-)-diethyltartrate (9 μL, 0.050 mmol) and the solution 
cooled to -20 °C and stirred for 20 min. Then a solution of 99 (21.6 mg, 0.044 mmol) in 
CH2Cl2 (1 mL) was added and the mixture was stirred at -20 °C for 20 min. Finally, TBHP 
(5.5M in decane, 20 μL, 0.109 mmol) was added dropwise and stirring was continued at -20 
°C for 16 h. The reaction was quenched with 40% NaOHaq and brine, and Et2O was added 
followed by celite. Filtration of the slurry over a pad of celite, concentration of the residue in 
vacuuo and purification on SiO2 (hexane - EtOAc, 75:25) afforded 100 (5.0 mg, 20%) as a 
colourless oil.  
 
1H NMR (600 MHz, CDCl3, 25 °C): δ = 0.82-0.88 (m, 12H, C13/17/21-CH3), 0.97-1.18 (m, 6H, 
H12/14/16/18/20), 1.13 (s, 3H, C7’-CH3), 1.17 (s, 6H, C5’/7’-CH3), 1.17-1.47 (m, 13H, 
H10/11/12/13/14/15/16/17/18/19), 1.48 (s, 3H, C9-CH3), 1.51 (sept, 1H, J=6.7 Hz, H21), 1.61 (m, 1H, 
H10), 1.78 (m, 1H, H4’), 2.00 (m, 1H, H4’), 2.07 (s, 3H, C2-CH3), 2.20 (s, 3H, C3-CH3), 2.22 
(m, 1H, H3’), 2.58 (m, 1H, H3’), 2.78-2.87 (m, 2H, H7), 3.04 (dt, 1H, J=9.8 and 2.60 Hz, H8) 
6.66 (s, 1H, H6), 7.37 (s, 1H, OH) ppm; 
13C NMR (125 MHz, CDCl3, 25 °C): δ =  9.8, 12.5, 13.1, 16.8, 16.9, 22.3, 22.5, 22.6, 24.7, 
27.9, 28.9, 31.1, 31.8, 32.8, 37.2, 37.7, 37.8, 38.7, 39.0, 54.9, 64.7, 90.8, 120.0, 126.2, 128.3, 
128.5, 141.4, 151.8, 177.6 ppm;  
MS (ESI - MeOH): 635.7+ (M + Na)+, 1248.2+ (2M + Na)+;  
HPLC (Protonsil® 120-5-CN, 3% iPrOH in n-heptane, 1 mL/min, 280 nm): tminor = 15.1 min, 
tmajor = 15.9 min; 
UV (n-heptane) λmax: 204 nm, 280 nm. 
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Monosylilation of 50 – General procedure. To 
a solution of 50 (14.44 mmol) and imidazole 
(57.8 mmol) in DMF (20 mL) at -30 °C, was 
added dropwise a solution of silyl chloride 
(17.3 mmol) in DMF (14 mL). The mixture 
was allowed to warm up to room temperature 
and stirred for 4 h. The reaction was quenched with water and extracted with CH2Cl2 (3 ×). 
Combined organic phases were washed with water, brine, dried over Na2SO4, and evaporated 
to dryness. The crude oil was purified by column chromatography on SiO2 using hexane – 
CH2Cl2 mixtures. 
 
Mono TBSO-hydroquinone 102a. 12.85 g (88% yield) as a slight yellow solid. Compound 
has already been described,125 selected data. 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 0.17 (s, 6H, CH3Si), 1.01 (s, 9H, (CH3)3CSi), 2.11 
(s, 3H, CAr-CH3), 2.16 (s, 3H, CAr-CH3), 2.18 (s, 3H, CAr-CH3), 4.24 (br, 1H, OH), 6.45 (s, 
1H, H6) ppm. 
 
Mono TIPSO-hydroquinone 102b. 800.9 mg (47% yield) as a slight yellow oil. 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.10 (d, 18H, J=7.2 Hz, CH(CH3)3), 1.30 (m, 3H, 
CH(CH3)3), 2.13 (s, 3H, CAr-CH3), 2.15 (s, 3H, CAr-CH3), 2.17 (s, 3H, CAr-CH3), 6.45 (s, 1H, 
H5) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 12.8, 13.3, 13.4, 16.5, 18.1, 18.5, 117.6, 120.4, 
123.6, 125.7, 146.1, 147.8 ppm. 
 
Mono DPSO-hydroquinone 102c. 5.29 g (94% yield) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 1.10 (s, 9H, tBu), 1.86 (s, 3H, C6-CH3), 2.19 (s, 3H, C2-
CH3), 2.30 (s, 3H, C3-CH3), 4.16 (s, 1H, OH), 6.08 (s, 1H, H5), 7.38 (m, 6H, Hm/Hp TBDPS-), 
7.73 (dd, 4H, J = 7.9 and 1.3 Hz, Ho TBDPS-) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.8, 13.4, 16.2, 20.0, 27.1, 118.0, 120.1, 123.6, 125.5, 
128.1, 130.1, 133.8, 135.9, 146.2, 147.3 ppm;  
MS (EI): 390.2;  
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IR (neat) υmax 3576, 2930, 2856, 1472, 1427, 1326, 1233, 1189, 1107, 1082, 876, 822, 698 
cm-1; 
anal. calcd. for C25H30O2Si: C 76.88, H 7.74; found: C 76.92, H 7.79.  
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Phytyl ether formation – General procedure. To a suspension of NaH (60% on mineral oil, 
8.75 mmol) in DMF (20 mL) at 0 °C was added a solution of 102 (7.36 mmol) in DMF (20 
mL). The mixture was stirred 30 min. at 0 °C and phytylbromide76 (8.18 mmol) was added 
dropwise in DMF (20 mL). The solution was allowed to warm up to room temperature and 
stirred for 5 h. The reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 
(3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness and the 
residue purified by column chromatography on SiO2 with hexane – EtOAc mixtures. 
 
TBSO-/phytylO- hydroquinone 104a. 4.29 g (87% yield) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 0.19 (s, 6H, CH3Si), 0.82-0.89 (m, 12H, C13/17/21-CH3), 
0.95-1.17 (m, 6H, H12/14/16/18/20), 1.01 (s, 9H, (CH3)3CSi), 1.17-1.48 (m, 12H, 
H11/12/13/14/15/16/17/18/19), 1.53 (sept, 1H, J=6.6 Hz, H21), 1.67 (s, 3H, C9-CH3), 2.03 (m, 2H, H10), 
2.09 (s, 3H, C6-CH3), 2.18 (s, 3H, C2-CH3), 2.22 (s, 3H, C3-CH3), 4.22 (d, 2H, J=6.8 Hz, H7), 
5.57 (t, 1H, J=6.8 Hz, H8), 6.45 (s, 1H, H5) ppm;  
13C NMR (100 MHz, CDCl3): δ = -3.8, 13.3, 13.6, 16.8, 16.9, 18.7, 20.1, 20.2, 23.0, 23.1, 
24.9, 25.2, 25.5, 26.2, 28.4, 33.1, 33.2, 37.1, 37.7, 37.8, 37.9, 39.8, 40.4, 69.8, 118.1, 118.4, 
120.6, 126.1, 128.4, 131.2, 141.3, 149.6, 150.3 ppm.  
 
TIPSO-/phytylO- hydroquinone 104b. 1.47 g (97% yield) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 0.80-0.90 (m, 12H, C13/17/21-CH3), 0.99-1.17 (m, 6H, 
H12/14/16/18/20), 1.10 (d, 18H, CH(CH3)3), 1.17-1.48 (m, 15H, H11/12/13/14/15/16/17/18/19, CH(CH3)3), 
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1.52 (sept, 1H, J=6.7 Hz, H21), 1.65 (s, 3H, C9-CH3), 2.02 (m, 2H, H10), 2.12 (s, 3H, C6-CH3), 
2.18 (s, 3H, C2-CH3), 2.21 (s, 3H, C3-CH3), 4.23 (d, 2H, J=7.3 Hz, H7), 5.56 (t, 1H, J=6.9 Hz, 
H8), 6.46 (s, 1H, H5) ppm;  
13C NMR (100 MHz, CDCl3): δ = 13.3, 13.5, 13.7, 16.8, 16.9, 18.5, 20.1, 20.2, 23.0, 23.1, 
24.9, 25.2, 25.5, 28.4, 33.1, 33.2, 37.1, 37.7, 37.8, 39.8, 40.4, 69.8, 117.8, 120.6, 125.7, 128.2, 
131.0, 141.3, 150.1 ppm;  
MS (ESI - MeOH): 610.0+ (M+Na)+.  
 
DPSO-/phytylO- hydroquinone 104c. 4.29 g (87% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3): δ = 0.83 (d, 3H, J = 4.1 Hz, C13/17-CH3), 0.85 (d, 3H, J = 4.1 
Hz, C13/17-CH3), 0.87 (d, 6H, J = 6.9 Hz, C21-CH3), 0.99-1.07 (m, 5H, H12/14/16/18), 1.10 (s, 9H, 
tBu), 1.14 (m, 2H, H20), 1.17-1.48 (m, 9H, H11/12/14/15/16/18/19), 1.38 (m, 2H, H13/17), 1.53 (sept, 
1H, J = 6.6 Hz, H21), 1.62 (s, 3H, C9-CH3), 1.89 (s, 3H, C6-CH3), 2.02 (m, 2H, H10), 2.21 (s, 
3H, C2-CH3), 2.27 (s, 3H, C3-CH3), 4.17 (d, 2H, J = 6.9 Hz, H7), 5.52 (t, 1H, J = 6.9 Hz, H8), 
6.10 (s, 1H, H5), 7.35 (m, 4H, Hm TBDPS-), 7.41 (m, 2H, Hp TBDPS-), 7.70 (d, 4H, J = 6.9 
Hz, Ho TBDPS-) ppm;  
13C NMR (125 MHz, CDCl3): δ = 13.0, 13.3, 16.2, 16.4, 19.7, 19.8, 22.7, 24.5, 24.8, 25.1, 
26.7, 28.0, 32.7, 32.8, 36.7, 37.3, 37.4, 39.4, 40.0, 69.3,  118.0, 120.2, 125.0, 127.6, 127.8, 
129.7, 130.5, 133.3, 135.5, 140.8, 149.2, 149.7 ppm;  
MS (EI): 668.4;  
IR (neat) υmax 2926, 2857, 1473, 1428, 1377, 1322, 1220, 1113, 1086, 981, 886, 700 cm-1; 
anal. calcd. for C45H68O2Si: C 80.78, H 10.24; found: C 80.64, H 10.22. 
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Double-Claisen rearrangement – General procedure. To a solution of 104 (6.41 mmol) in 
CH2Cl2 (150 mL) at -35 °C, was added BF3.Et2O (BF3 content: 48%, 9.62 mmol) dropwise. 
The yellow solution was stirred 10 min at -30 °C and quenched by the addition of water. The 
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mixture was warmed up to room temperature and extracted with CH2Cl2 (3 ×). Combined 
organic phases were dried over Na2SO4, evaporated to dryness and the residue purified three 
times by column chromatography on SiO2 using hexane – CH2Cl2 mixtures. 
 
TBSO- phytylhydroquinone 105a. 167.3 mg (66% yield) as a slight yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 0.12 (s, 6H, CH3Si), 0.80-0.90 (m, 12H, C13/17/21-CH3), 
0.95-1.17 (m, 6H, H12/14/16/18/20), 1.02 (s, 9H, (CH3)3CSi), 1.17-1.45 (m, 12H, 
H11/12/13/14/15/16/17/18/19), 1.52 (sept, 1H, J=6.7 Hz, H21), 1.63 (s, 0.06H, C(Z)9-CH3), 1.69 (s, 
2.98H, C(E)9-CH3), 1.91 (m, 2H, H10), 2.11 (s, 3H, C3-CH3), 2.12 (s, 3H, C2-CH3), 2.13 (s, 
3H, C6-CH3), 3.32 (d, 2H, J=6.1 Hz, H7), 4.28 (s, 1H, OH), 4.96 (t, 1H, J=5.6 Hz, H8) ppm;  
13C NMR (100 MHz, CDCl3): δ = -2.9, 12.8, 12.9, 15.1, 16.6, 19.1, 20.1, 23.0, 23.1, 24.9, 
25.2, 25.8, 26.6, 28.4, 33.1, 33.2, 37.1, 37.7, 37.8, 37.9, 39.8, 40.2, 120.4, 120.8, 124.0, 129.6, 
135.3, 145.1, 146.7 ppm;  
MS (EI): 544.4;  
E/Z ratio: 98:2. 
 
TIPSO- phytylhydroquinone 105b. 873.8 mg (59% yield) as a slight yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 0.80-0.90 (m, 12H, C13/17/21-CH3), 0.95-1.17 (m, 6H, 
H12/14/16/18/20), 1.10 (d, 18H, CH(CH3)3), 1.17-1.45 (m, 15H, H11/12/13/14/15/16/17/18/19, CH(CH3)3), 
1.52 (sept, 1H, J=6.9 Hz, H21), 1.64 (s, 0.04H, C(Z)9-CH3), 1.70 (s, 2.98H, C(E)9-CH3), 1.92 
(m, 2H, H10), 2.10 (s, 3H, C3-CH3), 2.14 (s, 3H, C2-CH3), 2.16 (s, 3H, C6-CH3), 3.32 (d, 2H, 
J=5.3 Hz, H7), 4.26 (s, 1H, OH), 4.98 (t, 1H, J=5.7 Hz, H8) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.7, 12.9, 14.6, 14.8, 16.6, 18.3, 18.6, 20.1, 23.0, 23.1, 
24.9, 25.2, 25.8, 27.2, 28.4, 33.1, 33.2, 37.0, 37.7, 37.8, 37.9, 39.8, 40.2, 120.3, 120.6, 124.2, 
125.0, 129.0, 135.4, 146.4, 147.0 ppm;  
MS (EI): 586.5;  
E/Z ratio: 98.7:1.3. 
 
DPSO- phytylhydroquinone 105c. 2.57 g (60% yield) as a slight yellow oil. 
1H NMR (500 MHz, CDCl3): δ = 0.82 (d, 3H, J = 6.6 Hz, C13/17-CH3), 0.84 (d, 3H, J = 6.6 
Hz, C13/17-CH3), 0.86 (d, 6H, J = 6.6 Hz, C21-CH3), 0.99-1.03 (m, 4H, H12/14/16/18), 1.10 (s, 9H, 
tBu), 1.13 (m, 2H, H20), 1.17-1.31 (m, 10H, H11/12/14/15/16/18/19), 1.31-1.43 (m, 2H, H13/17), 1.48 
(s, 3H, C9-CH3, E-isomer), 1.52 (sept, 1H, J = 6.6 Hz, H21), 1.81 (s, 3H, C3-CH3), 1.83 (m, 
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2H, H10), 2.03 (s, 3H, C2-CH3), 2.06 (s, 3H, C6-CH3), 3.26 (d, 2H, J = 5.4 Hz, H7), 4.29 (s, 
1H, OH), 4.84 (t, 1H, J = 5.7 Hz, H8), 7.31 (m, 4H, Hm TBDPS-), 7.39 (m, 2H, Hp TBDPS-), 
7.67 (d, 4H, J = 6.6 Hz, Ho TBDPS-) ppm;  
13C NMR (125 MHz, CDCl3): δ = 12.3, 12.6, 16.0, 16.3, 19.8, 20.4, 22.7, 22.8, 24.6, 24.9, 
25.4, 27.2, 27.4, 28.1, 32.8, 32.9, 36.8, 37.4, 37.5, 37.6, 39.5, 39.9, 120.2, 120.4, 123.5, 124.6, 
127.5, 128.8, 129.5, 134.8, 135.0, 135.3, 146.0, 146.3 ppm;  
MS (EI): 668.5;  
IR (neat) υmax 3465, 2926, 2856, 1462, 1428, 1376, 1251, 1190, 1112, 1086, 840, 821, 701 
cm-1; 
HPLC (Protonsil® 120-5-CN, 0.3% iPrOH in n-heptane, 0.4 mL/min, 220 nm): tE-isomer = 17.4 
min, tZ-isomer = 18.4 min;  
E:Z ratio = 98.3:1.7;  
UV (n-heptane) λmax : 206 nm, 287 nm;  
anal. calcd. for C45H68O2Si: C 80.78, H 10.24; found: C 80.38, H 10.15. 
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Synthesis of 106a, 106c-f – General procedure. To a suspension of NaH (60% on mineral oil, 
5.76 mmol) in DMF (20 mL) at 0 °C was added a solution of 105 (3.84 mmol) in DMF (20 
mL). The mixture was stirred 30 min at 0 °C and TIPSCl, DPSCl or MeI (7.68 mmol) was 
added dropwise. The solution was allowed to warm up to room temperature and stirred for 4 
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h. The reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue 
purified by column chromatography on SiO2 using hexane – CH2Cl2 mixtures. 
 
TIPSO-/TBSO- phytylhydroquinone 106a. 43.1 mg (60% yield) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 0.11 (s, 6H, CH3Si), 0.80-0.88 (m, 12H, C13/17/21-CH3), 
0.95-1.17 (m, 6H, H12/14/16/18/20), 1.00 (s, 9H, (CH3)3CSi), 1.07 (d, 18H, CH(CH3)3), 1.17-1.43 
(m, 15H, H11/12/13/14/15/16/17/18/19, CH(CH3)3), 1.52 (sept, 1H, J=6.6 Hz, H21), 1.61 (s, 0.03H, 
C(Z)9-CH3), 1.68 (s, 2.98H, C(E)9-CH3), 1.89 (m, 2H, H10), 2.09 (s, 3H, C3-CH3), 2.11 (s, 3H, 
C2-CH3), 2.12 (s, 3H, C6-CH3), 3.29 (d, 2H, J=5.9 Hz, H7), 4.92 (t, 1H, J=5.9 Hz, H8) ppm;  
13C NMR (100 MHz, CDCl3): δ = -2.9, 14.5, 14.6, 14.8, 15.4, 16.7, 18.4, 19.1, 20.1, 23.0, 
23.1, 24.9, 25.2, 25.8, 26.6, 27.4, 28.4, 33.1, 33.2, 37.1, 37.7, 37.8, 37.9, 39.8, 40.2, 124.0, 
125.4, 125.5, 129.5, 135.1, 145.5, 148.2 ppm;  
E:Z ratio = 98.5:1.5.  
 
TIPSO-/TIPSO- phytylhydroquinone 106c. Characterization made by A. Buss and reported 
in his Ph-D thesis. 
 
MeO-/TIPSO- phytylhydroquinone 106d. 15.1 mg (85% yield) as a colourless oil. 
1H NMR (400 MHz, CDCl3): δ = 0.80-0.90 (m, 12H, C13/17/21-CH3), 0.99-1.17 (m, 6H, 
H12/14/16/18/20), 1.09 (d, 18H, CH(CH3)3), 1.17-1.45 (m, 15H, H11/12/13/14/15/16/17/18/19, CH(CH3)3), 
1.52 (sept, 1H, J=6.6 Hz, H21), 1.64 (s, 0.04H, C(Z)9-CH3), 1.70 (s, 2.96H, C(E)9-CH3), 1.92 
(m, 2H, H10), 2.13 (s, 3H, C6-CH3), 2.14 (s, 3H, C2-CH3), 2.16 (s, 3H, C3-CH3), 3.30 (d, 2H, 
J=5.6 Hz, H7), 3.61 (s, 1H, CH3O), 4.99 (t, 1H, J=4.8 Hz, H8) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.8, 13.4, 14.7, 14.8, 16.6, 18.5, 20.1, 23.0, 23.1, 24.9, 
25.2, 25.8, 27.3, 28.4, 33.1, 33.2, 37.1, 37.7, 37.8, 37.9, 39.8, 40.2, 60.6, 124.0, 125.3, 127.7, 
127.8, 129.3, 135.4, 149.3, 151.4 ppm;  
E:Z ratio = 98.5:1.5. 
 
DPSO-/DPSO- phytylhydroquinone 106e. Characterization made by A. Buss and reported 
in his Ph-D thesis. 
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MeO-/DPSO- phytylhydroquinone 106f. 31.1 mg (81% yield) as a colourless oil. 
1H NMR (500 MHz, CDCl3): δ =  0.81 (d, 3H, J = 6.8 Hz, C13/17-CH3), 0.83 (d, 3H, J = 6.7 
Hz, C13/17-CH3), 0.86 (d, 6H, J = 6.6 Hz, C21-CH3), 0.94-1.09 (m, 4H, H12/14/16/18), 1.12 (s, 9H, 
tBu), 1.13 (m, 2H, H20), 1.16-1.41 (m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.17 (s, 3H, C9-CH3), 
1.52 (sept, 1H, J = 6.1 Hz, H21), 1.76 (s, 3H, C3-CH3), 2.04 (s, 3H, C2-CH3), 2.23 (s, 3H, C6-
CH3), 2.49 (m, 1H, H7), 2.76 (d, 1H, 5.7 Hz, H8), 3.22 (m, 1H, H7), 3.62 (s, 3H, CH3O), 7.32 
(m, 4H, Hm TBDPS-), 7.40 (m, 2H, Hp TBDPS-), 7.66 (d, 4H, J = 6.9 Hz, Ho TBDPS-) ppm;  
13C NMR (125 MHz, CDCl3): δ = 12.9, 13.2, 15.8, 16.1, 19.6, 19.7, 20.3, 22.2, 22.6, 22.7, 
24.5, 24.8, 27.1, 27.9, 28.0, 32.8, 37.1, 37.3, 37.4, 38.6, 39.4, 60.2, 60.7, 63.9, 125.0, 126.4, 
127.5, 127.6, 128.5, 129.6, 134.3, 135.1, 148.5, 151.3 ppm;  
MS (EI): 698.5;  
IR (neat) υmax 2926, 2858, 1461, 1404, 1246, 1111, 1086, 880, 701 cm-1; 
anal. calcd. for C46H70O3Si: C 79.03, H 10.09; found: C 78.88, H 9.79.  
 
 
CamphO-/TBSO- phytylhydroquinone 
106b. To a solution of 105a (51.6 mg, 
94.8 μmol) in CH2Cl2 (3 mL) at room 
temperature, was added DMAP (35.0 mg, 
0.28 mmol), followed by (-)-camphanoyl 
chloride (62.0 mg, 0.28 mmol). The mixture was stirred at room temperature for 5 h, 
quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases 
were dried over Na2SO4, evaporated to dryness and the residue purified by column 
chromatography on SiO2 (hexane – EtOAc, 95:5) to afford 106b (383.8 g, 99%) as a 
colourless oil. 
 
1H NMR (400 MHz, CDCl3): δ = 0.14 (s, 6H, CH3Si), 0.79-0.89 (m, 12H, C13/17/21-CH3), 
0.97-1.18 (m, 6H, H12/14/16/18/20), 1.02 (s, 9H, (CH3)3CSi), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, 
C7’-CH3), 1.18-1.44 (m, 12H, H11/12/13/14/15/16/17/18/19), 1.19 (s, 3H, C7’-CH3), 1.52 (sept, 1H, 
J=6.6 Hz, H21), 1.63 (s, 0.05H, C(Z)9-CH3), 1.67 (s, 2.97H, C(E)9-CH3), 1.78 (m, 1H, H4’), 
1.81 (m, 2H, H10), 1.99 (m, 1H, H4’), 2.00 (s, 3H, C3-CH3), 2.02 (s, 3H, C2-CH3), 2.12 (s, 3H, 
C6-CH3), 2.24 (m, 1H, H3’), 2.58 (m, 1H, H3’), 3.32 (m, 2H, H7), 4.95 (t, 1H, J=5.7 Hz, H8) 
ppm;  
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13C NMR (100 MHz, CDCl3): δ = -2.7, 10.1, 13.7, 14.0, 15.1, 16.6, 19.1, 20.1, 20.2, 23.0, 
23.1, 24.9, 25.2, 26.6, 28.4, 29.4, 31.8, 33.1, 33.2, 37.1, 37.7, 37.8, 39.8, 40.2, 54.6, 55.3, 
70.3, 70.9, 91.2, 91.6, 123.4, 126.7, 130.2, 135.7, 142.4, 149.6, 166.4, 178.4, 201.7 ppm;  
HPLC (Protonsil® 120-5-CN, 0.5% iPrOH in n-heptane, 0.6 mL/min, 220 nm): tE-isomer = 14.2 
min (96.0%), tZ-isomer = 14.7 min (2.3%);  
E:Z ratio = 98:2;  
UV (n-heptane) λmax : 211 nm, 280 nm. 
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MeO-/BnO- phytylhydroquinone 106g. Synthesis and characterization made by A. Buss and 
reported in his Ph-D thesis. 
 
TIPSO-/MOMO- phytylhydroquinone 106i. Synthesis and characterization made by A. 
Buss and reported in his Ph-D thesis. 
 
 
 
CamphO-/AnthrO- 
phytylhydroquinone 106h. 
To a solution of 106d (98.4 
mg, 0.126 mol) in THF (10 
mL) at room temperature, was 
added TBAF (1M in THF, 
150 μL, 0.15 mmol). The mixture was stirred at room temperature for 1 h, quenched with 
saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases were dried 
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over Na2SO4, evaporated to dryness and the residue purified by column chromatography on 
SiO2 (hexane – EtOAc, 9:1) to afford the free phenol (72.9 mg, 95%) as a colourless oil. 
 
To a suspension of NaH (60% on mineral oil, 6.0 mg, 0.143 mmol) in DMF (2 mL) at 0°C 
was added a solution of freshly prepared phenol (72.9 mg, 0.12 mmol) in DMF (2.5 mL). The 
mixture was stirred 30 min at 0 °C and 9-(chloromethyl)-anthracene (35.2 mg, 0.155 mmol) 
was added. The solution was allowed to warm up to room temperature and stirred for 3 h. The 
reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined 
organic phases are dried over Na2SO4, evaporated to dryness and the residue purified by 
column chromatography on SiO2 (hexane – EtOAc, 85:15) to afford 106h (84.0 mg, 87%) as 
a yellow oil/solid. 
 
1H NMR (400 MHz, CDCl3): δ = 0.74 (m, 3H, J=6.5 Hz, C13/17CH3), 0.79 (m, 3H, J=6.5 Hz, 
C13/17CH3), 0.85 (m, 6H, J=6.6 Hz, C21-CH3), 0.88-1.38 (m, 18H, H11/12/13/14/15/16/17/18/19/20), 
1.17 (s, 3H, C5’-CH3), 1.18 (s, 3H, C7’-CH3), 1.21 (s, 3H, C7’-CH3), 1.51 (sept, 1H, J=6.7 Hz, 
H21), 1.53 (s, 3H, C9-CH3), 1.76-1.90 (m, 3H, H10/4’), 1.98-2.02 (m, 4H, C6-CH3, H4’), 2.05 (s, 
3H, C2-CH3), 2.06 (s, 3H, C3-CH3), 2.27 (m, 1H, H3’), 2.60 (m, 1H, H3’), 3.41 (m, 2H, H7), 
4.96 (t, 1H, J=5.6 Hz, H8), 5.83 (s, 2H, OCH2Anth), 7.49 (m, 4H, HAr-Anth), 8.02 (d, 2H, J=7.9 
Hz, HAr-Anth), 8.36 (d, 2H, J=9.2 Hz, HAr-Anth), 8.49 (s, 1H, HAr-Anth) ppm;  
13C NMR (100 MHz, CDCl3): δ = 10.1, 13.5, 13.8, 14.4, 16.5, 17.4, 20.0, 20.1, 23.0, 23.1, 
24.8, 25.2, 25.8, 27.2, 28.4, 29.4, 31.9, 33.1, 33.2, 37.2, 37.7, 37.8, 39.8, 40.2, 54.7, 55.4, 
69.1,  91.5, 122.9, 124.9, 125.4, 126.6, 129.0, 129.4, 131.3, 132.9, 136.6, 144.3, 155.2, 166.3, 
178.4 ppm;  
MS (ESI - MeOH): 840.0+ (M+Na)+. 
 
 
Shi asymmetric epoxidation – General 
procedure to 108a-i. To a solution of 
106 (54.9 μmol) and catalyst ent-101 
(22.0 μmol) in MeCN:EtOH:CH2Cl2 
(1:1:2, 200 μL) was added a buffer 
solution of 2 M K2CO3/4.10-4 M EDTA (140 μL). The mixture was cooled down to 0 °C and 
H2O2 (30% aq, 0.3 mmol) was added in one portion. The reaction was stirred at 0 °C for 10 h, 
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and diluted with CH2Cl2 and H2O. The organic phase was extracted and the water phase 
further extracted with CH2Cl2 (2 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue was purified by column chromatography on SiO2 using 
hexane – EtOAc mixtures, to afford corresponding epoxides 108 as colourless oils. 
Characterization of compounds was made by A. Buss and reported in his Ph-D thesis. 
 
 
CamphO-/OH 
phytylhydroquinone epoxide 
111. To a solution of 99 (208.0 
mg, 0.35 mmol) in CH2Cl2 (35 
mL) at 0 °C was added mCPBA 
(93.6 mg, 0.56 mmol) at once. The solution was allowed to warm up to rt and stirred for 3 h. 
The reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
Combined organic phases are dried over Na2SO4, evaporated to dryness and the residue was 
purified by column chromatography on SiO2 (hexane – EtOAc, 8:2) to afford 111 (170.8 mg, 
80%) as a colourless oil. Analytics were identical to those of chiral epoxide 100 already 
described. 
 
 
‘Anti-Baldwin’ cyclisation 
screening – General 
procedure. To a solution of 
111 (10.5 μmol) in the 
corresponding solvent (3 mL, 
table 4) was added the 
Brönsted or Lewis acid, and 
the mixture stirred at room 
temperature for 24 h. The 
conversion and ratio between 5- and 6-membered ring products were determined by HPLC 
and by 1H NMR on a quenched sample. 
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Furan ring 112. 
1H NMR (400 MHz, CDCl3): δ = 0.81-0.89 (m, 12H, C5’/9’/13’-CH3), 0.99-1.18 (m, 6H, 
H4’/6’/8’/10’/12’), 1.12 (s, 3H, C7’’-CH3), 1.16 (s, 3H, C5’’/7’’-CH3), 1.17 (s, 3H, C5’’/7’’-CH3), 1.18-
1.47 (m, 14H, H2’/3’/4’/5’/6’/7’/8’/9’/10’/11’), 1.31 (d, 3H, C1-CH3), 1.48-1.56 (m, 1H, H13’), 1.72 (m, 
1H, OH), 1.77 (m, 1H, H4’’), 1.99 (m, 1H, H4’’), 2.03 (s, 3H, C8-CH3), 2.14 (s, 3H, C7-CH3), 
2.21 (m, 1H, H3’’), 2.56 (m, 1H, H3’’), 3.06 (dd, 1H, J=15.8 and 9.3 Hz, H3), 3.22 (dd, 1H, 
J=15.4 and 9.3 Hz, H3), 4.61 (t, 1H, J=9.3 Hz, H2), 6.68 (s, 1H, H5) ppm;  
13C NMR (100 MHz, CDCl3): δ = 9.9, 12.5, 12.8, 17.1, 19.9, 22.8, 23.5, 24.4, 28.4, 29.3, 
30.5, 30.7, 31.2, 31.3, 31.7, 33.2, 37.7, 38.0, 39.5, 55.0, 73.8, 89.1, 91.4, 115.4, 119.5, 127.8, 
127.9, 142.3, 156.5, 178.3 ppm;  
MS (ESI - MeOH): 635.7+ (M+Na)+, 651.5+ (M+K)+, 1248.0+ (2M+Na)+; 
HPLC (Protonsil® 120-5-CN, 3% iPrOH in n-heptane, 1 mL/min, 280 nm): t1 = 19.0 min, t2 = 
20.0 min;  
UV (n-heptane) λmax : 204 nm, 284 nm. 
 
Pyran ring 113. 
1H NMR (600 MHz, CDCl3): δ = 0.81-0.90 (m, 12H, C4’/8’/12’-CH3), 0.97-1.19 (m, 6H, 
H3’/5’/7’/9’/11’), 1.12 (s, 3H, C7’’-CH3), 1.16 (s, 3H, C5’’/7’’-CH3), 1.17 (s, 3H, C5’’/7’’-CH3), 1.19-
1.47 (m, 14H, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’), 1.31 (d, 3H, C1-CH3), 1.48-1.56 (m, 1H, H12’), 1.77 (m, 
1H, H4’’), 1.99 (m, 1H, H4’’), 2.05 (s, 3H, C7-CH3), 2.14 (s, 3H, C8-CH3), 2.21 (m, 1H, H3”), 
2.56 (m, 1H, H3”), 2.74 (dd, 1H, J=16.6 and 5.7 Hz, H4), 3.01 (dd, 1H, J=16.9 and 3.9 Hz, H4), 
3.83 (m, 1H, H3), 6.59 (s, 1H, H6) ppm;  
13C NMR (125 MHz, CDCl3): δ = 9.6, 12.7, 16.9, 19.5, 19.6, 19.9, 22.7, 24.7, 28.0, 28.9, 
29.4, 31.3, 31.7, 37.3, 37.4, 39.4, 55.0, 68.3, 78.8, 91.0, 119.3, 126.6, 127.5, 135.4, 141.8, 
148.7, 178.2 ppm;  
MS (ESI - MeOH): 635.7+ (M+Na)+, 651.5+ (M+K)+, 1248.0+ (2M+Na)+; 
HPLC (Protonsil® 120-5-CN, 3% iPrOH in n-heptane, 1 mL/min, 280 nm): t(3R,4R,4’R,8’R / 
3S,4S,4’R,8’R) = 24.7 min and 26.1 min, t(3R,4S,4’R,8’R / 3S,4R,4’R,8’R) = 23.2 and 23.8 min;  
UV (n-heptane) λmax : 204 nm, 287 nm. 
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Furan ring 115 from TBAF 
deprotection of 108f. To a solution of 
108f (24.2 mg, 0.034 mmol) in THF (1.5 
mL) at room temperature, was added 
TBAF (1 M in THF, 40 μL, 0.039 mmol). The mixture was stirred at room temperature for 1 
h, quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic 
phases were dried over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2 (hexane – EtOAc, 8:2) to afford 115 (15.9 mg, 99%) as a colourless 
oil. 
 
1H NMR (500 MHz, CDCl3): δ = 0.85 (d, 3H, J=6.6 Hz, C5’/9’-CH3), 0.87 (d, 9H, J=6.6 Hz, 
C5’/9’/13’-CH3), 0.96-1.10 (m, 3H, H4’/6’/8’/10’), 1.10-1.17 (m, 2H, H12’), 1.17-1.36 (m, 9H, 
H3’/4’/6’/7’/8’/10’/11’), 1.30 (m, 2H, H2’), 1.32 (s, 3H, C1-CH3), 1.32-1.46 (m, 2H, H5’/9’), 1.46-1.63 
(m, 2H, H4’/6’/8’/10’), 1.51 (sept, 1H, J=6.6 Hz, H13’), 1.80 (m, 1H, OH), 2.10 (s, 3H, C8-CH3), 
2.16 (s, 6H, C5/7-CH3), 2.98 (dd, 1H, J=15.5 and 9.1 Hz, H3), 3.11 (dd, 1H, J=15.1 and 9.1 Hz, 
H3), 3.63 (s, 3H, CH3O), 4.57 (t, J=9.5 Hz, 1H, H2) ppm;  
13C NMR (125 MHz, CDCl3): δ = 12.2, 12.3, 13.0, 20.0, 22.7, 22.6, 23.4, 24.5, 24.8, 28.0, 
30.0, 32.8, 37.3, 37.4, 37.5, 37.7, 39.4, 60.4, 73.6, 88.3, 115.9, 123.6, 124.1, 128.7, 150.5, 
153.5 ppm;  
MS (EI): 460.4;  
anal. calcd. for C30H52O3: C 78.21, H 11.38, O 10.42; found: C 78.01, H 11.13, O 10.86. 
 
 
CamphO-/TBSO- 
phytylhydroquinone epoxide 
(rac,R,R)-108b. To a solution of 
106b (120.1 mg, 0.166 mmol) in 
CH2Cl2 (5 mL) at 0 °C, was added 
mCPBA (46.0 mg, 0.265 mmol) at once. The solution was allowed to warm up to room 
temperature and stirred for 2 h. The reaction was quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and the residue was purified by column chromatography on SiO2 (hexane – EtOAc, 
9:1) to afford (rac,R,R)-108b (111.5 mg, 91%) as a colourless oil. 
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1H NMR (400 MHz, CDCl3): δ = 0.15 (s, 6H, CH3Si), 0.80-0.89 (m, 12H, C13/17/21-CH3), 
0.95-1.17 (m, 6H, H12/14/16/18/20), 1.04 (s, 9H, (CH3)3CSi), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, 
C7’-CH3), 1.19 (s, 3H, C7’-CH3), 1.20-1.46 (m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.52 (sept, 1H, 
J=6.8 Hz, H21), 1.57 (s, 3H, C9-CH3), 1.78 (m, 1H, H4’), 1.99 (m, 1H, H4’), 2.02 (s, 3H, C3-
CH3), 2.03 (s, 3H, C2-CH3), 2.12 (s, 3H, C6-CH3), 2.24 (m, 1H, H3’), 2.58 (m, 1H, H3’), 2.65 
(m, 1H, H7), 2.76 (m, 1H, H8), 3.18 (m, 1H, H7) ppm;  
13C NMR (100 MHz, CDCl3): δ = -2.9, 10.1, 12.8, 13.6, 13.8, 17.2, 17.4, 20.1, 20.2,  22.7, 
23.0, 23.1, 24.9, 25.2, 27.6, 27.9, 28.4, 29.4, 31.9, 33.1, 33.2, 37.3, 37.7, 37.8, 39.0, 39.8, 
54.7, 55.3, 91.5, 121.9, 125.3, 128.1, 152.2, 166.6, 178.4 ppm;  
MS (ESI - MeOH): 764.0+ (M+Na)+;  
HPLC (Chiracel AD-H, 2% iPrOH in n-heptane, 0.5 mL/min, 280 nm): mixture of 2 
stereoisomers,   t1 = 10.8 min (49.8 %), t2 = 11.8 min (47.5 %). 
 
 
TBS cleavage using aqeous HCl 
– General procedure.(scheme 55) 
To a solution of (rac,R,R)-108b 
(14.8 μmol) in the corresponding 
solvent (MeCN or MeCN:TFA, 
0.5 mL) was added aqueous HCl (1N or 6N, 1 mmol) and the reaction was stirred at rt for 18 h. 
The reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue was 
purified by column chromatography on SiO2 (hexane – EtOAc, 7:3). Reactions produced 
several unidentified side-products and yields of 118 and 119 were <10-15% in each cases. 
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(400 MHz, CDCl3): δ = 0.82-0.89 (m, 12H, C13/17/21-CH1H NMR 3), 0.95-1.20 (m, 6H, 
H12/14/16/18/20), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, C7’-CH3), 1.19 (s, 3H, C7’-CH3), 1.20-1.46 
(m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.52 (sept, 1H, J=6.8 Hz, H21), 1.56 (s, 3H, C9-CH3), 1.78 
(m, 1H, H4’), 2.00 (m, 1H, H4’), 2.05 (s, 6H, C2/3-CH3), 2.19 (s, 3H, C6-CH3), 2.25 (m, 1H, 
H3’), 2.58 (m, 1H, H3’), 2.77 (m, 2H, H8), 3.04 (br, 1H, OH), 3.62 (m, 1H, H7), 7.61 (br, 1H, 
OH) ppm;  
MS (ESI - MeOH): 667.8+ (M+Na)+, 1312.2+ (2M+Na)+.  
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Chlorhydrine 119.  
1H NMR (400 MHz, CDCl3): δ = 0.84-0.91 (m, 12H, C13/17/21-CH3), 0.95-1.21 (m, 6H, 
H12/14/16/18/20), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, C7’-CH3), 1.19 (s, 3H, C7’-CH3), 1.20-1.46 
(m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.52 (sept, 1H, J=6.8 Hz, H21), 1.56 (s, 3H, C9-CH3), 1.78 
(m, 1H, H4’), 1.98 (m, 1H, H4’), 2.06 (s, 3H, C3-CH3), 2.08 (s, 3H, C2-CH3), 2.19 (s, 3H, C6-
CH3), 2.26 (m, 1H, H3’), 2.58 (m, 1H, H3’), 2.78-2.88 (m, 1H, H8), 2.90-3.04 (m, 2H, OH, H8), 
3.86 (m, 1H, H7), 7.44 (br, 1H, OH) ppm;  
MS (ESI - MeOH): 686.0+ (M+Na)+, 701.6+ (M+K)+. 
BS cleavage using anhydrous 
 
 
T
HCl – General procedure. 
(scheme 56) To a solution of 
(rac,R,R)-108b (13.5 μmol) in 
MeCN (0.5 mL) was added 
anhydrous HCl (in MeOH, Et2O or dioxane, 1 mmol) and the reaction was stirred at rt 
between 7 h and 24 h. The reaction was quenched with saturated NaHCO3 and extracted with 
CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness and 
the residue was purified by column chromatography on SiO2 (hexane – EtOAc, 7:3). Yields 
are reported on scheme 56. 
 
Chlorhydrine 119. Analytics identical to those already described before. 
 
Methoxy ether 120. 
1H NMR (400 MHz, CDCl3): δ = 0.83-0.90 (m, 12H, C13/17/21-CH3), 0.95-1.21 (m, 6H, 
H12/14/16/18/20), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, C7’-CH3), 1.19 (s, 3H, C7’-CH3), 1.20-1.46 
(m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.52 (sept, 1H, J=6.8 Hz, H21), 1.55 (s, 3H, C9-CH3), 1.78 
(m, 1H, H4’), 2.00 (m, 1H, H4’), 2.05 (s, 6H, C2/3-CH3), 2.20 (s, 3H, C6-CH3), 2.25 (m, 1H, 
H3’), 2.57 (m, 1H, H3’), 2.78-2.88 (m, 2H, H8), 2.90-3.04 (m, 1H, OH), 3.22 (s, 3H, CH3O-) 
3.75 (m, 1H, H7), 7.82 (br, 1H, OH) ppm;  
MS (ESI - MeOH): 681.9+ (M+Na)+, 697.6+ (M+K)+. 
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CamphO-/OH 
phytylhydroquinone epoxide 116 
– TBS cleavage. To a solution of 
(rac,R,R)-108b (9.8 mg, 0.013 
mmol) in THF (0.5 mL) was added glacial AcOH (28 μL, 0.53 mmol) followed by TBAF (1 
M in THF, 53 μL, 0.053mmol). The solution was stirred a room temperature for 36 h 
quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases 
were dried over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2 (hexane – EtOAc, 8:2) to afford 116 (6.2 mg, 79%) as a colourless 
oil. 
 
1H NMR (400 MHz, CDCl3): δ = 0.82-0.89 (m, 12H, C13/17/21-CH3), 0.99-1.20 (m, 6H, 
H12/14/16/18/20), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, C7’-CH3), 1.19 (s, 3H, C7’-CH3), 1.20-1.46 
(m, 14H, H10/11/12/13/14/15/16/17/18/19), 1.51 (s, 3H, C9-CH3), 1.52 (sept, 1H, J=6.8 Hz, H21), 1.79 
(m, 1H, H4’), 1.99 (m, 1H, H4’), 2.06 (s, 3H, C3-CH3), 2.11 (s, 3H, C2-CH3), 2.18 (s, 3H, C6-
CH3), 2.26 (m, 1H, H3’), 2.58 (m, 1H, H3’), 2.67 (dd, 1H, J=14.9 and 10.6 Hz, H7), 2.94 (m, 
1H, H8), 3.15 (dd, 1H, J=14.9 and 1.5 Hz, H7), 7.17 (s, 1H, OH) ppm;  
13C NMR (100 MHz, CDCl3): δ = 10.1, 12.8, 13.6, 13.8, 17.2, 17.4, 20.1, 20.2,  22.7, 23.0, 
23.1, 24.9, 25.2, 27.6, 27.9, 28.4, 29.4, 31.9, 33.1, 33.2, 37.3, 37.7, 37.8, 39.0, 39.8, 54.7, 
55.3, 91.5, 121.9, 125.3, 128.1, 152.2, 166.6, 178.4 ppm;  
MS (ESI - MeOH): 649.7+ (M+Na)+, 1276.0+ (2M+Na)+;  
HPLC (Protonsil® 120-5-CN, 7% iPrOH in n-heptane, 1 mL/min, 280 nm, 25 °C): t116 = 7.6 
min; 
UV (n-heptane) λmax : 205 nm, 282 nm. 
 
 
Monoprotected epoxide 114. To a 
solution of 108f (63.8 mg, 91.3 μmol) 
in THF (4.5 mL) at room temperature, 
was added glacial AcOH (210 μL, 3.65 
mmol) followed by TBAF (1 M in THF, 370 μL, 0.365 mmol). The mixture was stirred at 
room temperature for 36 h, quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 
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×). Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue 
was purified by column chromatography on SiO2 (hexane – EtOAc, 95:5) to afford 114 (34.5 
mg, 82%) as a colourless oil.  
 
1H NMR (500 MHz, CDCl3): δ = 0.84 (d, 3H, J = 4.4 Hz, C13/17-CH3), 0.85 (d, 3H, J = 5.0 
Hz, C13/17-CH3), 0.86 (d, 6H, J = 6.9 Hz, C22-CH3), 0.97-1.10 (m, 4H, H12/14/16/18), 1.13 (m, 
2H, H20), 1.13-1.32 (m, 8H, H12/14/15/16/18/19), 1.32-1.46 (m, 6H, H10/11/13/17), 1.50 (s, 3H, C9-
CH3), 1.51(sept, 1H, J = 6.9 Hz, H21), 2.17(s, 3H, C3-CH3), 2.20 (s, 3H, C2-CH3), 2.26 (s, 3H, 
C6-CH3), 2.66 (dd, 1H, J = 14.8 and 10.7 Hz, H7), 2.95 (dd, 1H, J = 10.7 and 1.6 Hz, H8), 
3.14 (dd, 1H, J = 10.7 and 1.6 Hz, H7), 3.63 (s, 3H, CH3O), 6.92 (s, 1H, OH) ppm;  
13C NMR (125 MHz, CDCl3): δ = 12.4, 12.6, 12.7, 16.8, 19.6, 19.7, 22.3, 22.6, 22.7, 24.5, 
24.8, 27.1, 28.0, 32.7, 32.8, 36.9, 37.3, 37.4, 38.6, 39.4, 60.4, 63.8, 64.7, 121.3, 123.6, 126.2, 
129.2, 149.7, 150.5 ppm;  
MS (EI): 460.4;  
MS (ESI – MeOH): 944.4+ (2M+Na)+, 484.3+ (M+Na)+;  
IR (neat) υmax 3355, 2925, 2847, 1458, 1408, 1379, 1251, 1085, 856, 811, 665 cm-1;  
anal. calcd. for C30H52O3: C 78.21, H 11.38, O 10.42; found: C 78.24, H 11.19, O 10.57. 
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Cyclisation of 108f with aqueous HCl – Formation of furan 115 and pyran 121. To a 
solution of 108f (10.3 mg, 22.3 μmol) in MeCN (4.5 mL) at room temperature, was added 1 N 
HCl (1.5 mL) and the mixture was stirred at room temperature for 36 h. The mixture was 
quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases 
were dried over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2 (hexane – EtOAc, 85:15) to afford 115 (5.4 mg, 52%) and 121 (4.9 
mg, 48%) as colourless oils.  
 
Furan 115. Analytics identical to those already described before. 
 
 138
Experimental part 
Pyran 121. 
1H NMR (500 MHz, CDCl3): δ = 0.83 (d, 3H, J = 6.3 Hz, C4’/8’-CH3), 0.86 (d, 9H, J = 6.6 
Hz, C4’/8’/13’-CH3), 0.94-1.09 (m, 4H, H3’/5’/7’/9’), 1.09-1.19 (m, 3H, H2’/6’/10’/11’), 1.19-1.32 (m, 
9H, H2’/3’/5’/6’/7’/9’/10’), 1.29 (s, 3H, C2-CH3), 1.32-1.43 (m, 2H, H4’/8’), 1.48-1.60 (m, 2H, H1’), 
1.51 (sept, 1H, J = 6.9 Hz, H12’), 1.73 (m, 1H, OH), 2.10 (s, 3H, C8-CH3), 2.13 (s, 3H, C5-
CH3), 2.18 (s, 3H, C7-CH3), 2.62 (dd, 1H, J = 16.7 and 5.7 Hz, H4), 2.86 (dd, 1H, J = 17.0 
and 5.4 Hz, H4), 3.63 (s, 3H, CH3O), 3.85 (m, 1H, H3) ppm;  
13C NMR (125 MHz, CDCl3): δ = 11.6, 11.7, 12.4, 18.9, 19.5, 19.6, 22.5, 22.6, 24.3, 24.6, 
24.8, 27.8, 29.8, 32.5, 32.6, 37.0, 37.1, 37.2, 37.3, 39.2, 60.2, 68.6, 77.4, 115.6, 123.0, 126.1, 
128.2, 146.3, 149.9 ppm;  
MS (EI): 460.4;  
IR (neat) υmax 3405, 2923, 2846, 1458, 1405, 1377, 1249, 1089, 1003 cm-1;  
HPLC (Chiracel AD-H, 3% iPrOH in n-heptane, 0.5 mL/min, 290 nm): t(2S,3R,4’R,8’R) = 10.1 
min, t(2R,3S,4’R,8’R) = 14.3 min, t(2R,3R,4’R,8’R) and (2S,3S,4’R,8’R) = 10.6 and 12.3 min; 
UV (n-heptane) λmax : 206 nm, 287 nm; 
anal. calcd. for C30H52O3: C 78.21, H 11.38, O 10.42; found: C 78.24, H 11.19, O 10.57. 
 
 
(-)-CamphanoylO- / HO- phytylhydroquinone 122. To a solution of 106b (153.3 mg, 0.212 
mmol) in THF (6 mL) at room 
temperature, was added TBAF (1 M 
in THF, 240 μL, 0.240 mmol). The 
mixture was stirred at room 
temperature for 1 h, quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue was 
purified by column chromatography on SiO2 (hexane – EtOAc, 9:1) to afford 122 (120.6 mg, 
94%) as a colourless oil.  
 
1H NMR (400 MHz, CDCl3): δ = 0.82-0.88 (m, 12H, C13/17/21-CH3), 0.99-1.20 (m, 6H, 
H12/14/16/18/20), 1.15 (s, 3H, C5’-CH3), 1.17 (s, 3H, C7’-CH3), 1.19 (s, 3H, C7’-CH3), 1.20-1.46 
(m, 12H, H11/12/13/14/15/16/17/18/19), 1.52 (sept, 1H, J=6.6 Hz, H21), 1.79 (m, 1H, H4’), 1.81 (s, 3H, 
C9-CH3), 1.99 (m, 3H, H10/4’), 2.05 (s, 3H, C3-CH3), 2.08 (s, 3H, C2-CH3), 2.15 (s, 3H, C6-
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CH3), 2.25 (m, 1H, H3’), 2.58 (m, 1H, H3’), 3.37 (d, 2H, J=6.6 Hz, H7), 5.12 (t, 1H, J=6.8 Hz, 
H8), 5.13 (s, 1H, OH) ppm;  
13C NMR (100 MHz, CDCl3): δ = 10.1, 12.5, 13.5, 13.7, 16.7, 17.3, 17.4, 20.1, 20.2, 23.0, 
23.1, 24.9, 25.2, 26.7, 28.4, 29.4, 31.9, 33.1, 33.2, 37.1, 37.7, 37.8, 39.8, 40.4, 54.7, 55.3, 
91.5, 121.3, 122.1, 123.9, 125.6, 127.2, 139.6, 141.4, 151.1, 166.4, 178.4 ppm;  
MS (ESI - MeOH): 635.7+ (M+Na)+, 1245.0+ (2M+Na)+, 1854.8+ (3M+Na)+.  
 
 
CamphO-/OH phytylhydroquinone epoxide 116 – mCPBA epoxidation. To a solution of 
122 (101.1 mg, 0.165 mmol) in 
CH2Cl2 (15 mL) at 0 °C, was 
added mCPBA (45.7 mg, 0.26 
mmol) at once. The solution was 
allowed to warm up to room 
temperature and stirred for 3 h. The reaction was quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and the residue was purified by column chromatography on SiO2 (hexane – EtOAc, 
8:2) to afford 116 (95.2 mg, 92%) as a colourless oil. Analytics identical to those already 
described before.  
 
 
‘Anti-Baldwin’ cyclisation 
screening – General procedure. 
To a solution of 116 (5.42 μmol) 
in the corresponding solvent (1 
mL, table 6) was added the 
Brönsted acid, and the mixture 
stirred at room temperature for 
15 h. The conversion and ratio 
between 5- and 6-membered 
ring products were determined by HPLC and by 1H NMR on a quenched sample. 
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Experimental part 
Furan ring 123. 
1H NMR (400 MHz, CDCl3): δ = 0.81-0.90 (m, 12H, C5’/9’/13’-CH3), 0.97-1.20 (m, 6H, 
H4’/6’/8’/10’/12’), 1.15 (s, 3H, C5”-CH3), 1.17 (s, 3H, C7”-CH3), 1.19 (s, 3H, C7”-CH3), 1.20-1.47 
(m, 17H, H2’/3’/4’/5’/6’/7’/8’/9’/10’/11’, C1’-CH3), 1.47-1.59 (m, 1H, H13’), 1.79 (m, 1H, H4”), 1.96-
2.07 (m, 7H, C7-CH3, C8-CH3, H4”), 2.12 (s, 3H, C5-CH3), 2.25 (m, 1H, H3”), 2.58 (m, 1H, 
H3”), 3.00 (dd, 1H, J=16.4 and 9.5 Hz, H3), 3.14 (dd, 1H, J=15.4 and 8.9 Hz, H3), 4.61 (t, 1H, 
J=9.1 Hz, H2) ppm;  
13C NMR (100 MHz, CDCl3): δ = 10.1, 12.5, 13.5, 17.1, 19.9, 22.8, 23.5, 24.4, 28.4, 29.3, 
30.5, 30.7, 31.2, 31.3, 31.7, 33.2, 37.7, 38.0, 39.5, 55.0, 73.8, 89.1, 91.4, 115.4, 119.5, 127.8, 
127.9, 142.3, 156.5, 178.3 ppm;  
HPLC (Protonsil® 120-5-CN, 7% iPrOH in n-heptane, 1 mL/min, 220 nm): t123 = 8.6 min;  
UV (n-heptane) λmax : 204 nm, 287 nm. 
 
Pyran ring 124. 
1H NMR (400 MHz, CDCl3): δ = 0.81-0.90 (m, 12H, C4’/8’/12’-CH3), 0.97-1.20 (m, 6H, 
H3’/5’/7’/9’/11’), 1.15 (s, 3H, C5”-CH3), 1.17 (s, 3H, C7”-CH3), 1.19 (s, 3H, C7”-CH3), 1.20-1.47 
(m, 17H, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’, C2-CH3), 1.47-1.59 (m, 1H, H12’), 1.79 (m, 1H, H4”), 1.96-2.07 
(m, 7H, C7-CH3, C8-CH3, H4”), 2.12 (s, 3H, C5-CH3), 2.25 (m, 1H, H3”), 2.58 (m, 1H, H3”), 
2.63 (dd, 1H, J=18.5 and 5.3 Hz, H4), 2.88 (dd, 1H, J=16.4 and 5.2 Hz, H4), 3.86 (m, 1H, H3) 
ppm;  
13C NMR (100 MHz, CDCl3): δ = 10.1, 12.5, 13.5, 16.9, 19.5, 19.6, 19.9, 22.7, 24.7, 28.0, 
28.9, 29.4, 31.3, 31.7, 37.3, 37.4, 39.4, 55.0, 68.3, 78.8, 91.0, 119.3, 126.6, 127.5, 135.4, 
141.8, 148.7, 178.2 ppm;  
HPLC (Protonsil® 120-5-CN, 7% iPrOH in n-heptane, 1 mL/min, 220 nm): t124 = 10.1 min;  
UV (n-heptane) λmax : 204 nm, 284 nm. 
 
 
Cyclisation of 114 using optimized 
conditions – Pyran 121. To a solution 
of 114 (28.3 mg, 61.3 μmol) in MeCN 
(12.5 mL) at 0 °C, was added HCl (2 M 
in Et2O, 4.2mL). The solution was allowed to warm up to room temperature and stirred for 6 
h. The reaction was quenched with saturated NaHCO3 and extracted with CH2Cl2 (3 ×). 
121
8
6
O
2
4
4' 8 ' 12'
MeO OH
 141
Experimental part 
Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue was 
purified by column chromatography on SiO2 (hexane – EtOAc, 85:15) to afford 121 (22.3 mg, 
79%) as a colourless oil. Analytics identical to those already described before. 
 
 
Chromene 125. During 
chlorination/iodination attempts on 
121, using PPh3, I2 or CCl4 in 
refluxing toluene, chromene 125 was 
isolated as main side-product, by elimination of Ph3PO, up to 70% yield. Analytics were 
identical to those already reported126 – Selected data. 
 
1H NMR (400 MHz, CDCl3): δ = 0.81-0.90 (m, 12H, C4’/8’/12’-CH3), 0.97-1.20 (m, 6H, 
H3’/5’/7’/9’/11’), 1.20-1.47 (m, 17H, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’, C2-CH3), 1.47-1.59 (m, 1H, H12’), 1.79 
(m, 1H, H4”), 2.09 (s, 3H, C7/8-CH3), 2.17 (s, 3H, C7/8-CH3), 2.21 (s, 3H, C5-CH3), 3.62 (s, 3H, 
CH3O), 5.58 (d, 1H, J=10.1 Hz, H3/4), 6.50 (d, 1H, J=10.1 Hz, H3/4) ppm. 
 
 
Mesylate 126. To a solution of 121 (4.4 
mg, 0.010 mmol) in CH2Cl2 (1 mL) at 0 
°C, was added Et3N (3 μL, 0.020 mmol) 
followed by MsCl (2 μL, 0.020 mmol) and 
the mixture was stirred at room temperature for 5 h. The reaction was quenched with saturated 
NaHCO3 and extracted with Et2O (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue was purified by column chromatography on SiO2 
(hexane – EtOAc, 8:2) to afford 126 (4.7 mg, 91%) as a colourless oil.  
 
1H NMR (400 MHz, CDCl3): δ = 0.83 (d, 3H, J = 6.3 Hz, C4’/8’-CH3), 0.86 (d, 9H, J = 6.6 
Hz, C4’/8’/13’-CH3), 0.94-1.09 (m, 4H, H3’/5’/7’/9’), 1.09-1.19 (m, 3H, H2’/6’/10’/11’), 1.19-1.32 (m, 
9H, H2’/3’/5’/6’/7’/9’/10’), 1.29 (s, 3H, C2-CH3), 1.32-1.43 (m, 2H, H4’/8’), 1.48-1.60 (m, 2H, H1’), 
1.51 (sept, 1H, J = 6.9 Hz, H12’), 1.73 (m, 1H, OH), 2.10 (s, 3H, C8-CH3), 2.13 (s, 3H, C5-
CH3), 2.18 (s, 3H, C7-CH3), 2.66 (m, 1H, H4), 2.88 (m, 1H, H4), 3.07 (s, 3H, SO2CH3), 3.63 
(s, 3H, CH3O), 4.89 (m, 1H, H3) ppm;  
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13C NMR (125 MHz, CDCl3): δ = 11.5, 11.9, 12.5, 18.6, 19.6, 19.7, 22.6, 22.6, 22.7, 24.5, 
24.8, 27.7, 27.9, 32.4, 32.5, 37.1, 37.2, 37.5, 39.3, 60.3, 75.5, 79.3, 115.5, 123.2, 126.5, 128.8, 
146.4, 150.5 ppm; 
MS (ESI - MeOH): 561.7+ (M+Na)+, 577.5+ (M+K)+. 
 
 
Tosylate 128. To a solution of 121 (15.3 mg, 
33.2 μmol) in dry pyridine (250 μL) at 0 °C, 
was added tosyl chloride (19.1 mg, 99.6 
μmol) at once. The solution was allowed to 
warm up to room temperature and stirred for 36 h. The reaction was quenched with 1 N HCl 
and extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue was purified by column chromatography on SiO2 
(hexane – EtOAc, 85:15) to afford 128 (19.1 mg, 94%) as a colourless oil.  
 
1H NMR (500 MHz, CDCl3): δ = 0.81 (d, 3H, J = 6.6 Hz, C4’/8’-CH3), 0.84 (d, 3H, J = 6.9 
Hz, C4’/8’-CH3), 0.86 (d, 6H, J = 6.6 Hz, C13’-CH3); 0.90-1.09 (m, 4H, H3’/5’/7’/9’), 1.09-1.20 
(m, 4H, H2’/6’/10’/11’), 1.15 (s, 3H, C2-CH3), 1.19-1.39 (m, 10H, H2’/3’/4’/5’/6’/7’/8’/9’/10’/11’), 1.40-
1.47 (m, 2H, H1’), 1.52 (sept, 1H, J = 6.6 Hz, H12’), 2.01 (s, 3H, C5-CH3), 2.04 (s, 3H, C8-
CH3), 2.15 (s, 3H, C7-CH3), 2.45 (s, 3H, CH3-Tos), 2.70 (dd, 1H, J = 16.7 and 7.9 Hz, H4), 
2.92 (dd, 1H, J = 17.0 and 6.0 Hz, H4), 3.60 (s, 3H, CH3O), 4.65 (t, J = 5.8 Hz, 1H, H3), 7.34 
(d, 2H, J = 7.9 Hz, Hm-Tos), 7.81 (d, 2H, J = 8.2 Hz, Ho-Tos) ppm;  
13C NMR (125 MHz, CDCl3): δ = 11.6, 11.8, 12.5, 18.6, 19.6, 19.7, 21.6, 22.6, 22.7, 24.4, 
24.8, 27.8, 27.9, 32.6, 32.8, 37.2, 37.3, 37.4, 39.3, 60.3, 75.5, 79.2, 115.2, 123.2, 126.2, 128.0, 
128.8, 129.9, 134.2, 146.3, 144.9, 150.2 ppm; 
MS (EI): 614.4; 
IR (neat) υmax 2924, 2847, 1451, 1369, 1250, 1175, 1090, 976, 887, 814, 667 cm-1; 
anal. calcd. for C37H58O5S: C 72.27, H 9.51; found: C 72.29, H 9.32; 
[α]D20 = + 37.4 ± 0.2 (c = 0.89 in CHCl3). 
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α-Tocopheryl methylether (R,R,R)-84 – 
Tosyl elimination / Hydrogenation. To a 
solution of 128 (9.4 mg, 15.2 μmol) in 
THF (1 mL) at 0 °C, was added potassium 
tert-butoxide (8.5 mg, 76.0 μmol). The solution was stirred for 1 h at 0 °C, in the dark. The 
reaction was quenched with 1 N HCl and extracted with CH2Cl2 (3 ×). Combined organic 
phases were dried over Na2SO4, evaporated to dryness and used as such for next step without 
further purification. 
 
The residue was dissolved in EtOAc (1 mL) and Pd/C (Pd content: 10%, 5 mg) was 
added. The suspension was vigorously stirred under H2 (1 atm), at room temperature for 3 h. 
Solids were filtered off through a pad of celite, washed with EtOAc, and solvent was removed 
in vacuum. The crude oil was purified by column chromatography on SiO2 (hexane – EtOAc, 
9:1) to afford (R,R,R)-84 (6.6 mg, 96%) as a colourless oil. Analytics were identical to those 
already described before. 
 
HPLC (Chiracel OD-H, 0.2% iPrOH in n-heptane, 0.8 mL/min, 290 nm): t(2S,4’R,8’R) = 7.1 min, 
t(2R,4’R,8’R)  = 7.96 min;  
Diastereoisomeric excess: 93% (2R);  
UV (n-heptane) λmax : 203 nm, 288 nm;  
[α]D20 = + 0.9 ± 0.2 (c = 0.61 in CHCl3). 
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Bis-methoxy hydroquinone 148. To a solution of 2,3-dimethyl-
hydroquinone 68 (3.02 g, 21.9 mmol) in acetone (120 mL) was added 
K2CO3 (21.0 g, 152.0 mmol) followed by Me2SO4 (3.0 mL, 32.0 mmol). 
The suspension was vigorously stirred under reflux for 18 h and allowed 
to cool down to rt. The solids were filtered off through a pad of celite, washed with acetone, 
and the solvents removed in vacuuo. The residue was purified by column chromatography on 
SiO2 (hexane –CH2Cl2, 6:4) to afford 148 (3.21 g, 87%) as a white solid.  
 
m.p.: 80-81 °C; 
1H NMR (400 MHz, DMSO): δ = 2.04 (s, 6H, CAr-CH3), 3.67 (s, 6H, CH3O), 6.69 (s, 2H, 
HAr) ppm;  
13C NMR (100 MHz, DMSO): δ = 12.7, 56.5, 108.8, 126.2, 152.1 ppm; 
MS (EI): 166.1; 
IR (neat) υmax 2955, 2839, 1466, 1257, 1095, 794 cm-1. 
 
 
Crotonoyl hydroquinone 149. To a solution of 146 (198.2 mg, 
2.0 mmol) in CH2Cl2 (4 mL) was added DMF (1 drop) followed 
by C2O2Cl2 (170 μL, 2.0 mmol). The mixture was stirred at room 
temperature till no evolution of gas was observed, and a solution 
of 148 (200.2 mg, 1.20 mmol) in CH2Cl2 (1 mL) was added. The 
mixture was cooled down to 0 °C, and TiCl4 (130 μL, 1.19 mmol) was added, and stirring was 
continued at room temperature for 9 h.  The reaction was quenched with 1 N HCl and 
extracted with CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to 
dryness and the residue was purified by column chromatography on SiO2 (hexane – EtOAc, 
8:2) to afford 149 (125.1 mg, 42%) as a slight yellow oil. 
 
1H NMR (400 MHz, CDCl3): δ = 1.98 (s, 3H, CH3-C=C), 2.17 (s, 3H, CAr-CH3), 2.22 (s, 3H, 
CAr-CH3), 2.24 (s, 3H, CH3-C=C), 3.62 (s, 6H, CH3O), 3.81 (s, 6H, CH3O), 6.77 (s, 1H, 
CH=C), 6.94 (s, 1H, HAr) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.8, 12.9, 22.0, 28.4, 56.2, 63.0, 108.6, 125.5, 131.1, 
132.0, 132.4, 151.6, 154.2, 155.6, 193.6 ppm; 
MS (ESI - MeOH): 271.0+ (M+Na)+, 519.0+ (2M+Na)+. 
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Bismethoxymethylether hydroquinone 150. To a solution of 
2,3-dimethyl-hydroquinone 68 (1.49 g, 10.9 mmol) in DMF (15 
mL) at 0 °C, was added NaH (60% on mineral oil, 1.5 g, 65.2 
mmol) followed by MOMCl (3.8 mL, 65.2 mmol). The 
suspension was allowed to warm up to room temperature and stirred for 4 h. The reaction was 
quenched with saturated NaHCO3 and extracted with EtOAc (3 ×). Combined organic phases 
were dried over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2 (hexane – EtOAc, 8:2) to afford 150 (2.16 g, 88%) as a colourless 
oil. 
 
1H NMR (400 MHz, CDCl3): δ = 2.19 (s, 6H, CAr-CH3), 3.48 (s, 6H, CH3O), 5.12 (s, 4H, O-
CH2-O), 6.86 (s, 2H, HAr) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.8, 56.4, 95.8, 112.8, 128.1, 150.7 ppm. 
 
 
E-(R,R)-Phytal 145. To a solution of E-(R,R)-
phytol 34 (1.02 g, 3.45 mmol) in CH2Cl2 (40 
mL) was added MnO2 (5.9 g, 67.9 mmol) and 
the suspension was vigorously stirred for 1 h at 
room temperature. The solids were filtered off through a pad of celite, washed with CH2Cl2, 
and the solvents removed in vacuuo. The residue was purified by column chromatography on 
SiO2 (hexane –EtOAc, 10:1) to afford 145 (833.0 g, 82%) as a colourless oil. 
 
1H NMR (250 MHz, CDCl3): δ = 0.80-0.88 (m, 12H, C7/11/15-CH3), 0.95-1.90 (m, 19H, 
H5/6/7/8/9/10/11/12/13/14/15), 2.16 (s, 3H, C3-CH3), 2.18 (m, 2H, H4), 5.87 (d, 1H, J=8.2 Hz, H2), 
9.98 (d, 1H, J=7.9 Hz, CHO) ppm;  
13C NMR (100 MHz, CDCl3): δ = 17.9, 20.0, 20.1, 23.0, 23.1, 24.8, 25.0, 25.2, 28.4, 33.0, 
33.2, 36.9, 37.7, 37.8, 39.7, 41.3, 127.7, 164.9, 191.8 ppm; 
MS (ESI - MeOH): 317.3+ (M+Na)+, 611.4+ (2M+Na)+; 
IR (neat) υmax 2924, 2862, 1674, 1458, 1381, 1196, 833, 648 cm-1. 
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E-(R,R)-Phytylic acid 152. To a solution of 145 
(698.1 mg, 2.37 mmol) in tBuOH (50 mL) was 
added 2-methyl-2-butene (13 mL, 118.5 mmol) 
and a solution of NaClO2 (1.28 g, 14.2 mmol) and 
NaH2PO4 (1.0 g, 8.3 mmol) in H2O (14 mL) was added dropwise at room temperature. The 
mixture was stirred for 19 h, and the reaction quenched by the addition of 3 M NaOH. The 
solvents were removed in vacuuo and the residue saturated with NaCl, extracted with n-
hexane. The organic layer was extracted with H2O and the combined aqueous layer were 
acidified to pH<3 with 1N HCl, and extracted with EtOAc. Combined organic phases were 
dried over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2 (hexane – EtOAc, 7:3) to afford 152 (530.2 mg, 72%) as a 
colourless oil. 
 
1H NMR (250 MHz, CDCl3): δ = 0.79-0.91 (m, 12H, C7/11/15-CH3), 0.96-1.62 (m, 19H, 
H5/6/7/8/9/10/11/12/13/14/15), 2.14 (m, 2H, H4), 2.16 (s, 3H, C3-CH3), 5.70 (s, 1H, H2) ppm;  
13C NMR (100 MHz, CDCl3): δ = 19.4, 20.0, 20.2, 23.0, 23.1, 24.8, 25.2, 25.3, 28.4, 33.0, 
33.2, 36.9, 37.7, 37.8, 39.8, 41.9, 115.1, 164.1, 171.7 ppm; 
MS (EI): 310.2; 
IR (neat) υmax 2916, 2862, 1689, 1643, 1458, 1427, 1373, 1259, 594 cm-1. 
 
 
Bis-methoxy phytoyl hydroquinone 
153 – F-C acylation. To a solution of 
152 (152.1 mg, 0.49 mmol) in CH2Cl2 
(1 mL) was added DMF (1 drop) 
followed by C2O2Cl2 (41 μL, 0.48 
mmol). The mixture was stirred at room temperature till no evolution of gas was observed, 
and a solution of 148 (57.6 mg, 0.35 mmol) in CH2Cl2 (1 mL) was added. The mixture was 
cooled down to -40 °C, and TiCl4 (70 μL, 0.64 mmol) was added, and stirring was continued 
at room temperature for 2 h.  The reaction was quenched with 1 N HCl and extracted with 
EtOAc (3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness and 
the residue was purified by column chromatography on SiO2 (CH2Cl2) to afford E-153 (57.4 
mg, 36%) and Z-153 (24.6 mg, 15%) as slight yellow oils. 
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1H NMR (400 MHz, CDCl3): δ = Common signals: 0.81-0.89 (m, 12H, C13/17/21-CH3), 0.98-
1.59 (m, 19H, H11/12/13/14/15/16/17/18/19/20/21), 2.17 (s, 3H, C2/3-CH3), 2.22 (s, 3H, C2/3-CH3), 3.62 
(s, 3H, CH3O), 3.82 (s, 3H, CH3O); Typical signals for E-153: 2.21 (m, 2H, H10), 2.23 (s, 3H, 
C9-CH3), 6.78 (s, 1H, H8), 6.95 (s, 1H, H6); Typical signals for Z-153: 1.96 (s, 3H, C9-CH3), 
2.61-2.66 (m, 2H, H10), 6.74 (s, 1H, H8), 6.94 (s, 1H, H6) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.8, 12.9, 20.0, 20.1, 20.2, 23.0, 23.1, 24.9, 25.2, 25.6, 
28.4, 33.1, 33.2, 37.1, 37.7, 37.8, 39.8, 42.3, 56.1, 63.0, 108.7, 124.9, 131.1, 132.0, 132.4, 
154.1, 159.8, 193.7 ppm; 
MS (ESI - MeOH): 481.3+ (M+Na)+, 939.4+ (2M+Na)+. 
 
 
Bis-sylilation of 68 – General procedure. To 
a solution of 68 (1.93 mmol) and imidazole 
(9.99 mmol) in DMF (10 mL) at room 
temperature, was added the silyl chloride 
(4.9 mmol) and the mixture was stirred for 2 
h. The reaction was quenched with water and extracted with EtOAc (3 ×). Combined organic 
phases were washed with water, brine, dried over Na2SO4, and evaporated to dryness. The 
crude oil was purified by column chromatography on SiO2 using hexane – EtOAc mixtures. 
 
Bis-TBSO-hydroquinone 154. 543.8 mg (>99% yield) as a slight yellow oil.  
1H NMR (400 MHz, CDCl3, 25 °C): δ = 0.16 (s, 12H, CH3Si), 1.00 (s, 18H, (CH3)3CSi), 2.11 
(s, 6H, CAr-CH3), 6.50 (s, 2H, HAr) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = -3.8, 13.7, 18.7, 26.3, 116.2, 128.9, 147.9 ppm; 
MS (EI): 366.2; 
IR (neat) υmax 2955, 2854, 1473, 1242, 1095, 918, 833, 779 cm-1. 
 
Bis-TBSO-hydroquinone 154. 705.1 mg (>99% yield) as a light brown liquid. 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.66-0.79 (m, 12H, CH3CH2Si), 0.90-102 (m, 18H, 
CH3CH2Si), 2.14 (s, 3H, CAr-CH3), 6.50 (s, 1H, HAr) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 5.6, 7.1, 13.5, 116.1, 128.7, 148.1 ppm; 
IR (neat) υmax 2955, 2877, 1473, 1250, 1095, 1010, 918, 825, 725 cm-1. 
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Bis-AcO-hydroquinone 156. To a solution of 68 (269.2 mg, 1.95 mmol) 
in pyridine (4 mL) was added acetic anhydride (3 mL). The mixture was 
stirred at room temperature for 2 h.  The reaction was quenched with 
H2O and extracted with EtOAc (3 ×). Combined organic phases were 
dried over Na2SO4, evaporated to dryness and the residue was purified 
by column chromatography on SiO2 (hexane – EtOAc, 7:3) to afford 156 (421.0 mg, 97%) as 
a white solid. 
 
m.p.: 108-109 °C; 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 2.09 (s, 6H, CAr-CH3), 2.32 (s, 6H, CH3CO), 6.88 (s, 
2H, HAr) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 13.5, 21.2, 120.3, 130.9, 147.2, 169.8 ppm; 
IR (neat) υmax 2955, 2854, 1751, 1473, 1365, 1218, 1180, 1080, 1010, 894, 733 cm-1; 
UV (MeOH) λmax : 206 nm, 263 nm. 
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Bromination of aromatics – 
General procedure. To a 
solution of bis-protected 
aromatic (2.19 mmol) in 
DMF (25 mL) at room 
temperature, was added NBS (2.4 mmol) and the mixture was stirred for 15 h. The reaction 
was quenched with water and extracted with EtOAc (3 ×). Combined organic phases were 
washed with water, brine, dried over Na2SO4, and evaporated to dryness. The crude oil was 
purified by column chromatography on SiO2 using hexane – EtOAc mixtures. 
 
Bis-TBSO-bromohydroquinone 157. 866.2 mg (89% yield) as a white solid. 
m.p.: 67-68 °C;  
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.18 (s, 6H, CH3Si), 0.22 (s, 6H, CH3Si), 1.00 (s, 
9H, (CH3)3CSi), 1.04 (s, 9H, (CH3)3CSi), 2.06 (s, 3H, CAr-CH3), 2.14 (s, 3H, CAr-CH3), 6.82 
(s, 1H, HAr) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = -3.9, -2.3, 13.7, 15.7, 18.6, 19.2, 26.2, 26.6, 111.6, 
120.7, 128.4, 130.4, 145.3, 148.4 ppm; 
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MS (EI): 444.1, 446.1; 
IR (neat) υmax 2955, 2854, 1473, 1242, 1095, 918, 833, 779 cm-1. 
 
Bis-MOMO-bromohydroquinone 158. 297.5 mg (44% yield) as a yellow oil. 
1H NMR (400 MHz, CDCl3): δ = 2.12 (s, 3H, CAr-CH3), 2.27 (s, 3H, CAr-CH3), 3.46 (s, 3H, 
CH3O), 3.65 (s, 3H, CH3O), 4.99 (s, 2H, O-CH2-O), 5.12 (s, 2H, O-CH2-O), 7.15 (s, 1H, HAr) 
ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.9, 14.5, 56.5, 58.3, 95.5, 100.2, 114.1, 116.9, 127.4, 
133.3, 147.8, 152.5 ppm; 
MS (EI): 304.0, 306.0. 
 
Bis-MeO-bromohydroquinone 159. 587.0 mg (90% yield) as a colourless oil. 
1H NMR (250 MHz, CDCl3): δ = 2.09 (s, 3H, CAr-CH3), 2.24 (s, 3H, CAr-CH3), 3.73 (s, 3H, 
CH3O), 3.77 (s, 3H, CH3O), 6.86 (s, 1H, HAr) ppm;  
13C NMR (100 MHz, CDCl3): δ = 12.5, 13.7, 56.3, 60.9, 112.7, 113.8, 126.4, 132.8, 149.4, 
154.6 ppm; 
MS (EI): 243.9, 245.9. 
 
 
Bis-MeO-phytol-hydroquinone 160. 
To a solution of freshly dried Mg (1.16 
g, 48.1 mmol) in dry Et2O (5 mL), was 
added a crystal of I2. A solution of 159 
(5.67 g, 23.1 mmol) in THF (8 mL) was added stepwise over 45’ and the solution stirred at 
room temperature for 2 h. Then the mixture was cooled down to 0 °C and a solution of E-
(R,R)-145 (2.8 g, 9.6 mmol) in THF (8 mL) was added dropwise. The mixture was allowed to 
warm up to room temperature and stirred for 12 h. The reaction was quenched with saturated 
NH4Cl and extracted with Et2O (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue was purified by column chromatography on SiO2 
(hexane – EtOAc, 85:15) to afford 160 (4.03 g, 91%) as a colourless oil. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.81-0.89 (m, 12H, C13/17/21-CH3), 0.98-1.59 (m, 
19H, H11/12/13/14/15/16/17/18/19/20/21), 1.79 (s, 3H, C9-CH3), 2.00 (m, 2H, H10), 2.12 (s, 3H, C2/3-
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CH3), 2.20 (s, 3H, C2/3-CH3), 2.24 (br, 1H, OH), 3.70 (s, 3H, CH3O), 3.81 (s, 3H, CH3O), 5.45 
(dd, 1H, J=8.6 and 1.1 Hz, H8), 5.77 (dd, 1H, J=8.6 and 2.9 Hz, H7), 6.82 (s, 1H, H6) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 12.4, 13.2, 17.1, 20.1, 23.0, 23.1, 24.9, 25.2, 25.6, 
28.4, 33.1, 33.2, 37.2, 37.7, 37.8, 39.8, 40.4, 56.2, 61.6, 66.7, 106.5, 126.1, 127.2, 131.2, 
134.5, 139.8, 149.8, 154.4 ppm; 
MS (ESI - MeOH): 483.3+ (M+Na)+, 943.5+ (2M+Na)+; 
IR (neat) υmax 3394, 2924, 2862, 1466, 1404, 1380, 1218, 1118, 1088, 1018, 849, 640 cm-1; 
UV (MeOH) λmax : 206 nm, 287 nm. 
 
 
Bis-methoxy phytoyl hydroquinone E-
153 – Oxidation of benzylic alcohol. 
To a solution of 160 (4.03 g, 8.76 mmol) 
in CH2Cl2 (150 mL) was added MnO2 
(19.0 g, 0.29 mol) and the mixture was stirred for 6 h at room temperature. Solids were 
filtered through a pad of celite, washed with CH2Cl2 and EtOAc, solvents were removed in 
vacuuo and the residue was purified by column chromatography on SiO2 (hexane – EtOAc, 
9:1) to afford E-153 (2.94 g, 72%) as a slight yellow oil. Analytics were identical to those 
already described before. 
 
 
Phytoyl hydroquinone 161. To a 
solution of E-153 (2.23 g, 4.86 mmol) in 
CH2Cl2 (100 mL) at -78 °C, was carefully 
added BBr3 (1 M in CH2Cl2, 10.7 mL, 
10.7 mmol) and the mixture was allowed to warm up to room temperature and stirred for 1 h. 
The reaction was quenched with MeOH, saturated NaHCO3 and extracted with EtOAc (3 ×). 
Combined organic phases were dried over Na2SO4, evaporated to dryness and the residue was 
purified by column chromatography on SiO2 (hexane – EtOAc, 85:15) to afford E-161 (887.1 
mg, 43%) and Z-161 (577.7 mg, 28%) as yellow oils. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = Common signals: 0.81-0.89 (m, 12H, C13/17/21-CH3), 
0.98-1.59 (m, 19H, H11/12/13/14/15/16/17/18/19/20/21), 2.20 (s, 3H, C2/3-CH3), 2.22 (s, 3H, C2/3-CH3),  
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12.8 (s, 1H, OH); Typical signals for E-161: 2.16 (s, 3H, C9-CH3), 2.21 (m, 2H, H10), 4.47 
(br, 1H, OH), 6.64 (s, 1H, H8), 7.04 (s, 1H, H6); Typical signals for Z-161: 1.99 (s, 3H, C9-
CH3), 2.53 (m, 2H, H10), 4.37 (br, 1H, OH), 6.61 (s, 1H, H8), 7.05 (s, 1H, H6) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = Common signals: 12.0, 13.4, 20.1, 20.2, 23.0, 23.1, 
24.9, 25.2, 28.4, 33.1, 33.2, 37.7, 37.8, 39.8, 111.9, 117.8, 127.2, 133.7, 145.5, 156.5, 160.9; 
Typical signals for E-161: 25.6, 37.1, 42.3, 120.1, 196.4; Typical signals for Z-161: 26.1, 
30.1, 34.9, 37.5, 120.8, 196.1 ppm; 
MS (ESI - MeOH): 429.5- (M-H)-, 859.7- (2M-H)-; 
IR (neat) υmax 3408, 2924, 2866, 1631, 1589, 1462, 1365, 1313, 1211, 1143, 1086, 835 cm-1; 
HPLC (Protonsil® 120-5-CN, 1% to 2% iPrOH in n-heptane, 1 mL/min, 270 nm): tE-isomer = 
12.2 min, tZ-isomer = 12.8 min.  
 
 
Mono-MeO Phytoyl hydroquinone 
162. To a solution of E-153 (497.1 
mg, 1.09 mmol) in CH2Cl2 (15 mL) 
at -78 °C, was carefully added BBr3 
(1 M in CH2Cl2, 2.73 mL, 2.73 mmol) and the mixture stirred for 1 h at -78 °C. The reaction 
was quenched with MeOH, saturated NaHCO3 and extracted with EtOAc (3 ×). Combined 
organic phases were dried over Na2SO4, evaporated to dryness and the residue was purified by 
column chromatography on SiO2 (hexane – CH2Cl2, 7:3) to afford E-162 (222.2 mg, 46%) 
and Z-162 (90.1 mg, 19%) as yellow oils. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = Common signals: 0.81-0.89 (m, 12H, C13/17/21-CH3), 
0.98-1.59 (m, 19H, H11/12/13/14/15/16/17/18/19/20/21), 2.21 (s, 6H, C2/3-CH3), 3.80 (s, 3H, CH3O), 
13.0 (s, 1H, OH); Typical signals for E-162: 2.15 (s, 3H, C9-CH3), 2.25 (m, 2H, H10), 6.67 (s, 
1H, H8), 7.00 (s, 1H, H6); Typical signals for Z-162: 2.02 (s, 3H, C9-CH3), 2.53 (m, 2H, H10), 
6.65 (s, 1H, H8), 6.99 (s, 1H, H6) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = Common signals: 11.9, 13.3, 20.0, 20.1, 23.0, 23.1, 
24.9, 28.3, 33.0, 33.2, 37.7, 37.8, 39.8, 56.6, 107.7, 117.3, 127.3, 136.3, 149.9, 157.0; Typical 
signals for E-161: 25.2, 25.5, 36.1, 37.1, 42.2, 120.4, 160.0, 196.8; Typical signals for Z-161: 
26.1, 34.9, 37.5, 120.9, 160.5, 196.3 ppm; 
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MS (ESI - MeOH): 445.2+ (M+H)+, 889.3+ (2M+H)+; 
HPLC (Chiralpak AD-H, 1% to 3% iPrOH in n-heptane, 0.5 mL/min, 270 nm): tZ-isomer = 8.6 
min, tE-isomer = 9.0 min. 
 
 
Lewis acid mediated cyclisation of E-161 
– General procedure (table 7, table 8). To 
a solution of the Lewis acid in the 
corresponding solvent (MeCN, CH2Cl2, 
THF or CF3CH2OH; 0.5 mL) was added the additive is prescripted, followed by a solution of 
E-161 (0.023 mmol) in the corresponding solvent (MeCN, CH2Cl2, THF, CF3CH2OH; 0.5 
mL). The reaction was stirred between 15 h and 24 h at the temperature described, and 
quenched samples (H2O/Hexane) are analysed by HPLC (Protonsil® 120-5-CN, 1% to 2% 
iPrOH in n-heptane, 1 mL/min, 270 nm). A pure sample was obtained by column 
chromatography purification on SiO2 (hexane – EtOAc, 8:2) for analysis. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.81-0.89 (m, 12H, C4’/8’/12’-CH3), 0.98-1.59 (m, 
21H, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’/11’/12’), 1.37 (s, 3H, C2-CH3), 2.15 (s, 3H, C7/8-CH3), 2.22 (s, 3H, 7/8-
CH3), 2.61 (d, 1H, H3), 2.74 (d, 1H, H3), 5.89 (s, 1H, OH), 7.25 (s, 1H, H6) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 12.3, 13.4, 20.0, 20.1, 21.4, 23.0, 23.1, 24.3, 24.8, 
25.2, 28.4, 33.0, 33.2, 37.5, 37.7, 37.8, 39.8, 39.9, 40.0, 48.0, 81.0, 107.6, 118.0, 127.6, 134.5, 
148.3, 152.8, 194.4 ppm; 
MS (ESI - MeOH): 453.3+ (M+Na)+, 883.5+ (2M+Na)+; 
IR (neat) υmax 3404, 2924, 2866, 1668, 1608, 1441, 1230, 1089, 804 cm-1; 
HPLC (Protonsil® 120-5-CN, 1% to 2% iPrOH in n-heptane, 1 mL/min, 270 nm): t163 = 8.2 
min; 
HPLC (Chiralpak AD-H, 1% to 3% iPrOH in n-heptane, 0.5 mL/min, 270 nm): mixture of 2 
diastereoisomers, t(2R,4‘R,8‘R) = 35.0 min, t(2S,4‘R,8‘R) = 43.2 min; 
UV (MeOH) λmax : 271 nm, 365 nm. 
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Lewis acid mediated cyclisation of E-162 
– General procedure. To a solution of the 
Lewis acid in CH2Cl2 (1 mL) was added 
the additive is prescripted, followed by a 
solution of E-162 (0.046 mmol) in CH2Cl2 (1 mL). The reaction was stirred between 15 h and 
24 h at room temperature, quenched with H2O and extracted with EtOAc (3 ×). Combined 
organic phases were dried over Na2SO4, evaporated to dryness and the residue was purified by 
preparative TLC on SiO2 (hexane – EtOAc, 85:15) to afford 168 as a slight yellow oil. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.81-0.89 (m, 12H, C4’/8’/12’-CH3), 0.98-1.59 (m, 
21H, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’/11’/12’), 1.38 (s, 3H, C2-CH3), 2.15 (s, 3H, C7/8-CH3), 2.19 (s, 3H, 7/8-
CH3), 2.61 (d, 1H, H3), 2.73 (d, 1H, H3), 3.81 (s, 3H, CH3O), 7.13 (s, 1H, H6) ppm; 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 12.3, 13.4, 20.0, 20.1, 21.4, 23.0, 23.1, 24.3, 24.8, 
25.2, 28.4, 33.0, 33.2, 37.5, 37.7, 37.8, 39.8, 39.9, 40.0, 48.0, 60.2, 81.0, 107.6, 118.0, 127.6, 
134.5, 149.9, 156.7, 194.4 ppm; 
MS (ESI - MeOH): 467.2+ (M+Na)+, 911.3+ (2M+Na)+; 
HPLC (Chiralpak AD-H, 0.5% to 5% iPrOH in n-heptane, 0.5 mL/min, 270 nm): mixture of 
2 diastereoisomers, t(2R,4‘R,8‘R) = 10.2 min, t(2S,4‘R,8‘R) = 11.1 min. 
 
 
Bis-tosylated cyclohexyldiamine 170. To a solution of 
(1R,2R)-1,2-cyclohexanediamine 169 (62.6 mg, 0.55 
mmol) in THF (4 mL) was added TsCl (267.3 mg, 1.41 
mmol) followed by Et3N (0.3 mL, 1.64 mmol) and the 
mixture stirred for 17 h at room temperature. The 
reaction was quenched with 1 N HCl and extracted with EtOAc (3 ×). Combined organic 
phases were dried over Na2SO4, evaporated to dryness and the residue was purified by column 
chromatography on SiO2 (hexane – EtOAc, 6:4) to afford 170 (234.2 mg, 99%) as a white 
solid. Analytics were identical to those already reported127 – Selected data. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.03-1.25 (m, 4H, H4/5), 1.50-1.60 (m, 2H, H3/6), 
1.82-1.95 (m, 2H, H3/6), 2.46 (s, 6H, CH3-Ts), 2.70-2.80 (m, 2H, H1/2), 4.71 (d, 2H, J=4.9 Hz, 
NH), 7.26-7.33 (m, 4H, HAr), 7.72-7.77 (m, 4H, HAr) ppm. 
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Experimental part 
Bis-tosylated cyclohexyldiamine – Silver complex [Ag-170-(SbF6)]. A solution of 170 (9.5 
mg, 0.023 mmol) and AgSbF6 (7.7 mg, 0.023 mmol) in CH2Cl2 (2 mL) was stirred for 2 h at 
room temperature and solvents were removed in vacuuo to afford the silver complex (16.6 
mg, 96%) as a white solid, highly light sensitive. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 0.80-0.99 (m, 2H, H4/5), 1.01-1.18 (m, 2H, H4/5), 
1.18-1.45 (m, 4H, H3/6), 2.40 (s, 6H, CH3-Ts), 2.94 (m, 2H, H1/2), 5.82 (d, 2H, J=6.5 Hz, NH), 
7.26-7.28 (m, 4H, HAr), 7.77-7.79 (m, 4H, HAr) ppm; 
MS (ESI - MeCN): 528.9+/530.9+ (Ag-170)+, 950.8+/952.8+ (Ag-(170)2)+. 
 
 
Bis-tosylated DABN 172. To a solution of (R)-DABN 
171 (48.3 mg, 0.17 mmol) in pyridine (4 mL) was 
added TsCl (162.1 mg, 0.85 mmol) followed and the 
mixture stirred for 17 h at room temperature. The 
reaction was quenched with 1 N HCl and extracted with 
EtOAc (3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness and 
the residue was purified by column chromatography on SiO2 (hexane – EtOAc, 5:5) to afford 
172 (99.8 mg, 99%) as a white solid. Analytics were identical to those already reported128 – 
Selected data. 
 
1H NMR (400 MHz, CDCl3, 25 °C): δ = 1.92 (s, 6H, CH3-Ts), 6.10 (s, 2H, NH), 6.51 (m, 2H, 
HAr), 6.59 (m, 2H, HAr), 6.64 (m, 4H, HAr), 6.97 (m, 2H, HAr), 7.41 (m, 2H, HAr), 7.48 (m, 4H, 
HAr), 7.58 (m, 2H, HAr), 8.37 (m, 2H, HAr) ppm. 
 
 
‘Helmchen Ligand’ 173.121
1H NMR (250 MHz, CD2Cl2, 25 °C): δ = 0.61 (s, 3H, C6-CH3), 
1.00 (s, 6H, C7-CH3), 1.20 (m, 1H, H5), 1.50-1.72 (m, 3H, H4/5), 
2.13 (br, 3H, C2”/4”-CH3), 2.34 (br, 3H, C2”/4”-CH3), 3.55 (d, 1H, 
J=6.0 Hz, H1), 3.67 (d, 1H, J= 2.7 Hz, OH), 3.97 (dd, 1H, J= 6.0 
and 2.7 Hz, H2), 5.85 (br, 1H, H1”/5”), 6.98 (br, 1H, H1”/5”), 7.44-
7.56 (m, 4H, HAr), 7.62-7.72 (m, 1H, H3’) ppm. 
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Experimental part 
‘Helmchen Ligand’ 173 – Silver complex [Ag-173-(SbF6)]. A solution of 173 (4.3 mg, 
0.010 mmol) and AgSbF6 (3.6 mg, 0.010 mmol) in CH2Cl2 (2 mL) was stirred for 1 h at room 
temperature and solvents were removed in vacuuo to afford the silver complex (7.9 mg, 
>99%) as a white solid, highly light sensitive. 
 
1H NMR (250 MHz, CD2Cl2, 25 °C): δ = 0.64 (s, 3H, C6-CH3), 0.95 (s, 3H, C7-CH3), 1.06 (s, 
3H, C7-CH3), 1.07 (m, 1H, H5), 1.26 (m, 1H, H5), 1.50-1.80 (m, 2H, H4), 2.15 (br, 3H, C2”/4”-
CH3), 2.32 (br, 3H, C2”/4”-CH3), 2.40-3.40 (br, 1H, OH), 3.79 (d, 1H, J=6.6 Hz, H1), 4.05 (d, 
1H, J= 6.6 Hz, H2), 5.79 (br, 1H, H1”/5”), 7.11 (br, 1H, H1”/5”), 7.44-7.56 (m, 4H, HAr), 7.64-
7.75 (m, 1H, H3’) ppm; 
MS (ESI - MeCN): 519.9+ / 521.9+ (Ag-173)+, 560.9+ / 562.9+ (Ag-173-(MeCN))+, 592.9+ / 
594.9+ (Ag-173-(MeCN)(MeOH))+, 932.9+/934.9+ (Ag-(173)2)+. 
 
 
γ-Tocopheryl camphanate 174 – 
Silver mediated cyclisation – 
General procedure. To a solution 
of the silver complex [Ag-170-
(SbF6)] or [Ag-173-(SbF6)] (0.009 
mmol) in CH2Cl2 (1 mL) was added a solution of 99 (0.030 mmol) in CH2Cl2 (1 mL) and the 
mixture stirred for 15 h at room temperature. The reaction was quenched with saturated 
NaHCO3 and extracted with EtOAc (3 ×). Combined organic phases were dried over Na2SO4, 
evaporated to dryness and the residue was purified by column chromatography on SiO2 
(hexane – CH2Cl2, 8:2) to afford 174 as a colourless oil. Analytics were identical to those 
already reported31b – Selected data. 
 
HPLC (Protonsil® 120-5-CN, 0.5% to 3% iPrOH in n-heptane, 0.5 mL/min, 270 nm): 
mixture of two diastereoisomers, t(R,R,R) = 10.4 min, t(S,R,R) = 11.2 min. 
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Experimental part 
Mono-tosylated (R,R)-cyclohexanediamine 177. To a solution of 
169 (242.2 mg, 2.12 mmol) in CH2Cl2 (10 mL) was added Et3N 
(0.35 mL, 2.04 mmol) and the solution cooled down to 0 °C. Then 
a solution of TsCl (331.1 mg, 1.74 mmol) in CH2Cl2 (5 mL) was 
added dropwise and the mixture stirred at room temperature for 4 
h. The solvents were removed in vacuuo and the residue flash chromatographied on SiO2 
(CH2Cl2 – MeOH – Et3N, 100:10:1). The product was solved in CH2Cl2, and extracted with 1 
N HCl (3 ×). Combined aqueous layers were washed with 1 N NaOH and extracted with 
CH2Cl2 (3 ×). Combined organic phases were dried over Na2SO4, evaporated to dryness to 
afford 177 (337.2 mg, 72%) as white solid. Analytics were identical to those already 
described129 – Selected data. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 1.03-1.25 (m, 4H, H4/5), 1.50-1.60 (m, 2H, H3/6), 
1.82-1.95 (m, 2H, H3/6), 2.31 (m, 1H, H1/2), 2.43 (s, 3H, CH3-Ts), 2.60 (m, 1H, H1/2), 7.26-
7.33 (m, 2H, HAr), 7.72-7.79 (m, 2H, HAr) ppm. 
 
 
Mannich reaction – Formation of 178. To 
a solution of 177 (130.1 mg, 0.48 mmol) in 
MeOH (2 mL) was added HCHO (50 μL, 
0.48 mmol) followed by glacial AcOH (50 
μL, 0.50 mmol) and the solution stirred at 
80 °C under a steam of N2 for 30’. Then a 
solution of 176 (143.1 mg, 0.29 mmol) and 
glacial AcOH (50 μL, 0.50 mmol) in MeOH 
(5 mL) was added and stirring continued at 80 °C for 24 h. The reaction was quenched with 
saturated NaHCO3 and extracted with CH2Cl2 (3 ×). Combined organic phases were dried 
over Na2SO4, evaporated to dryness and purified on SiO2 (CH2Cl2 – MeOH, 10:0 to 9:1) to 
afford 178 (105.5 mg, 46%) as a yellow oil. Compound was not stable and full 
characterization was not possible. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.81-0.89 (m, 12H, C13/17/21-CH3), 0.98-1.70 (m, 
28H, H11/12/13/14/15/16/17/18/19/20/21/3’/5’/3”/4”/5”/6”), 1.70 (s, 3H, C9-CH3), 1-85-2.10 (m, 7H, 
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Experimental part 
H10/4’/5’/3”/6”), 2.06 (s, 3H, C2/3-CH3), 2.18 (s, 3H, C2/3-CH3), 2.43 (m, 1H, H1”/2”), 2.48 (s, 3H, 
CH3-Ts), 2.64 (m, 1H, H1”/2”), 3.15-3.70 (m, 4H, H7/2’, CH2-N), 3.74-3.90 (m, 1H, N-CH2-O), 
4.02 (m, 1H, H2’), 4.25-4.35 (m, 1H, N-CH2-O), 4.60 (m, 1H, H1’), 4.95 (m, 1H, H8), 7.30-
7.36 (m, 2H, HAr), 7.59-7.65 (m, 2H, HAr) ppm; 
MS (ESI - MeOH): 793.3+ (M+H)+, 815.2+ (M+Na)+. 
 
 
Mono-tosylated quinone 179. To a 
solution of 178 (100.1 mg, 0.126 mmol) 
in THF (10 mL) was added 1 N HCl (2.5 
mL) and the solution was stirred at room 
temperature for 2 h. The reaction was 
quenched with saturated NaHCO3 and 
extracted with CH2Cl2 (3 ×). Combined 
organic phases were dried over Na2SO4, evaporated to dryness and used as such for the next 
step. 
 
The residue was solved in CH2Cl2 (10 mL) and MnO2 (220 mg, 2.52 mmol) was added. The 
suspension was stirred at room temperature for 30’, solids were filtered off through a pad of 
celite and washed with CH2Cl2 and EtOAc. Solvents were removed in vacuuo and the residue 
was purified on SiO2 (CH2Cl2 – MeOH, 96:4) to afford 179 (61.5 mg, 70%) as a strong orange 
oil. Compound was not stable (highly light sensitive) and full characterization was not 
possible. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.81-0.89 (m, 12H, C13/17/21-CH3), 0.98-1.70 (m, 
28H, H11/12/13/14/15/16/17/18/19/20/21/3’/4’/5’/6’), 1.70 (s, 3H, C9-CH3), 1-85-2.10 (m, 4H, H10/3’/6’), 2.04 
(s, 6H, C2/3-CH3), 2.10-2.20 (m, 1H, H1’/2’), 2.38 (s, 3H, CH3-Ts), 2.56 (m, 1H, H1’/2’), 3.17-
3.22 (m, 2H, H7), 3.34 (d, 1H, J= 12.0 Hz, CH2-NH-), 3.64 (d, 1H, J= 12.0 Hz, CH2-NH-), 
4.87 (m, 1H, H8), 7.21 (d, 2H, J= 8.5 Hz, HAr), 7.68 (d, 2H, J= 8.5 Hz, HAr) ppm; 
MS (ESI - MeOH): 695.3+ (M+H)+, 717.3+ (M+Na)+. 
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Experimental part 
Bis-tosylated quinone 180. To a 
solution of 179 (146.1 mg, 0.211 
mmol) in CH2Cl2 (12 mL) was 
added DMAP (51.1 mg, 0.42 
mmol) followed by TsCl (88.4 
mg, 0.46 mmol) and the solution 
was stirred at room temperature 
for 15 h. Solvents were removed in vacuuo and the residue was purified on SiO2 (CH2Cl2 – 
MeOH, 99:1) to afford 180 (133.6 mg, 75%) as a yellow oil. Compound was not stable 
(highly light sensitive) and full characterization was not possible. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.79-0.87 (m, 12H, C13/17/21-CH3), 0.98-1.70 (m, 
28H, H11/12/13/14/15/16/17/18/19/20/21/3’/4’/5’/6’), 1-71-1.90 (m, 4H, H10/3’/6’), 1.75 (s, 3H, C9-CH3), 1.88 
(s, 6H, C2/3-CH3), 2.00-2.20 (m, 2H, H1’/2’), 2.35 (s, 3H, CH3-Ts), 2.40 (s, 3H, CH3-Ts), 3.43-
3.47 (m, 2H, H7), 4.11 (m, 2H, CH2-NH-), 5.52 (m, 1H, H8), 7.10-7.17 (m, 2H, HAr), 7.24-
7.32 (m, 2H, HAr), 7.45-7.53 (m, 2H, HAr), 7.80-7.87 (m, 2H, HAr) ppm; 
MS (ESI - MeOH): 871.1+ (M+Na)+, 887.1+ (M+K)+. 
 
 
Mono-tosylated chromene 181. A solution of 
179 (34.8 mg, 0.036 mmol) in pyridine (8 mL) 
was stirred at room temperature for 8 h. The 
reaction was quenched with 1 N HCl, 
extracted with CH2Cl2 (3 ×), and combined 
organic phases were dried over Na2SO4, 
evaporated to dryness and purified on SiO2 
(CH2Cl2 – MeOH, 95:5) to afford 181 (10.2 mg, 40%) as a yellow oil. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.82-0.88 (m, 12H, C4’/8’/12’-CH3), 0.98-1.70 (m, 
33H, C2-CH3, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’/11’/12’/3’’/4’’/5’’/6’’), 1-71-1.80 (m, 2H, H3’’/6’’), 2.11 (s, 3H, 
C7/8-CH3), 2.13 (s, 3H, C7/8-CH3), 2.00-2.10 (m, 1H, H1’’/2’’), 2.33 (s, 3H, CH3-Ts), 2.95-3.05 
(m, 1H, H1’’/2’’), 3.88 (s, 2H, CH2-NH-), 5.59 (d, 1H, J= 9.9 Hz, H3/4), 6.44 (d, 1H, J= 9.8 Hz, 
H3/4), 7.15-7.22 (m, 2H, HAr), 7.70-7.77 (m, 2H, HAr) ppm; 
1'
2'
3 '
4 '
5'
6 '
180
1
2
3
4
56 7
8
9O 13 17 21
N
O
N
H
S
O
O
S
O
O
1"
2"
3"
4"
5"
6"
181
8 2
3
4
4'
6
HN
N
H
S
O
O
O
HO
8' 12 '
 159
Experimental part 
13C NMR (100 MHz, CDCl3, 25 °C): δ = 12.1, 12.4, 20.0, 20.1, 20.2, 21.7, 21.8, 21.9, 23.0, 
23.1, 24.4, 24.9, 25.2, 25.4, 28.4, 33.2, 37.7, 37.8, 37.9, 39.8, 40.8, 44.5, 61.1, 76.8, 114.9, 
116.8, 119.6, 124.8, 125.1, 127.3, 130.2, 130.9, 138.0, 143.7, 144.1, 149.7 ppm; 
MS (ESI – MeOH): 695.3+ (M+H)+. 
 
 
Chromene 183. To a solution of E-162 (22.2 
mg, 0.050 mmol) in THF (2 mL) at -78 °C was 
added (R)-Alpine-hydride (0.5 M in THF, 0.25 
mL, 0.125 mmol) and the mixture was stirred 
at -60 °C for 1 h and allowed to warm up to room temperature. Stirring was continued for 12 
h and the reaction was quenched with H2O, extracted with CH2Cl2 (3 ×), and combined 
organic phases were dried over Na2SO4, evaporated to dryness and purified on SiO2 (hexane – 
EtOAc, 85:15) to afford 183 (26.6 mg, 30%) as a pale yellow oil. Analytics were identical to 
those already described31b – Selected data. 
 
1H NMR (250 MHz, CDCl3, 25 °C): δ = 0.82-0.88 (m, 12H, C4’/8’/12’-CH3), 0.98-1.55(m, 24H, 
C2-CH3, H1’/2’/3’/4’/5’/6’/7’/8’/9’/10’/11’/12’), 2.12 (s, 6H, C8/9-CH3), 3.76 (s, 3H, CH3O), 5.53 (d, 1H, 
J= 9.7 Hz, H3/4), 6.28 (d, 1H, J= 9.6 Hz, H3/4), 6.37 (s, 1H, H6) ppm. 
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Experimental part 
5.3. X-Ray data for [Ag-173-(SbF6)] 
 
Crystal and Structure Refinement Data for [Ag-173-(SbF6)] complex. 
 
 
[Ag-173-(SbF6)] 
Formula C24H31AgF6NO3SSb 
Composition C24H31AgNO3S, F6Sb 
FW 757.19 
Crystal size (mm) 0.04x0.05x0.44 
Morphology plate 
Cryst color colorless 
Wavelength (Å) 0.71073 
Crystal system Orthorhombic 
Space group P21 21 21
T, K 173 
a/Å 11.46540(10) 
b/Å 14.0539(2) 
c/Å 17.2269(2) 
α, deg 90.00 
β, deg 90.00 
γ, deg 90.00 
V, Å3 2775.83(6) 
Z 4 
θ (min, max) 1.870, 30.011 
h, k, l (min, max) (-16, 16), (-19, 19), (-24, 24) 
no. of refln measured 28400 
no. of unique reflns 6099 
no. of parameters 335 
ρcalc (g/cm3) 1.812 
µ, mm-1 0.1820 
F(000) 1496 
R indexes R1 = 0.0209 
    [I>3.00σ(I)]     wR2 = 0.0224 
R (all data) R1 = 0.0324 
     wR2 = 0.0303 
GoF 1.1055 
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Structure (mercury view) and atoms coordination for [Ag-173-(SbF6)] complex. 
 
 
Atoms  X           Y         Z            Atoms   X           Y         Z 
 
Sb1  0.1856  /0.4746/ 0.4873 
Ag1  0.4262  /0.2565/ 0.4766 
S1  0.6919  /0.4004/ 0.4641 
F1  0.3142  /0.4146/ 0.4410 
F2  0.0595  /0.5328/ 0.5366 
F3  0.1317  /0.5151/ 0.3905 
F4  0.2375  /0.4275/ 0.5840 
F5  0.2735  /0.5845/ 0.5009 
F6  0.1001  /0.3625/ 0.4767 
O1  0.8877  /0.2322/ 0.3911 
O2  0.8078  /0.3885/ 0.4941 
O3  0.5946  /0.3648/ 0.5072 
N1  0.6909  /0.3483/ 0.3779 
C1  0.6719  /0.5235/ 0.4502 
C2  0.7678  /0.5838/ 0.4434 
C3  0.7479  /0.6800/ 0.4298 
C4  0.6356  /0.7141/ 0.4233 
C5  0.5411  /0.6545/ 0.4305 
C6  0.5581  /0.5580/ 0.4447 
C7  0.5772  /0.3286/ 0.3452 
C8  0.5159  /0.3972/ 0.3047 
C9  0.4070  /0.3762/ 0.2725 
C10  0.3388  /0.4516/ 0.2306 
C11  0.3636  /0.2851/ 0.2807 
C12  0.4228  /0.2142/ 0.3207 
C13  0.3750  /0.1142/ 0.3226 
C14  0.5308  /0.2371/ 0.3543 
C15  0.7930  /0.3762/ 0.3282 
C16  0.9040  /0.3131/ 0.3416 
C17  0.9432  /0.2885/ 0.2580 
C18  0.9906  /0.3846/ 0.2263 
C19  0.8776  /0.4432/ 0.2105 
C20  0.7808  /0.3757/ 0.2387 
C21  0.8278  /0.2780/ 0.2127 
C22  0.7532  /0.1926/ 0.2354 
C23  0.8443  /0.2705/ 0.1241 
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C24  1.0300  /0.2073/ 0.2549 H111  0.2871  /0.2707/ 0.2573 
H1  0.8303  /0.2043/ 0.3742 H131  0.2957  /0.1123/ 0.3426 
H21  0.8460  /0.5592/ 0.4487 H132  0.3720  /0.0919/ 0.2686 
H31  0.8136  /0.7219/ 0.4253 H133  0.4249  /0.0727/ 0.3533 
H41  0.6215  /0.7820/ 0.4144 H141  0.5778  /0.1878/ 0.3778 
H51  0.4631  /0.6813/ 0.4261 H151  0.8138  /0.4409/ 0.3427 
H61  0.4927  /0.5156/ 0.4505 H161  0.9637  /0.3523/ 0.3673 
H81  0.5496  /0.4612/ 0.2986 H181  1.0355  /0.3755/ 0.1781 
H101  0.3908  /0.5023/ 0.2167 H182  1.0392  /0.4159/ 0.2653 
H102  0.2768  /0.4772/ 0.2618 H191  0.8685  /0.4573/ 0.1545 
H103  0.3059  /0.4244/ 0.1844 
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6. Appendix 
6.1. Abbreviations 
 
Ac  acetyl 
Anthr  9-methylanthracenyl 
Ar  aromatic 
Asp  aspartic acid 
BINAP 2,2’-bis(diphenylphosphino)-1,1’-binaphtalene 
BINOL 1,1’-binaphtalene-2,2’-diol 
Bn  benzyl 
Boc  t-butyloxycarbonyl 
BOX  bis-oxazoline 
Camph camphanoyl 
conv  conversion 
CSA  camphorsulfonic acid 
d  days 
DABN  1,1'-binaphthalene-2,2'-diamine 
dba  dibenzylideneacetone 
de  diastereoisomeric excess 
DIBAL-H diisobutylaluminium hydride 
DIEA  diisopropyl-ethylamine 
DMAP 4-dimethylamino-pyridine 
DMF  N,N-dimethylformamide 
DNBA  dinitro-benzyl alcohol 
DPPB  o-diphenylphosphanyl benzoate 
dppp  1,3-bis(diphenylphosphino)propane 
DPS  t-butyl-diphenylsilyl 
e-  electron 
EC50  median effective concentration 
EDTA  ethylenediaminetetraacetic acid 
ee  enantiomeric excess 
ESI  electrospray ionisation 
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Et  ethyl 
FID  flame ionization detector 
GC  gas chromatography 
HCTU  2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate 
HIV  human immunodeficiency virus 
HMPA hexamethylphosphoramide 
HPLC  high pressure liquid chromatography 
Hz  hertz 
iPr  isopropyl 
KHMDS potassium bis(trimethylsilyl)amide 
KLH  keyhole limpet hemocyanin 
load  loading 
mCPBA m-chloroperbenzoic acid 
Me  methyl 
MOM  methoxy methyl 
Ms  mesyl 
MS  mass spectroscopy 
NBS  N-bromosuccinimide 
nBu  n-butyl 
NMR  nuclear magnetic resonance  
NOE  nuclear Overhauser effect 
NOESY nuclear Overhauser effect spectroscopy 
Nuc  nucleophile 
PC  propylene carbonate 
PCC  pyridium chlorochromate 
Ph  phenyl 
PFP  pentafluorophenol 
ppm  parts per million 
Pro  proline 
pTsOH p-toluene sulfonic acid 
PyBOX pyridyl bis-oxazoline 
rt  room temperature 
temp  temperature 
 166
Appendix 
TADDOL α,α,α’,α’-tetraaryl-1,3-dioxolane-4,5-dimethanols 
TBAF  tetrabutylammonium fluoride 
TBHP  t-butylhydroperoxide 
TBS  t-butyl-dimethylsilyl 
tBu  t-butyl 
TES  triethylsilyl 
THF  tetrahydrofuran 
THP  tetrahydropyran 
TIPS  triisopropylsilyl 
TMEDA N,N,N’,N’-tetramethylethylendiamine 
TMS  trimethylsilyl 
Tf  triflate 
TFA  trifuoracetic acid 
Ts  tosyl 
v  volume 
w  weight 
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   Registration of compounds in the Novartis database, according to 
   their chemical and physical properties. 
   Literature search 
   Formation of new trainees    
  2004 : Novartis Pharma AG – Basel (CH) 
   6 months trainee: “Combinatorial synthesis on solid support” 
   Solid phase synthesis of a 4,6-diaminopyridine library – over 10000 
   compound synthesised 
   Optimisation of reaction conditions 
   Screening for suitable reagents 
   Use of analytics (LC, LC-MS, NMR) 
   
 
Publications & Contributions 
 
  2007 J. Chapelat, A. Chougnet, W.-D. Woggon, “Biomimetic syntheses of 
tocotrienols and tocopherols” Oral presentation at the Fall Spring Meeting 
of the Swiss Chemical Society, September 12. 2007, Lausanne, 
Switzerland. 
  
  2008 J. Chapelat, A. Buss, A. Chougnet, W.-D. Woggon, “Diastereoselective 
Synhtesis of α-Tocopherol – a New Concept for the Formation of 
Chromanols”, Org. Lett. 2008, 10, 5123.  
 
 J. Chapelat, A. Chougnet, W.-D. Woggon, “Biomimetic Chromanol 
Cyclisation: a Common Route to α-Tocotrienol and α-Tocopherol.”, Eur. J. 
Org. Chem., 2008, in preparation. 
 
Languages & Computer 
 
  French : Mother tongue 
  English : Fluent – TOEIC 2004: 900/990 
  German : Basic level 
  Computer : Windows XP, Vista, Microsoft Office 2003/2007 
   WinNMR, MestreC, MestReNova, IconNMR, IsisDraw, ChemDraw,  
  Belstein, SciFindrer, HPLC (Agilent, Shimadzu), IR (Shimadzu),  
  MS (Bruker), UV (Agilent). 
 
Hobbies 
 
  Sports : Tennis, Basket-Ball 
  Music : Musical Studies in Saxophone Alto & Baryton (Superior Degree, 2nd place 
   at the European Contest for Young Solists – Gap, 1996) 
  Culture       : Music, Books, Movies, Travel, Computer
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